_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,expertdecision,relation,sent_id,orig_sentence,term1,term2
502244389,7/11/2014 10:56:48,,1320663693,7/11/2014 10:56:45,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,95,58,,,117,79,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,"spondyloarthropathies, especially in ANKYLOSING SPONDYLITIS.",58-81-92-95-106,42-51-54-58-81-92-95,"hallmark of the SPONDYLOARTHROPATHIES, especially in ankylosing","Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis.",95 106,58,95,58,117,79,-1,RO-has_manifestation,906306,"Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis",ankylosing spondylitis,spondyloarthropathies
502244389,7/11/2014 11:00:25,,1320664997,7/11/2014 11:00:13,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,95,58,,,117,79,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,ANKYLOSING SPONDYLITIS.,95-106,58,"SPONDYLOARTHROPATHIES,","Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis.",95 106,58,95,58,117,79,-1,RO-has_manifestation,906306,"Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis",ankylosing spondylitis,spondyloarthropathies
502244389,7/11/2014 11:07:04,,1320668095,7/11/2014 11:06:42,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,95,58,,,117,79,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,ANKYLOSING SPONDYLITIS.,95-106,58,"SPONDYLOARTHROPATHIES,","Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis.",95 106,58,95,58,117,79,-1,RO-has_manifestation,906306,"Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis",ankylosing spondylitis,spondyloarthropathies
502244389,7/11/2014 11:09:30,,1320669211,7/11/2014 11:08:53,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,95,58,,,117,79,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,ANKYLOSING SPONDYLITIS.,95-106,58,"SPONDYLOARTHROPATHIES,","Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis.",95 106,58,95,58,117,79,-1,RO-has_manifestation,906306,"Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis",ankylosing spondylitis,spondyloarthropathies
502244389,7/11/2014 11:11:52,,1320670903,7/11/2014 11:11:34,instagc,1,23149109,USA,NC,Durham,75.189.206.205,95,58,,,117,79,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,ANKYLOSING SPONDYLITIS.,95-106,58,"SPONDYLOARTHROPATHIES,","Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis.",95 106,58,95,58,117,79,-1,RO-has_manifestation,906306,"Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis",ankylosing spondylitis,spondyloarthropathies
502244389,7/11/2014 11:12:03,,1320671040,7/11/2014 11:11:49,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,95,58,,,117,79,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,ANKYLOSING SPONDYLITIS.,95-106,54-58,"the SPONDYLOARTHROPATHIES,","Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis.",95 106,58,95,58,117,79,-1,RO-has_manifestation,906306,"Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis",ankylosing spondylitis,spondyloarthropathies
502244389,7/11/2014 11:48:11,,1320685497,7/11/2014 11:47:05,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,95,58,,,117,79,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,"hallmark of the spondyloarthropathies, in ANKYLOSING SPONDYLITIS.",42-51-58-92-95-106-54,19-30-37-42-51-54-58-40,"sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES,","Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis.",95 106,58,95,58,117,79,-1,RO-has_manifestation,906306,"Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis",ankylosing spondylitis,spondyloarthropathies
502244389,7/11/2014 11:48:53,,1320685711,7/11/2014 11:48:32,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.197,95,58,,,117,79,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,ANKYLOSING SPONDYLITIS.,95-106,58,"SPONDYLOARTHROPATHIES,","Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis.",95 106,58,95,58,117,79,-1,RO-has_manifestation,906306,"Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis",ankylosing spondylitis,spondyloarthropathies
502244389,7/11/2014 11:50:11,,1320686151,7/11/2014 11:49:29,prodege,1,27969454,USA,,,69.76.133.211,95,58,,,117,79,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,"spondyloarthropathies, especially in ANKYLOSING SPONDYLITIS.",58-81-92-95-106,42-51-54-58-81-92-95-106,"hallmark of the SPONDYLOARTHROPATHIES, especially in ankylosing spondylitis.","Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis.",95 106,58,95,58,117,79,-1,RO-has_manifestation,906306,"Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis",ankylosing spondylitis,spondyloarthropathies
502244389,7/11/2014 11:50:47,,1320686498,7/11/2014 11:49:56,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,95,58,,,117,79,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES,"spondyloarthropathies, ANKYLOSING SPONDYLITIS.",58-95-106,58,"SPONDYLOARTHROPATHIES,","Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis.",95 106,58,95,58,117,79,-1,RO-has_manifestation,906306,"Involvement of the sacroiliac joints is a hallmark of the spondyloarthropathies, especially in ankylosing spondylitis",ankylosing spondylitis,spondyloarthropathies
502244390,7/11/2014 10:56:13,,1320663507,7/11/2014 10:55:12,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,105,41,,,110,52,LUPUS,THALIDOMIDE,LUPUS erythematosus:,105-111,41,THALIDOMIDE,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.",105,41,105,41,110,52,1,RO-may_treat,907641,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients",lupus,Thalidomide
502244390,7/11/2014 10:56:23,,1320663566,7/11/2014 10:56:06,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,105,41,,,110,52,LUPUS,THALIDOMIDE,LUPUS erythematosus:,105-111,41,THALIDOMIDE,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.",105,41,105,41,110,52,1,RO-may_treat,907641,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients",lupus,Thalidomide
502244390,7/11/2014 11:05:24,,1320667487,7/11/2014 11:04:36,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,105,41,,,110,52,LUPUS,THALIDOMIDE,LUPUS erythematosus:,105-111,41,THALIDOMIDE,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.",105,41,105,41,110,52,1,RO-may_treat,907641,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients",lupus,Thalidomide
502244390,7/11/2014 11:07:11,,1320668136,7/11/2014 11:06:54,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,105,41,,,110,52,LUPUS,THALIDOMIDE,cutaneous manifestations of LUPUS erythematosus:,77-87-102-105-111,41,THALIDOMIDE,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.",105,41,105,41,110,52,1,RO-may_treat,907641,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients",lupus,Thalidomide
502244390,7/11/2014 11:07:28,,1320668239,7/11/2014 11:07:12,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,105,41,,,110,52,LUPUS,THALIDOMIDE,LUPUS erythematosus:,105-111,41,THALIDOMIDE,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.",105,41,105,41,110,52,1,RO-may_treat,907641,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients",lupus,Thalidomide
502244390,7/11/2014 11:09:35,,1320669227,7/11/2014 11:09:23,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,105,41,,,110,52,LUPUS,THALIDOMIDE,LUPUS,105,41,THALIDOMIDE,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.",105,41,105,41,110,52,1,RO-may_treat,907641,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients",lupus,Thalidomide
502244390,7/11/2014 11:30:11,,1320679088,7/11/2014 11:29:51,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,105,41,,,110,52,LUPUS,THALIDOMIDE,LUPUS,105,41,THALIDOMIDE,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.",105,41,105,41,110,52,1,RO-may_treat,907641,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients",lupus,Thalidomide
502244390,7/11/2014 11:30:44,,1320679296,7/11/2014 11:30:31,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,105,41,,,110,52,LUPUS,THALIDOMIDE,LUPUS,105,41,THALIDOMIDE,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.",105,41,105,41,110,52,1,RO-may_treat,907641,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients",lupus,Thalidomide
502244390,7/11/2014 11:40:35,,1320682550,7/11/2014 11:39:39,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,105,41,,,110,52,LUPUS,THALIDOMIDE,cutaneous manifestations of LUPUS erythematosus:,77-87-102-105-111,41-53-56-60,THALIDOMIDE in the treatment,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.",105,41,105,41,110,52,1,RO-may_treat,907641,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients",lupus,Thalidomide
502244390,7/11/2014 11:41:20,,1320682733,7/11/2014 11:41:11,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,105,41,,,110,52,LUPUS,THALIDOMIDE,cutaneous manifestations of LUPUS erythematosus: experience in,77-87-102-105-111-126-137,31-34-37-41-53-56-60,CJ et al. THALIDOMIDE in the treatment,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.",105,41,105,41,110,52,1,RO-may_treat,907641,"Stevens RJ, Andujar C, Edwards CJ et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients",lupus,Thalidomide
502244391,7/11/2014 10:50:04,,1320661703,7/11/2014 10:49:15,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,107,59,,,124,65,ATOPIC DERMATITIS,ATOPIC,its chronic relapsing ATOPIC DERMATITIS as well as,85-89-97-107-114-125-128-133,48-50-56-59-66-74-82,a model of ATOPIC disease because of,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness.,107 114,59,107,59,124,65,-1,RO-cause_of,900111,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness,atopic dermatitis,atopic
502244391,7/11/2014 10:55:51,,1320663376,7/11/2014 10:55:14,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,107,59,,,124,65,ATOPIC DERMATITIS,ATOPIC,chronic relapsing ATOPIC DERMATITIS,97-107-114-89,59,ATOPIC,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness.,107 114,59,107,59,124,65,-1,RO-cause_of,900111,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness,atopic dermatitis,atopic
502244391,7/11/2014 10:57:28,,1320663931,7/11/2014 10:57:25,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,107,59,,,124,65,ATOPIC DERMATITIS,ATOPIC,its chronic relapsing ATOPIC DERMATITIS as well as,85-89-97-107-114-125-128-133,48-50-56-59-66-74-82,a model of ATOPIC disease because of,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness.,107 114,59,107,59,124,65,-1,RO-cause_of,900111,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness,atopic dermatitis,atopic
502244391,7/11/2014 11:00:07,,1320664878,7/11/2014 10:59:34,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,107,59,,,124,65,ATOPIC DERMATITIS,ATOPIC,chronic relapsing ATOPIC DERMATITIS,89-97-107-114,59-66,ATOPIC disease,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness.,107 114,59,107,59,124,65,-1,RO-cause_of,900111,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness,atopic dermatitis,atopic
502244391,7/11/2014 11:01:30,,1320665581,7/11/2014 11:00:47,clixsense,1,23138831,NLD,,,77.174.95.58,107,59,,,124,65,ATOPIC DERMATITIS,ATOPIC,atopic disease chronic relapsing ATOPIC DERMATITIS as well as airway hyperresponsiveness.,59-89-97-107-114-125-128-133-136-143-66,48-50-56-59-66,a model of ATOPIC disease,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness.,107 114,59,107,59,124,65,-1,RO-cause_of,900111,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness,atopic dermatitis,atopic
502244391,7/11/2014 11:03:44,,1320666745,7/11/2014 11:03:03,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,107,59,,,124,65,ATOPIC DERMATITIS,ATOPIC,chronic relapsing ATOPIC DERMATITIS,89-97-107-114,59-66,ATOPIC disease,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness.,107 114,59,107,59,124,65,-1,RO-cause_of,900111,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness,atopic dermatitis,atopic
502244391,7/11/2014 11:05:37,,1320667609,7/11/2014 11:05:22,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,107,59,,,124,65,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,107-114,59,ATOPIC,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness.,107 114,59,107,59,124,65,-1,RO-cause_of,900111,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness,atopic dermatitis,atopic
502244391,7/11/2014 11:10:22,,1320669826,7/11/2014 11:09:57,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,107,59,,,124,65,ATOPIC DERMATITIS,ATOPIC,chronic relapsing ATOPIC DERMATITIS,89-97-107-114,59-66,ATOPIC disease,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness.,107 114,59,107,59,124,65,-1,RO-cause_of,900111,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness,atopic dermatitis,atopic
502244391,7/11/2014 11:11:25,,1320670592,7/11/2014 11:11:07,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,107,59,,,124,65,ATOPIC DERMATITIS,ATOPIC,relapsing ATOPIC DERMATITIS,97-107-114,59-66,ATOPIC disease,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness.,107 114,59,107,59,124,65,-1,RO-cause_of,900111,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness,atopic dermatitis,atopic
502244391,7/11/2014 11:29:30,,1320678903,7/11/2014 11:29:15,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,107,59,,,124,65,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,107-114,59,ATOPIC,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness.,107 114,59,107,59,124,65,-1,RO-cause_of,900111,The Basenji greyhound (BG) has been proposed as a model of atopic disease because of its chronic relapsing atopic dermatitis as well as airway hyperresponsiveness,atopic dermatitis,atopic
502244392,7/11/2014 10:54:50,,1320663052,7/11/2014 10:54:31,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,13,45,,,34,72,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,ARTERIAL HYPERTENSION,13-22,45-58,HYPERTENSIVE ENCEPHALOPATHY,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system.,13 22,45 58,13,45,34,72,1,RO-disease_has_finding,901903,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system,arterial hypertension,hypertensive encephalopathy
502244392,7/11/2014 10:57:24,,1320663909,7/11/2014 10:57:21,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,13,45,,,34,72,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,Treatment of ARTERIAL HYPERTENSION in severe hypertensive,0-10-13-22-35-38-45,22-35-38-45-58-73-78-82,hypertension in severe HYPERTENSIVE ENCEPHALOPATHY does not always,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system.,13 22,45 58,13,45,34,72,1,RO-disease_has_finding,901903,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system,arterial hypertension,hypertensive encephalopathy
502244392,7/11/2014 11:07:33,,1320668265,7/11/2014 11:07:15,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,13,45,,,34,72,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,ARTERIAL HYPERTENSION,13-22,45-58,HYPERTENSIVE ENCEPHALOPATHY,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system.,13 22,45 58,13,45,34,72,1,RO-disease_has_finding,901903,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system,arterial hypertension,hypertensive encephalopathy
502244392,7/11/2014 11:08:23,,1320668638,7/11/2014 11:08:08,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,13,45,,,34,72,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,ARTERIAL HYPERTENSION,13-22,45-58,HYPERTENSIVE ENCEPHALOPATHY,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system.,13 22,45 58,13,45,34,72,1,RO-disease_has_finding,901903,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system,arterial hypertension,hypertensive encephalopathy
502244392,7/11/2014 11:12:16,,1320671182,7/11/2014 11:11:43,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,13,45,,,34,72,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,ARTERIAL HYPERTENSION,13-22,45-58,HYPERTENSIVE ENCEPHALOPATHY,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system.,13 22,45 58,13,45,34,72,1,RO-disease_has_finding,901903,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system,arterial hypertension,hypertensive encephalopathy
502244392,7/11/2014 11:20:49,,1320675502,7/11/2014 11:20:37,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,13,45,,,34,72,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,ARTERIAL HYPERTENSION,13-22,45-58,HYPERTENSIVE ENCEPHALOPATHY,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system.,13 22,45 58,13,45,34,72,1,RO-disease_has_finding,901903,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system,arterial hypertension,hypertensive encephalopathy
502244392,7/11/2014 11:26:58,,1320677837,7/11/2014 11:26:45,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,13,45,,,34,72,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,ARTERIAL HYPERTENSION,13-22,45-58,HYPERTENSIVE ENCEPHALOPATHY,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system.,13 22,45 58,13,45,34,72,1,RO-disease_has_finding,901903,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system,arterial hypertension,hypertensive encephalopathy
502244392,7/11/2014 11:34:36,,1320680712,7/11/2014 11:34:14,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,13,45,,,34,72,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,ARTERIAL HYPERTENSION,13-22,45-58,HYPERTENSIVE ENCEPHALOPATHY,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system.,13 22,45 58,13,45,34,72,1,RO-disease_has_finding,901903,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system,arterial hypertension,hypertensive encephalopathy
502244392,7/11/2014 11:44:18,,1320683658,7/11/2014 11:43:31,prodege,1,27969454,USA,,,69.76.133.211,13,45,,,34,72,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,Treatment of ARTERIAL HYPERTENSION in severe hypertensive,0-10-13-22-35-38-45,22-35-38-45-58-73-78-82,hypertension in severe HYPERTENSIVE ENCEPHALOPATHY does not always,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system.,13 22,45 58,13,45,34,72,1,RO-disease_has_finding,901903,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system,arterial hypertension,hypertensive encephalopathy
502244392,7/11/2014 11:44:25,,1320683699,7/11/2014 11:44:13,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,13,45,,,34,72,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,Treatment of ARTERIAL HYPERTENSION in severe hypertensive,0-10-13-22-35-38-45,22-35-38-45-58-73-78-82-89,hypertension in severe HYPERTENSIVE ENCEPHALOPATHY does not always result,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system.,13 22,45 58,13,45,34,72,1,RO-disease_has_finding,901903,Treatment of arterial hypertension in severe hypertensive encephalopathy does not always result in clinical improvement in the patient's central nervous system,arterial hypertension,hypertensive encephalopathy
502244393,7/11/2014 10:58:44,,1320664367,7/11/2014 10:58:15,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,3,33,,,10,57,SEIZURE,COMPLEX PARTIAL SEIZURES,SEIZURE,3,33-41-49,COMPLEX PARTIAL SEIZURES,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control.",3,33 41 49,3,33,10,57,-1,RO-has_definitional_manifestation,904810,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control",seizure,complex partial seizures
502244393,7/11/2014 11:03:16,,1320666534,7/11/2014 11:02:33,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,3,33,,,10,57,SEIZURE,COMPLEX PARTIAL SEIZURES,"In SEIZURE type analysis,",0-3-11-16,0-3-11-16-26-30-33-41-49,"In seizure type analysis, 26% of COMPLEX PARTIAL SEIZURES","In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control.",3,33 41 49,3,33,10,57,-1,RO-has_definitional_manifestation,904810,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control",seizure,complex partial seizures
502244393,7/11/2014 11:03:49,,1320666804,7/11/2014 11:03:28,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,3,33,,,10,57,SEIZURE,COMPLEX PARTIAL SEIZURES,SEIZURE,3,33-41-49,COMPLEX PARTIAL SEIZURES,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control.",3,33 41 49,3,33,10,57,-1,RO-has_definitional_manifestation,904810,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control",seizure,complex partial seizures
502244393,7/11/2014 11:05:49,,1320667672,7/11/2014 11:05:38,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,3,33,,,10,57,SEIZURE,COMPLEX PARTIAL SEIZURES,SEIZURE,3,33-41-49,COMPLEX PARTIAL SEIZURES,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control.",3,33 41 49,3,33,10,57,-1,RO-has_definitional_manifestation,904810,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control",seizure,complex partial seizures
502244393,7/11/2014 11:09:08,,1320668998,7/11/2014 11:08:47,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,3,33,,,10,57,SEIZURE,COMPLEX PARTIAL SEIZURES,"SEIZURE type analysis,",3-11-16,33-41-49-58,"COMPLEX PARTIAL SEIZURES (CPS),","In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control.",3,33 41 49,3,33,10,57,-1,RO-has_definitional_manifestation,904810,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control",seizure,complex partial seizures
502244393,7/11/2014 11:11:15,,1320670453,7/11/2014 11:10:49,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,3,33,,,10,57,SEIZURE,COMPLEX PARTIAL SEIZURES,SEIZURE,3,33-41-49,COMPLEX PARTIAL SEIZURES,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control.",3,33 41 49,3,33,10,57,-1,RO-has_definitional_manifestation,904810,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control",seizure,complex partial seizures
502244393,7/11/2014 11:13:43,,1320672258,7/11/2014 11:13:17,instagc,1,23149109,USA,NC,Durham,75.189.206.205,3,33,,,10,57,SEIZURE,COMPLEX PARTIAL SEIZURES,SEIZURE,3,33-41-49,COMPLEX PARTIAL SEIZURES,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control.",3,33 41 49,3,33,10,57,-1,RO-has_definitional_manifestation,904810,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control",seizure,complex partial seizures
502244393,7/11/2014 11:21:04,,1320675556,7/11/2014 11:20:50,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,3,33,,,10,57,SEIZURE,COMPLEX PARTIAL SEIZURES,SEIZURE,3,33-41-49,COMPLEX PARTIAL SEIZURES,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control.",3,33 41 49,3,33,10,57,-1,RO-has_definitional_manifestation,904810,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control",seizure,complex partial seizures
502244393,7/11/2014 11:35:37,,1320680996,7/11/2014 11:34:04,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,3,33,,,10,57,SEIZURE,COMPLEX PARTIAL SEIZURES,"In SEIZURE type analysis,",0-3-11-16,16-26-30-33-41-49-65,"analysis, 26% of COMPLEX PARTIAL SEIZURES 64%","In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control.",3,33 41 49,3,33,10,57,-1,RO-has_definitional_manifestation,904810,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control",seizure,complex partial seizures
502244393,7/11/2014 11:36:40,,1320681355,7/11/2014 11:35:10,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,3,33,,,10,57,SEIZURE,COMPLEX PARTIAL SEIZURES,"In SEIZURE type analysis, 26% complex partial seizures simple partial seizures generalized tonic clonic seizures",0-3-11-16-26-33-41-49-72-79-87-113-125-131-138,16-26-30-33-41-49-65-69-72-79-87-113-125-131-138-153-162-167,"analysis, 26% of COMPLEX PARTIAL SEIZURES 64% of simple partial seizures generalized tonic clonic seizures showed good control.","In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control.",3,33 41 49,3,33,10,57,-1,RO-has_definitional_manifestation,904810,"In seizure type analysis, 26% of complex partial seizures (CPS), 64% of simple partial seizures (SPS) and 86% of generalized tonic-clonic seizures (GTC) showed a good control",seizure,complex partial seizures
502244394,7/11/2014 10:50:21,,1320661795,7/11/2014 10:50:16,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,100,122,,,106,137,OXYGEN,OXYGEN TOXICITY,mask Improved arterial OXYGEN saturation No oxygen,76-82-91-100-107-119-122,100-107-119-122-129-138-141-146,oxygen saturation No OXYGEN TOXICITY at this oxygen,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",100,122 129,100,122,106,137,-1,RO-has_causative_agent,903578,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml",oxygen,oxygen toxicity
502244394,7/11/2014 10:58:18,,1320664221,7/11/2014 10:58:00,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,100,122,,,106,137,OXYGEN,OXYGEN TOXICITY,arterial OXYGEN saturation,91-100-107,122-129,OXYGEN TOXICITY,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",100,122 129,100,122,106,137,-1,RO-has_causative_agent,903578,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml",oxygen,oxygen toxicity
502244394,7/11/2014 11:01:53,,1320665815,7/11/2014 11:01:31,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,100,122,,,106,137,OXYGEN,OXYGEN TOXICITY,OXYGEN,100,122-129,OXYGEN TOXICITY,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",100,122 129,100,122,106,137,-1,RO-has_causative_agent,903578,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml",oxygen,oxygen toxicity
502244394,7/11/2014 11:11:33,,1320670677,7/11/2014 11:11:13,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,100,122,,,106,137,OXYGEN,OXYGEN TOXICITY,arterial OXYGEN saturation,91-100-107,122-129,OXYGEN TOXICITY,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",100,122 129,100,122,106,137,-1,RO-has_causative_agent,903578,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml",oxygen,oxygen toxicity
502244394,7/11/2014 11:13:14,,1320671900,7/11/2014 11:12:53,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,100,122,,,106,137,OXYGEN,OXYGEN TOXICITY,OXYGEN saturation oxygen,100-107-122,122-129,OXYGEN TOXICITY,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",100,122 129,100,122,106,137,-1,RO-has_causative_agent,903578,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml",oxygen,oxygen toxicity
502244394,7/11/2014 11:24:01,,1320676739,7/11/2014 11:23:42,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,100,122,,,106,137,OXYGEN,OXYGEN TOXICITY,OXYGEN,100,122-129,OXYGEN TOXICITY,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",100,122 129,100,122,106,137,-1,RO-has_causative_agent,903578,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml",oxygen,oxygen toxicity
502244394,7/11/2014 11:24:00,,1320676745,7/11/2014 11:23:19,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,100,122,,,106,137,OXYGEN,OXYGEN TOXICITY,OXYGEN,100,122-129,OXYGEN TOXICITY,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",100,122 129,100,122,106,137,-1,RO-has_causative_agent,903578,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml",oxygen,oxygen toxicity
502244394,7/11/2014 11:38:10,,1320681791,7/11/2014 11:37:51,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,100,122,,,106,137,OXYGEN,OXYGEN TOXICITY,mask Improved arterial OXYGEN saturation No oxygen,76-82-91-100-107-119-122,100-107-119-122-129-138-141-146,oxygen saturation No OXYGEN TOXICITY at this oxygen,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",100,122 129,100,122,106,137,-1,RO-has_causative_agent,903578,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml",oxygen,oxygen toxicity
502244394,7/11/2014 11:39:13,,1320682144,7/11/2014 11:38:38,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,100,122,,,106,137,OXYGEN,OXYGEN TOXICITY,mask Improved arterial OXYGEN saturation No oxygen toxicity oxygen concentration,76-82-91-100-107-119-122-129-146-153,100-107-119-122-129-138-141-146-153-168-173-181-186-195-200,oxygen saturation No OXYGEN TOXICITY at this oxygen concentration tvml 3tvml tvml 87tvml tvml 142tvml.,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",100,122 129,100,122,106,137,-1,RO-has_causative_agent,903578,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml",oxygen,oxygen toxicity
502244394,7/11/2014 11:48:13,,1320685523,7/11/2014 11:47:47,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.197,100,122,,,106,137,OXYGEN,OXYGEN TOXICITY,arterial OXYGEN saturation,91-100-107,122-129,OXYGEN TOXICITY,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",100,122 129,100,122,106,137,-1,RO-has_causative_agent,903578,"HAPE, 2-6 L/min nasal canula; &gt;5 L/min, simple mask; 10-15 L/min, reservoir mask  Improved arterial oxygen saturation  No oxygen toxicity at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml",oxygen,oxygen toxicity
502244395,7/11/2014 10:54:09,,1320662790,7/11/2014 10:53:20,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,148,69,,,182,83,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,CYCLOSPORINE A,4 with FOCAL SEGMENTAL GLOMERULOSCLEROSIS,141-143-148-154-164,0-9-18-23-31-41-51-60-69-82,Eighteen children with steroid resistant nephrotic syndrome received CYCLOSPORINE A,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity.",148 154 164,69 82,148,69,182,83,1,RO-may_treat,908111,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity",focal segmental glomerulosclerosis,cyclosporine A
502244395,7/11/2014 10:55:13,,1320663170,7/11/2014 10:54:51,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,148,69,,,182,83,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,CYCLOSPORINE A,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,148-154-164,69-82,CYCLOSPORINE A,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity.",148 154 164,69 82,148,69,182,83,1,RO-may_treat,908111,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity",focal segmental glomerulosclerosis,cyclosporine A
502244395,7/11/2014 10:56:23,,1320663567,7/11/2014 10:56:18,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,148,69,,,182,83,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,CYCLOSPORINE A,"disease, 4 with FOCAL SEGMENTAL GLOMERULOSCLEROSIS and 7 with",132-141-143-148-154-164-183-187-189,41-51-60-69-82-91-101,nephrotic syndrome received CYCLOSPORINE A including 7,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity.",148 154 164,69 82,148,69,182,83,1,RO-may_treat,908111,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity",focal segmental glomerulosclerosis,cyclosporine A
502244395,7/11/2014 11:09:18,,1320669113,7/11/2014 11:08:52,instagc,1,23149109,USA,NC,Durham,75.189.206.205,148,69,,,182,83,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,CYCLOSPORINE A,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,148-154-164,69-82,CYCLOSPORINE A,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity.",148 154 164,69 82,148,69,182,83,1,RO-may_treat,908111,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity",focal segmental glomerulosclerosis,cyclosporine A
502244395,7/11/2014 11:14:46,,1320672848,7/11/2014 11:14:26,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,148,69,,,182,83,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,CYCLOSPORINE A,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,148-154-164,41-51-69-82,nephrotic syndrome CYCLOSPORINE A,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity.",148 154 164,69 82,148,69,182,83,1,RO-may_treat,908111,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity",focal segmental glomerulosclerosis,cyclosporine A
502244395,7/11/2014 11:24:58,,1320677097,7/11/2014 11:24:45,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,148,69,,,182,83,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,CYCLOSPORINE A,"disease, 4 with FOCAL SEGMENTAL GLOMERULOSCLEROSIS",132-141-143-148-154-164,69-82,CYCLOSPORINE A,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity.",148 154 164,69 82,148,69,182,83,1,RO-may_treat,908111,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity",focal segmental glomerulosclerosis,cyclosporine A
502244395,7/11/2014 11:26:07,,1320677546,7/11/2014 11:25:43,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,148,69,,,182,83,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,CYCLOSPORINE A,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,148-154-164,69-82,CYCLOSPORINE A,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity.",148 154 164,69 82,148,69,182,83,1,RO-may_treat,908111,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity",focal segmental glomerulosclerosis,cyclosporine A
502244395,7/11/2014 11:31:34,,1320679599,7/11/2014 11:30:37,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,148,69,,,182,83,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,CYCLOSPORINE A,"minimal change disease, 4 with FOCAL SEGMENTAL GLOMERULOSCLEROSIS and 7 with mesangial hypercellurarity.",117-125-132-141-143-148-154-164-183-187-189-194-204,9-18-23-31-41-51-60-69-82-84,"children with steroid resistant nephrotic syndrome received CYCLOSPORINE A (CsA),","Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity.",148 154 164,69 82,148,69,182,83,1,RO-may_treat,908111,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity",focal segmental glomerulosclerosis,cyclosporine A
502244395,7/11/2014 11:42:55,,1320683159,7/11/2014 11:42:35,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,148,69,,,182,83,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,CYCLOSPORINE A,FOCAL SEGMENTAL GLOMERULOSCLEROSIS 7,148-154-164-187,41-51-69-82,nephrotic syndrome CYCLOSPORINE A,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity.",148 154 164,69 82,148,69,182,83,1,RO-may_treat,908111,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity",focal segmental glomerulosclerosis,cyclosporine A
502244395,7/11/2014 11:43:16,,1320683276,7/11/2014 11:43:10,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,148,69,,,182,83,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,CYCLOSPORINE A,"disease, 4 with FOCAL SEGMENTAL GLOMERULOSCLEROSIS and 7 with",132-141-143-148-154-164-183-187-189,41-51-60-69-82-91-101,nephrotic syndrome received CYCLOSPORINE A including 7,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity.",148 154 164,69 82,148,69,182,83,1,RO-may_treat,908111,"Eighteen children with steroid-resistant nephrotic syndrome received cyclosporine A (CsA), including 7 patients with minimal change disease, 4 with focal segmental glomerulosclerosis and 7 with mesangial hypercellurarity",focal segmental glomerulosclerosis,cyclosporine A
502244396,7/11/2014 10:57:12,,1320663802,7/11/2014 10:57:09,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,136,125,,,151,131,TRAUMATIC SHOCK,TRAUMA,mechanical trauma and TRAUMATIC SHOCK at the prehospital,114-125-132-136-146-152-155-159,102-107-114-125-132-136-146,with severe mechanical TRAUMA and traumatic shock,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage.,136 146,125,136,125,151,131,1,RO-cause_of,900388,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage,traumatic shock,trauma
502244396,7/11/2014 11:06:01,,1320667770,7/11/2014 11:05:25,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,136,125,,,151,131,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,136-146,125,TRAUMA,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage.,136 146,125,136,125,151,131,1,RO-cause_of,900388,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage,traumatic shock,trauma
502244396,7/11/2014 11:10:12,,1320669718,7/11/2014 11:09:55,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,136,125,,,151,131,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,136-146,114-125,mechanical TRAUMA,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage.,136 146,125,136,125,151,131,1,RO-cause_of,900388,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage,traumatic shock,trauma
502244396,7/11/2014 11:12:08,,1320671073,7/11/2014 11:11:41,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,136,125,,,151,131,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,136-146,107-114-125,severe mechanical TRAUMA,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage.,136 146,125,136,125,151,131,1,RO-cause_of,900388,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage,traumatic shock,trauma
502244396,7/11/2014 11:13:24,,1320672018,7/11/2014 11:13:05,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,136,125,,,151,131,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,136-146,114-125-107,severe mechanical TRAUMA,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage.,136 146,125,136,125,151,131,1,RO-cause_of,900388,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage,traumatic shock,trauma
502244396,7/11/2014 11:13:53,,1320672398,7/11/2014 11:13:27,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,136,125,,,151,131,TRAUMATIC SHOCK,TRAUMA,mechanical trauma and TRAUMATIC SHOCK,114-125-132-136-146,114-125-136-146-132,mechanical TRAUMA and traumatic shock,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage.,136 146,125,136,125,151,131,1,RO-cause_of,900388,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage,traumatic shock,trauma
502244396,7/11/2014 11:24:30,,1320676875,7/11/2014 11:24:15,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,136,125,,,151,131,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,136-146,125,TRAUMA,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage.,136 146,125,136,125,151,131,1,RO-cause_of,900388,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage,traumatic shock,trauma
502244396,7/11/2014 11:30:01,,1320679040,7/11/2014 11:29:47,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,136,125,,,151,131,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,136-146,125,TRAUMA,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage.,136 146,125,136,125,151,131,1,RO-cause_of,900388,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage,traumatic shock,trauma
502244396,7/11/2014 11:31:21,,1320679536,7/11/2014 11:30:58,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,136,125,,,151,131,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,136-146,125,TRAUMA,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage.,136 146,125,136,125,151,131,1,RO-cause_of,900388,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage,traumatic shock,trauma
502244396,7/11/2014 11:41:49,,1320682847,7/11/2014 11:41:19,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,136,125,,,151,131,TRAUMATIC SHOCK,TRAUMA,mechanical trauma and TRAUMATIC SHOCK at the prehospital,114-125-132-136-146-152-155-159,102-107-114-125-132-136-146,with severe mechanical TRAUMA and traumatic shock,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage.,136 146,125,136,125,151,131,1,RO-cause_of,900388,The article presents the first experience with the use of steroid anesthetic drug Ketalar in patients with severe mechanical trauma and traumatic shock at the prehospital stage,traumatic shock,trauma
502244397,7/11/2014 10:51:31,,1320662127,7/11/2014 10:51:26,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,53,23,,,65,31,HEPATOMEGALY,HEPATOMA,had evidence of HEPATOMEGALY.,37-41-50-53,3-9-18-23-33-37-41,"those patients with HEPATOMA, 56% had evidence","Of those patients with hepatoma, 56% had evidence of hepatomegaly.",53,23,53,23,65,31,1,RO-disease_may_have_finding,902609,"Of those patients with hepatoma, 56% had evidence of hepatomegaly",hepatomegaly,hepatoma
502244397,7/11/2014 10:55:37,,1320663310,7/11/2014 10:55:17,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,53,23,,,65,31,HEPATOMEGALY,HEPATOMA,"hepatoma, HEPATOMEGALY.",53-23,23-53,"HEPATOMA, hepatomegaly.","Of those patients with hepatoma, 56% had evidence of hepatomegaly.",53,23,53,23,65,31,1,RO-disease_may_have_finding,902609,"Of those patients with hepatoma, 56% had evidence of hepatomegaly",hepatomegaly,hepatoma
502244397,7/11/2014 10:56:33,,1320663594,7/11/2014 10:56:24,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,53,23,,,65,31,HEPATOMEGALY,HEPATOMA,HEPATOMEGALY.,53,23,"HEPATOMA,","Of those patients with hepatoma, 56% had evidence of hepatomegaly.",53,23,53,23,65,31,1,RO-disease_may_have_finding,902609,"Of those patients with hepatoma, 56% had evidence of hepatomegaly",hepatomegaly,hepatoma
502244397,7/11/2014 11:10:25,,1320669871,7/11/2014 11:10:14,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,53,23,,,65,31,HEPATOMEGALY,HEPATOMA,HEPATOMEGALY.,53,23,"HEPATOMA,","Of those patients with hepatoma, 56% had evidence of hepatomegaly.",53,23,53,23,65,31,1,RO-disease_may_have_finding,902609,"Of those patients with hepatoma, 56% had evidence of hepatomegaly",hepatomegaly,hepatoma
502244397,7/11/2014 11:10:38,,1320669979,7/11/2014 11:10:22,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,53,23,,,65,31,HEPATOMEGALY,HEPATOMA,HEPATOMEGALY.,53,23,"HEPATOMA,","Of those patients with hepatoma, 56% had evidence of hepatomegaly.",53,23,53,23,65,31,1,RO-disease_may_have_finding,902609,"Of those patients with hepatoma, 56% had evidence of hepatomegaly",hepatomegaly,hepatoma
502244397,7/11/2014 11:11:03,,1320670293,7/11/2014 11:10:47,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,53,23,,,65,31,HEPATOMEGALY,HEPATOMA,HEPATOMEGALY.,53,23,"HEPATOMA,","Of those patients with hepatoma, 56% had evidence of hepatomegaly.",53,23,53,23,65,31,1,RO-disease_may_have_finding,902609,"Of those patients with hepatoma, 56% had evidence of hepatomegaly",hepatomegaly,hepatoma
502244397,7/11/2014 11:13:04,,1320671817,7/11/2014 11:12:50,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,53,23,,,65,31,HEPATOMEGALY,HEPATOMA,HEPATOMEGALY.,53,23,"HEPATOMA,","Of those patients with hepatoma, 56% had evidence of hepatomegaly.",53,23,53,23,65,31,1,RO-disease_may_have_finding,902609,"Of those patients with hepatoma, 56% had evidence of hepatomegaly",hepatomegaly,hepatoma
502244397,7/11/2014 11:20:32,,1320675333,7/11/2014 11:17:21,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,53,23,,,65,31,HEPATOMEGALY,HEPATOMA,"patients with hepatoma, 56% had evidence of HEPATOMEGALY.",9-18-23-37-41-50-53-33,9-18-23-33-37-41-50-53,"patients with HEPATOMA, 56% had evidence of hepatomegaly.","Of those patients with hepatoma, 56% had evidence of hepatomegaly.",53,23,53,23,65,31,1,RO-disease_may_have_finding,902609,"Of those patients with hepatoma, 56% had evidence of hepatomegaly",hepatomegaly,hepatoma
502244397,7/11/2014 11:30:59,,1320679386,7/11/2014 11:30:46,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,53,23,,,65,31,HEPATOMEGALY,HEPATOMA,HEPATOMEGALY.,53,23,"HEPATOMA,","Of those patients with hepatoma, 56% had evidence of hepatomegaly.",53,23,53,23,65,31,1,RO-disease_may_have_finding,902609,"Of those patients with hepatoma, 56% had evidence of hepatomegaly",hepatomegaly,hepatoma
502244397,7/11/2014 11:34:04,,1320680545,7/11/2014 11:33:46,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,53,23,,,65,31,HEPATOMEGALY,HEPATOMA,had evidence of HEPATOMEGALY.,37-41-50-53,3-9-18-23-33-37-41,"those patients with HEPATOMA, 56% had evidence","Of those patients with hepatoma, 56% had evidence of hepatomegaly.",53,23,53,23,65,31,1,RO-disease_may_have_finding,902609,"Of those patients with hepatoma, 56% had evidence of hepatomegaly",hepatomegaly,hepatoma
502244398,7/11/2014 10:57:16,,1320663842,7/11/2014 10:57:14,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,176,205,,,193,231,SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS,"nine of 18 SEVERE DYSPLASIAS, six of 12",165-170-173-176-183-195-199-202,195-199-202-205-221-233-237-242,"six of 12 INTRAEPITHELIAL CARCINOMAS, and nine of","In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas.",176 183,205 221,176,205,193,231,-1,RO-disease_has_finding,901919,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas",severe dysplasias,intraepithelial carcinomas
502244398,7/11/2014 11:01:10,,1320665333,7/11/2014 11:00:41,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,176,205,,,193,231,SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS,"SEVERE DYSPLASIAS,",176-183,205-221,"INTRAEPITHELIAL CARCINOMAS,","In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas.",176 183,205 221,176,205,193,231,-1,RO-disease_has_finding,901919,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas",severe dysplasias,intraepithelial carcinomas
502244398,7/11/2014 11:06:30,,1320667922,7/11/2014 11:06:05,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,176,205,,,193,231,SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS,"SEVERE DYSPLASIAS,",176-183,205-221,"INTRAEPITHELIAL CARCINOMAS,","In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas.",176 183,205 221,176,205,193,231,-1,RO-disease_has_finding,901919,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas",severe dysplasias,intraepithelial carcinomas
502244398,7/11/2014 11:09:15,,1320669093,7/11/2014 11:08:54,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,176,205,,,193,231,SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS,"SEVERE DYSPLASIAS,",176-183,205-221,"INTRAEPITHELIAL CARCINOMAS,","In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas.",176 183,205 221,176,205,193,231,-1,RO-disease_has_finding,901919,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas",severe dysplasias,intraepithelial carcinomas
502244398,7/11/2014 11:10:05,,1320669617,7/11/2014 11:09:52,instagc,1,23149109,USA,NC,Durham,75.189.206.205,176,205,,,193,231,SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS,"SEVERE DYSPLASIAS,",176-183,205-221,"INTRAEPITHELIAL CARCINOMAS,","In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas.",176 183,205 221,176,205,193,231,-1,RO-disease_has_finding,901919,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas",severe dysplasias,intraepithelial carcinomas
502244398,7/11/2014 11:11:55,,1320670920,7/11/2014 11:11:37,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,176,205,,,193,231,SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS,"SEVERE DYSPLASIAS,",176-183,205-221,"INTRAEPITHELIAL CARCINOMAS,","In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas.",176 183,205 221,176,205,193,231,-1,RO-disease_has_finding,901919,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas",severe dysplasias,intraepithelial carcinomas
502244398,7/11/2014 11:30:57,,1320679372,7/11/2014 11:30:38,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,176,205,,,193,231,SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS,"SEVERE DYSPLASIAS,",176-183,205-221,"INTRAEPITHELIAL CARCINOMAS,","In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas.",176 183,205 221,176,205,193,231,-1,RO-disease_has_finding,901919,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas",severe dysplasias,intraepithelial carcinomas
502244398,7/11/2014 11:33:32,,1320680351,7/11/2014 11:32:30,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,176,205,,,193,231,SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS,"SEVERE DYSPLASIAS, of intraepithelial carcinomas, and advanced carcinomas.",176-183-199-205-221-233-248-257,205-221-233-248-257,"INTRAEPITHELIAL CARCINOMAS, and advanced carcinomas.","In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas.",176 183,205 221,176,205,193,231,-1,RO-disease_has_finding,901919,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas",severe dysplasias,intraepithelial carcinomas
502244398,7/11/2014 11:41:05,,1320682657,7/11/2014 11:40:43,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,176,205,,,193,231,SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS,"moderate dysplasias, SEVERE DYSPLASIAS,",144-176-183-153,205-221-248-257,"INTRAEPITHELIAL CARCINOMAS, advanced carcinomas.","In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas.",176 183,205 221,176,205,193,231,-1,RO-disease_has_finding,901919,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas",severe dysplasias,intraepithelial carcinomas
502244398,7/11/2014 11:45:20,,1320684196,7/11/2014 11:44:57,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,176,205,,,193,231,SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS,"SEVERE DYSPLASIAS,",176-183,205-221,"INTRAEPITHELIAL CARCINOMAS,","In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas.",176 183,205 221,176,205,193,231,-1,RO-disease_has_finding,901919,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 severe dysplasias, six of 12 intraepithelial carcinomas, and nine of 22 advanced carcinomas",severe dysplasias,intraepithelial carcinomas
502244399,7/11/2014 10:52:38,,1320662425,7/11/2014 10:52:35,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,101,126,,,113,142,HYPERTENSION,PHEOCHROMOCYTOMA,Secondary causes of HYPERTENSION pheochromocytoma and,81-91-98-101-126-143,98-101-114-126-143-147-153,of hypertension (especially PHEOCHROMOCYTOMA and renal disease),"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome.",101,126,101,126,113,142,1,RO-disease_may_have_finding,902998,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome",hypertension,pheochromocytoma
502244399,7/11/2014 10:59:32,,1320664656,7/11/2014 10:58:46,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,101,126,,,113,142,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,101,126-143-147-153,PHEOCHROMOCYTOMA and renal disease),"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome.",101,126,101,126,113,142,1,RO-disease_may_have_finding,902998,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome",hypertension,pheochromocytoma
502244399,7/11/2014 11:04:13,,1320666957,7/11/2014 11:03:25,instagc,1,23149109,USA,NC,Durham,75.189.206.205,101,126,,,113,142,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,101,126,PHEOCHROMOCYTOMA,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome.",101,126,101,126,113,142,1,RO-disease_may_have_finding,902998,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome",hypertension,pheochromocytoma
502244399,7/11/2014 11:11:06,,1320670377,7/11/2014 11:10:44,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,101,126,,,113,142,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,101,126,PHEOCHROMOCYTOMA,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome.",101,126,101,126,113,142,1,RO-disease_may_have_finding,902998,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome",hypertension,pheochromocytoma
502244399,7/11/2014 11:11:22,,1320670606,7/11/2014 11:11:05,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,101,126,,,113,142,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,101,126,PHEOCHROMOCYTOMA,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome.",101,126,101,126,113,142,1,RO-disease_may_have_finding,902998,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome",hypertension,pheochromocytoma
502244399,7/11/2014 11:23:16,,1320676449,7/11/2014 11:22:45,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,101,126,,,113,142,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION pheochromocytoma,101-126,101-126-147-153,hypertension PHEOCHROMOCYTOMA renal disease),"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome.",101,126,101,126,113,142,1,RO-disease_may_have_finding,902998,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome",hypertension,pheochromocytoma
502244399,7/11/2014 11:38:45,,1320681966,7/11/2014 11:38:26,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,101,126,,,113,142,HYPERTENSION,PHEOCHROMOCYTOMA,Secondary causes of HYPERTENSION pheochromocytoma,81-91-98-101-126,98-101-114-126-143-147-153,of hypertension (especially PHEOCHROMOCYTOMA and renal disease),"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome.",101,126,101,126,113,142,1,RO-disease_may_have_finding,902998,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome",hypertension,pheochromocytoma
502244399,7/11/2014 11:46:16,,1320684637,7/11/2014 11:45:50,prodege,1,27969454,USA,,,69.76.133.211,101,126,,,113,142,HYPERTENSION,PHEOCHROMOCYTOMA,Secondary causes of HYPERTENSION (especially pheochromocytoma and renal disease),81-91-98-101-126-143-147-153-114,91-98-101-114-126-143-147-153-81,Secondary causes of hypertension (especially PHEOCHROMOCYTOMA and renal disease),"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome.",101,126,101,126,113,142,1,RO-disease_may_have_finding,902998,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome",hypertension,pheochromocytoma
502244399,7/11/2014 11:47:09,,1320685099,7/11/2014 11:46:38,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,101,126,,,113,142,HYPERTENSION,PHEOCHROMOCYTOMA,"secondary hypertension, Secondary causes of HYPERTENSION pheochromocytoma and",11-81-91-98-101-126-143-21,98-101-114-126-143-147-153-169-182-190-218-225-235-244,of hypertension (especially PHEOCHROMOCYTOMA and renal disease) increase risk preeclampsia direct effect maternal outcome.,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome.",101,126,101,126,113,142,1,RO-disease_may_have_finding,902998,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome",hypertension,pheochromocytoma
502244399,7/11/2014 11:50:16,,1320686181,7/11/2014 11:49:49,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.197,101,126,,,113,142,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,101,126,PHEOCHROMOCYTOMA,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome.",101,126,101,126,113,142,1,RO-disease_may_have_finding,902998,"? Consider secondary hypertension, particularly if the patient is   Rationale: ? Secondary causes of hypertension (especially pheochromocytoma and renal disease) likely increase the risk of preeclampsia and may have a direct effect on maternal outcome",hypertension,pheochromocytoma
502244400,7/11/2014 10:52:46,,1320662462,7/11/2014 10:52:43,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,12,29,,,24,48,HYPERTENSION,HYPERTENSIVE CRISIS,333 Severe HYPERTENSION and Hypertensive Crisis,0-5-12-25-29-42,5-12-25-29-42-60-63-74,Severe Hypertension and HYPERTENSIVE CRISIS IV Injection Children,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection.,12,29 42,12,29,24,48,-1,RO-disease_has_finding,901988,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection,Hypertension,Hypertensive Crisis
502244400,7/11/2014 10:59:26,,1320664624,7/11/2014 10:59:15,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,12,29,,,24,48,HYPERTENSION,HYPERTENSIVE CRISIS,Severe HYPERTENSION,5-12,29-42,HYPERTENSIVE CRISIS,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection.,12,29 42,12,29,24,48,-1,RO-disease_has_finding,901988,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection,Hypertension,Hypertensive Crisis
502244400,7/11/2014 11:00:46,,1320665143,7/11/2014 11:00:19,clixsense,1,23138831,NLD,,,77.174.95.58,12,29,,,24,48,HYPERTENSION,HYPERTENSIVE CRISIS,333 Severe HYPERTENSION and Hypertensive Crisis,0-5-12-25-29-42,0-5-12-25-29-42,333 Severe Hypertension and HYPERTENSIVE CRISIS,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection.,12,29 42,12,29,24,48,-1,RO-disease_has_finding,901988,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection,Hypertension,Hypertensive Crisis
502244400,7/11/2014 11:03:27,,1320666598,7/11/2014 11:03:11,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,12,29,,,24,48,HYPERTENSION,HYPERTENSIVE CRISIS,HYPERTENSION and Hypertensive Crisis,12-25-29-42,5-12-25-29-42,Severe Hypertension and HYPERTENSIVE CRISIS,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection.,12,29 42,12,29,24,48,-1,RO-disease_has_finding,901988,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection,Hypertension,Hypertensive Crisis
502244400,7/11/2014 11:13:16,,1320671934,7/11/2014 11:13:02,instagc,1,23149109,USA,NC,Durham,75.189.206.205,12,29,,,24,48,HYPERTENSION,HYPERTENSIVE CRISIS,HYPERTENSION,12,29-42,HYPERTENSIVE CRISIS,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection.,12,29 42,12,29,24,48,-1,RO-disease_has_finding,901988,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection,Hypertension,Hypertensive Crisis
502244400,7/11/2014 11:26:44,,1320677748,7/11/2014 11:26:29,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,12,29,,,24,48,HYPERTENSION,HYPERTENSIVE CRISIS,HYPERTENSION,12,29-42,HYPERTENSIVE CRISIS,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection.,12,29 42,12,29,24,48,-1,RO-disease_has_finding,901988,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection,Hypertension,Hypertensive Crisis
502244400,7/11/2014 11:28:01,,1320678250,7/11/2014 11:27:37,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,12,29,,,24,48,HYPERTENSION,HYPERTENSIVE CRISIS,HYPERTENSION,12,29-42,HYPERTENSIVE CRISIS,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection.,12,29 42,12,29,24,48,-1,RO-disease_has_finding,901988,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection,Hypertension,Hypertensive Crisis
502244400,7/11/2014 11:33:36,,1320680398,7/11/2014 11:32:55,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,12,29,,,24,48,HYPERTENSION,HYPERTENSIVE CRISIS,333 Severe HYPERTENSION and Hypertensive Crisis,0-5-12-25-29-42,5-12-25-29-42-60-63-74,Severe Hypertension and HYPERTENSIVE CRISIS IV Injection Children,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection.,12,29 42,12,29,24,48,-1,RO-disease_has_finding,901988,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection,Hypertension,Hypertensive Crisis
502244400,7/11/2014 11:41:31,,1320682771,7/11/2014 11:40:57,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,12,29,,,24,48,HYPERTENSION,HYPERTENSIVE CRISIS,333 Severe HYPERTENSION and Hypertensive Crisis IV Injection,0-5-12-25-29-42-60-63,5-12-25-29-42-60-63-74-102-106-108-111-114-117-120-131-134-137-141,Severe Hypertension and HYPERTENSIVE CRISIS IV Injection Children 0.2 1 mg kg up to maximum 40 mg per dose,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection.,12,29 42,12,29,24,48,-1,RO-disease_has_finding,901988,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection,Hypertension,Hypertensive Crisis
502244400,7/11/2014 11:42:33,,1320683062,7/11/2014 11:42:19,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,12,29,,,24,48,HYPERTENSION,HYPERTENSIVE CRISIS,Severe HYPERTENSION Hypertensive Crisis,5-12-29-42,5-12-29-42,Severe Hypertension HYPERTENSIVE CRISIS,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection.,12,29 42,12,29,24,48,-1,RO-disease_has_finding,901988,333  Severe Hypertension and Hypertensive Crisis   +  &gt;     IV Injection  Children 1-17 years of age: 0.2-1 mg/kg up to maximum of 40 mg per dose by direct IV injection,Hypertension,Hypertensive Crisis
502244401,7/11/2014 10:50:30,,1320661848,7/11/2014 10:50:26,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,48,77,,,73,89,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,cedar asthma demonstrated BRONCHIAL HYPERREACTIVITY to methacholine to,22-28-35-48-58-74-77-90,48-58-74-77-90-93-97,bronchial hyperreactivity to METHACHOLINE to the same,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma.,48 58,77,48,77,73,89,1,RO-may_diagnose,906850,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma,bronchial hyperreactivity,methacholine
502244401,7/11/2014 10:54:36,,1320662968,7/11/2014 10:53:54,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,48,77,,,73,89,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,cedar asthma BRONCHIAL HYPERREACTIVITY,22-48-58-28,22-28-48-58-77,cedar asthma bronchial hyperreactivity METHACHOLINE,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma.,48 58,77,48,77,73,89,1,RO-may_diagnose,906850,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma,bronchial hyperreactivity,methacholine
502244401,7/11/2014 10:58:32,,1320664312,7/11/2014 10:58:21,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,48,77,,,73,89,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,48-58,77,METHACHOLINE,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma.,48 58,77,48,77,73,89,1,RO-may_diagnose,906850,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma,bronchial hyperreactivity,methacholine
502244401,7/11/2014 11:05:19,,1320667460,7/11/2014 11:04:58,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,48,77,,,73,89,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,48-58,48-58-74-77,bronchial hyperreactivity to METHACHOLINE,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma.,48 58,77,48,77,73,89,1,RO-may_diagnose,906850,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma,bronchial hyperreactivity,methacholine
502244401,7/11/2014 11:09:26,,1320669167,7/11/2014 11:09:04,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,48,77,,,73,89,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,48-58,77,METHACHOLINE,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma.,48 58,77,48,77,73,89,1,RO-may_diagnose,906850,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma,bronchial hyperreactivity,methacholine
502244401,7/11/2014 11:13:01,,1320671780,7/11/2014 11:12:10,instagc,1,23149109,USA,NC,Durham,75.189.206.205,48,77,,,73,89,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,48-58,77,METHACHOLINE,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma.,48 58,77,48,77,73,89,1,RO-may_diagnose,906850,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma,bronchial hyperreactivity,methacholine
502244401,7/11/2014 11:15:28,,1320673160,7/11/2014 11:14:51,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,48,77,,,73,89,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,48-58,77,METHACHOLINE,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma.,48 58,77,48,77,73,89,1,RO-may_diagnose,906850,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma,bronchial hyperreactivity,methacholine
502244401,7/11/2014 11:26:52,,1320677781,7/11/2014 11:26:34,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,48,77,,,73,89,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,48-58,77,METHACHOLINE,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma.,48 58,77,48,77,73,89,1,RO-may_diagnose,906850,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma,bronchial hyperreactivity,methacholine
502244401,7/11/2014 11:45:05,,1320684054,7/11/2014 11:44:51,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,48,77,,,73,89,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,red cedar asthma demonstrated BRONCHIAL HYPERREACTIVITY,18-22-28-35-48-58,48-58-74-77-126-142,bronchial hyperreactivity to METHACHOLINE nonoccupational asthma.,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma.,48 58,77,48,77,73,89,1,RO-may_diagnose,906850,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma,bronchial hyperreactivity,methacholine
502244401,7/11/2014 11:46:20,,1320684659,7/11/2014 11:45:56,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,48,77,,,73,89,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,cedar asthma demonstrated BRONCHIAL HYPERREACTIVITY to methacholine to nonoccupational asthma.,22-28-35-48-58-74-77-90-126-142,18-22-28-48-58-74-77-90-93-97-126-142,red cedar asthma bronchial hyperreactivity to METHACHOLINE to the same nonoccupational asthma.,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma.,48 58,77,48,77,73,89,1,RO-may_diagnose,906850,All patients with red cedar asthma demonstrated bronchial hyperreactivity to methacholine to the same extent as patients with nonoccupational asthma,bronchial hyperreactivity,methacholine
502244402,7/11/2014 10:57:45,,1320664066,7/11/2014 10:57:19,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,106,98,,,121,102,RHEUMATIC FEVER,PART,RHEUMATIC FEVER.,106-116,98-103-106-116,PART of rheumatic fever.,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever.,106 116,98,106,98,121,102,-1,RO-cause_of,900430,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever,rheumatic fever,part
502244402,7/11/2014 11:03:59,,1320666854,7/11/2014 11:03:31,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,106,98,,,121,102,RHEUMATIC FEVER,PART,RHEUMATIC FEVER.,106-116,98-103-106-116,PART of rheumatic fever.,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever.,106 116,98,106,98,121,102,-1,RO-cause_of,900430,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever,rheumatic fever,part
502244402,7/11/2014 11:05:28,,1320667549,7/11/2014 11:05:04,instagc,1,23149109,USA,NC,Durham,75.189.206.205,106,98,,,121,102,RHEUMATIC FEVER,PART,RHEUMATIC FEVER.,106-116,98-103-106-116,PART of rheumatic fever.,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever.,106 116,98,106,98,121,102,-1,RO-cause_of,900430,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever,rheumatic fever,part
502244402,7/11/2014 11:10:07,,1320669623,7/11/2014 11:09:31,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,106,98,,,121,102,RHEUMATIC FEVER,PART,RHEUMATIC FEVER.,106-116,98-103-106-116,PART of rheumatic fever.,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever.,106 116,98,106,98,121,102,-1,RO-cause_of,900430,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever,rheumatic fever,part
502244402,7/11/2014 11:10:25,,1320669870,7/11/2014 11:09:48,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,106,98,,,121,102,RHEUMATIC FEVER,PART,RHEUMATIC FEVER.,106-116,98,PART,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever.,106 116,98,106,98,121,102,-1,RO-cause_of,900430,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever,rheumatic fever,part
502244402,7/11/2014 11:12:17,,1320671189,7/11/2014 11:12:04,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,106,98,,,121,102,RHEUMATIC FEVER,PART,RHEUMATIC FEVER.,106-116,98-103-106-116,PART of rheumatic fever.,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever.,106 116,98,106,98,121,102,-1,RO-cause_of,900430,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever,rheumatic fever,part
502244402,7/11/2014 11:22:43,,1320676201,7/11/2014 11:21:57,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,106,98,,,121,102,RHEUMATIC FEVER,PART,RHEUMATIC FEVER.,106-116,98-106-116,PART rheumatic fever.,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever.,106 116,98,106,98,121,102,-1,RO-cause_of,900430,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever,rheumatic fever,part
502244402,7/11/2014 11:25:37,,1320677355,7/11/2014 11:25:23,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,106,98,,,121,102,RHEUMATIC FEVER,PART,RHEUMATIC FEVER.,106-116,98-103-106-116,PART of rheumatic fever.,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever.,106 116,98,106,98,121,102,-1,RO-cause_of,900430,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever,rheumatic fever,part
502244402,7/11/2014 11:27:36,,1320678129,7/11/2014 11:27:16,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,106,98,,,121,102,RHEUMATIC FEVER,PART,RHEUMATIC FEVER.,106-116,98,PART,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever.,106 116,98,106,98,121,102,-1,RO-cause_of,900430,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever,rheumatic fever,part
502244402,7/11/2014 11:41:49,,1320682849,7/11/2014 11:41:37,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,106,98,,,121,102,RHEUMATIC FEVER,PART,RHEUMATIC FEVER.,106-116,98-106-116,PART rheumatic fever.,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever.,106 116,98,106,98,121,102,-1,RO-cause_of,900430,Poststreptococcal reactive arthritis (PSRA) has been described as a different entity as well as a part of rheumatic fever,rheumatic fever,part
502244403,7/11/2014 10:48:32,,1320661154,7/11/2014 10:48:18,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,0,44,,,19,52,VARIOLA MAJOR VIRUS,SMALLPOX,"VARIOLA MAJOR VIRUS,",0-8-14,44,"SMALLPOX,","Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase.",0 8 14,44,0,44,19,52,1,RO-has_causative_agent,903785,"Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase",Variola major virus,smallpox
502244403,7/11/2014 11:04:00,,1320666857,7/11/2014 11:03:11,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,0,44,,,19,52,VARIOLA MAJOR VIRUS,SMALLPOX,"VARIOLA MAJOR VIRUS,",0-8-14,44,"SMALLPOX,","Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase.",0 8 14,44,0,44,19,52,1,RO-has_causative_agent,903785,"Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase",Variola major virus,smallpox
502244403,7/11/2014 11:04:04,,1320666912,7/11/2014 11:03:50,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,0,44,,,19,52,VARIOLA MAJOR VIRUS,SMALLPOX,"VARIOLA MAJOR VIRUS,",0-8-14,44,"SMALLPOX,","Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase.",0 8 14,44,0,44,19,52,1,RO-has_causative_agent,903785,"Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase",Variola major virus,smallpox
502244403,7/11/2014 11:06:41,,1320667965,7/11/2014 11:06:27,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,0,44,,,19,52,VARIOLA MAJOR VIRUS,SMALLPOX,"VARIOLA MAJOR VIRUS,",0-8-14,44,"SMALLPOX,","Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase.",0 8 14,44,0,44,19,52,1,RO-has_causative_agent,903785,"Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase",Variola major virus,smallpox
502244403,7/11/2014 11:08:05,,1320668502,7/11/2014 11:07:47,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,0,44,,,19,52,VARIOLA MAJOR VIRUS,SMALLPOX,"VARIOLA MAJOR VIRUS,",0-8-14,44,"SMALLPOX,","Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase.",0 8 14,44,0,44,19,52,1,RO-has_causative_agent,903785,"Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase",Variola major virus,smallpox
502244403,7/11/2014 11:08:13,,1320668529,7/11/2014 11:07:54,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,0,44,,,19,52,VARIOLA MAJOR VIRUS,SMALLPOX,"VARIOLA MAJOR VIRUS,",0-8-14,44,"SMALLPOX,","Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase.",0 8 14,44,0,44,19,52,1,RO-has_causative_agent,903785,"Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase",Variola major virus,smallpox
502244403,7/11/2014 11:09:51,,1320669409,7/11/2014 11:09:31,instagc,1,23149109,USA,NC,Durham,75.189.206.205,0,44,,,19,52,VARIOLA MAJOR VIRUS,SMALLPOX,"VARIOLA MAJOR VIRUS,",0-8-14,44,"SMALLPOX,","Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase.",0 8 14,44,0,44,19,52,1,RO-has_causative_agent,903785,"Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase",Variola major virus,smallpox
502244403,7/11/2014 11:13:50,,1320672334,7/11/2014 11:13:25,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,0,44,,,19,52,VARIOLA MAJOR VIRUS,SMALLPOX,"VARIOLA MAJOR VIRUS,",0-8-14,44,"SMALLPOX,","Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase.",0 8 14,44,0,44,19,52,1,RO-has_causative_agent,903785,"Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase",Variola major virus,smallpox
502244403,7/11/2014 11:22:48,,1320676229,7/11/2014 11:22:39,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,0,44,,,19,52,VARIOLA MAJOR VIRUS,SMALLPOX,"VARIOLA MAJOR VIRUS,",0-8-14,44,"SMALLPOX,","Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase.",0 8 14,44,0,44,19,52,1,RO-has_causative_agent,903785,"Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase",Variola major virus,smallpox
502244403,7/11/2014 11:28:04,,1320678260,7/11/2014 11:27:50,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,0,44,,,19,52,VARIOLA MAJOR VIRUS,SMALLPOX,"VARIOLA MAJOR VIRUS,",0-8-14,44,"SMALLPOX,","Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase.",0 8 14,44,0,44,19,52,1,RO-has_causative_agent,903785,"Variola major virus, the causative agent of smallpox, encodes the dual-specificity H1 phosphatase",Variola major virus,smallpox
502244404,7/11/2014 11:05:21,,1320667463,7/11/2014 11:05:06,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,96,45,,,122,56,BILATERAL HILAR ADENOPATHY,SARCOIDOSIS,"BILATERAL HILAR ADENOPATHY,",96-106-112,45,SARCOIDOSIS,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with ""tumorous"" adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",96 106 112,45,96,45,122,56,-1,RO-has_manifestation,906106,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with &quot;tumorous&quot; adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs",bilateral hilar adenopathy,sarcoidosis
502244404,7/11/2014 11:08:37,,1320668753,7/11/2014 11:07:42,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,96,45,,,122,56,BILATERAL HILAR ADENOPATHY,SARCOIDOSIS,"BILATERAL HILAR ADENOPATHY,",96-106-112,45,SARCOIDOSIS,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with ""tumorous"" adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",96 106 112,45,96,45,122,56,-1,RO-has_manifestation,906106,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with &quot;tumorous&quot; adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs",bilateral hilar adenopathy,sarcoidosis
502244404,7/11/2014 11:11:49,,1320670889,7/11/2014 11:11:34,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,96,45,,,122,56,BILATERAL HILAR ADENOPATHY,SARCOIDOSIS,"BILATERAL HILAR ADENOPATHY,",96-106-112,28-37-42-45,thoracic form of SARCOIDOSIS,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with ""tumorous"" adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",96 106 112,45,96,45,122,56,-1,RO-has_manifestation,906106,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with &quot;tumorous&quot; adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs",bilateral hilar adenopathy,sarcoidosis
502244404,7/11/2014 11:12:52,,1320671634,7/11/2014 11:12:32,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,96,45,,,122,56,BILATERAL HILAR ADENOPATHY,SARCOIDOSIS,"BILATERAL HILAR ADENOPATHY,",96-106-112,28-37-42-45,thoracic form of SARCOIDOSIS,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with ""tumorous"" adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",96 106 112,45,96,45,122,56,-1,RO-has_manifestation,906106,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with &quot;tumorous&quot; adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs",bilateral hilar adenopathy,sarcoidosis
502244404,7/11/2014 11:26:33,,1320677701,7/11/2014 11:26:08,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,96,45,,,122,56,BILATERAL HILAR ADENOPATHY,SARCOIDOSIS,"BILATERAL HILAR ADENOPATHY,",96-106-112,45,SARCOIDOSIS,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with ""tumorous"" adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",96 106 112,45,96,45,122,56,-1,RO-has_manifestation,906106,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with &quot;tumorous&quot; adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs",bilateral hilar adenopathy,sarcoidosis
502244404,7/11/2014 11:36:38,,1320681349,7/11/2014 11:35:37,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,96,45,,,122,56,BILATERAL HILAR ADENOPATHY,SARCOIDOSIS,"6 cases mild BILATERAL HILAR ADENOPATHY,",83-85-91-96-106-112,28-37-42-45,thoracic form of SARCOIDOSIS,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with ""tumorous"" adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",96 106 112,45,96,45,122,56,-1,RO-has_manifestation,906106,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with &quot;tumorous&quot; adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs",bilateral hilar adenopathy,sarcoidosis
502244404,7/11/2014 11:40:41,,1320682583,7/11/2014 11:40:26,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,96,45,,,122,56,BILATERAL HILAR ADENOPATHY,SARCOIDOSIS,"BILATERAL HILAR ADENOPATHY,",96-106-112,45,SARCOIDOSIS,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with ""tumorous"" adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",96 106 112,45,96,45,122,56,-1,RO-has_manifestation,906106,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with &quot;tumorous&quot; adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs",bilateral hilar adenopathy,sarcoidosis
502244404,7/11/2014 11:41:18,,1320682724,7/11/2014 11:40:35,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,96,45,,,122,56,BILATERAL HILAR ADENOPATHY,SARCOIDOSIS,"6 cases mild BILATERAL HILAR ADENOPATHY,",83-85-91-96-106-112,28-37-42-45,thoracic form of SARCOIDOSIS,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with ""tumorous"" adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",96 106 112,45,96,45,122,56,-1,RO-has_manifestation,906106,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with &quot;tumorous&quot; adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs",bilateral hilar adenopathy,sarcoidosis
502244404,7/11/2014 11:50:02,,1320686061,7/11/2014 11:49:26,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,96,45,,,122,56,BILATERAL HILAR ADENOPATHY,SARCOIDOSIS,"thoracic form of sarcoidosis was in the foreground 6 cases mild BILATERAL HILAR ADENOPATHY, in 2 cases",28-37-42-45-57-61-64-83-85-91-96-106-112-124-127-129-68,28-37-42-45-57-61-64-68-79-83-85-91-96-106-112,"thoracic form of SARCOIDOSIS was in the foreground (in 6 cases mild bilateral hilar adenopathy,","In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with ""tumorous"" adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",96 106 112,45,96,45,122,56,-1,RO-has_manifestation,906106,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with &quot;tumorous&quot; adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs",bilateral hilar adenopathy,sarcoidosis
502244404,7/11/2014 11:50:53,,1320686517,7/11/2014 11:50:19,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,96,45,,,122,56,BILATERAL HILAR ADENOPATHY,SARCOIDOSIS,"mild BILATERAL HILAR ADENOPATHY,",91-96-106-112,28-37-42-45-24,the thoracic form of SARCOIDOSIS,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with ""tumorous"" adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",96 106 112,45,96,45,122,56,-1,RO-has_manifestation,906106,"In each of the patients the thoracic form of sarcoidosis was in the foreground (in 6 cases mild bilateral hilar adenopathy, in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL-syndrome sometimes with &quot;tumorous&quot; adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs",bilateral hilar adenopathy,sarcoidosis
502244405,7/11/2014 10:52:36,,1320662401,7/11/2014 10:52:19,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,87,4,,,91,28,SKIN,EPIDERMAL NEVUS SYNDROME,characterized by distinctive SKIN and often,58-72-75-87-100-104,0-4-14-20-29-32-34,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities.,87,4 14 20,87,4,91,28,1,RO-has_finding_site,905337,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities,skin,epidermal nevus syndrome
502244405,7/11/2014 11:06:53,,1320668037,7/11/2014 11:06:35,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,87,4,,,91,28,SKIN,EPIDERMAL NEVUS SYNDROME,distinctive SKIN lesions,75-87-92,4-14-20,EPIDERMAL NEVUS SYNDROME,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities.,87,4 14 20,87,4,91,28,1,RO-has_finding_site,905337,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities,skin,epidermal nevus syndrome
502244405,7/11/2014 11:07:02,,1320668083,7/11/2014 11:06:52,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,87,4,,,91,28,SKIN,EPIDERMAL NEVUS SYNDROME,SKIN,87,4-14-20,EPIDERMAL NEVUS SYNDROME,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities.,87,4 14 20,87,4,91,28,1,RO-has_finding_site,905337,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities,skin,epidermal nevus syndrome
502244405,7/11/2014 11:22:56,,1320676267,7/11/2014 11:22:23,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,87,4,,,91,28,SKIN,EPIDERMAL NEVUS SYNDROME,SKIN,87,4-14-20,EPIDERMAL NEVUS SYNDROME,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities.,87,4 14 20,87,4,91,28,1,RO-has_finding_site,905337,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities,skin,epidermal nevus syndrome
502244405,7/11/2014 11:25:09,,1320677182,7/11/2014 11:24:59,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,87,4,,,91,28,SKIN,EPIDERMAL NEVUS SYNDROME,SKIN lesions,87-92,4-14-20,EPIDERMAL NEVUS SYNDROME,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities.,87,4 14 20,87,4,91,28,1,RO-has_finding_site,905337,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities,skin,epidermal nevus syndrome
502244405,7/11/2014 11:30:16,,1320679138,7/11/2014 11:30:02,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,87,4,,,91,28,SKIN,EPIDERMAL NEVUS SYNDROME,SKIN,87,4-14-20,EPIDERMAL NEVUS SYNDROME,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities.,87,4 14 20,87,4,91,28,1,RO-has_finding_site,905337,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities,skin,epidermal nevus syndrome
502244405,7/11/2014 11:38:59,,1320682054,7/11/2014 11:38:47,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,87,4,,,91,28,SKIN,EPIDERMAL NEVUS SYNDROME,characterized by distinctive SKIN lesions and often abnormalities.,58-72-75-87-92-100-104-159,0-4-14-20-29-32-34-49,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities.,87,4 14 20,87,4,91,28,1,RO-has_finding_site,905337,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities,skin,epidermal nevus syndrome
502244405,7/11/2014 11:46:58,,1320685003,7/11/2014 11:46:46,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,87,4,,,91,28,SKIN,EPIDERMAL NEVUS SYNDROME,SKIN lesions,87-92,4-14-20,EPIDERMAL NEVUS SYNDROME,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities.,87,4 14 20,87,4,91,28,1,RO-has_finding_site,905337,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities,skin,epidermal nevus syndrome
502244405,7/11/2014 11:47:04,,1320685063,7/11/2014 11:46:33,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,87,4,,,91,28,SKIN,EPIDERMAL NEVUS SYNDROME,characterized by distinctive SKIN lesions,58-72-75-87-92,4-14-20-29-32-34-49,EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities.,87,4 14 20,87,4,91,28,1,RO-has_finding_site,905337,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities,skin,epidermal nevus syndrome
502244405,7/11/2014 11:48:27,,1320685590,7/11/2014 11:47:53,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,87,4,,,91,28,SKIN,EPIDERMAL NEVUS SYNDROME,epidermal nevus syndrome neurocutaneous disorder characterized by distinctive SKIN lesions and often,4-14-20-34-58-72-75-87-92-100-104-49,0-4-14-20-29-32-34-49-75-87-92-110-118-130-138-146-159,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder distinctive skin lesions serious somatic central nervous system abnormalities.,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities.,87,4 14 20,87,4,91,28,1,RO-has_finding_site,905337,The epidermal nevus syndrome is a neurocutaneous disorder characterized by distinctive skin lesions and often serious somatic and central nervous system (CNS) abnormalities,skin,epidermal nevus syndrome
502244406,7/11/2014 10:52:29,,1320662385,7/11/2014 10:52:26,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,119,36,,,123,57,LUNG,PULMONARY SARCOIDOSIS,sharing the pathological LUNG hallmark of the,94-102-106-119-124-133-136,18-26-32-36-46-58-62-66,disease (CBD) and PULMONARY SARCOIDOSIS are two distinct,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease.",119,36 46,119,36,123,57,1,RO-disease_has_primary_anatomic_site,902241,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease",lung,pulmonary sarcoidosis
502244406,7/11/2014 10:53:02,,1320662511,7/11/2014 10:52:51,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,119,36,,,123,57,LUNG,PULMONARY SARCOIDOSIS,sharing the pathological LUNG hallmark of the,94-102-106-119-124-133-136,18-32-36-46-58-62-66,disease and PULMONARY SARCOIDOSIS are two distinct,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease.",119,36 46,119,36,123,57,1,RO-disease_has_primary_anatomic_site,902241,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease",lung,pulmonary sarcoidosis
502244406,7/11/2014 10:58:14,,1320664191,7/11/2014 10:57:27,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,119,36,,,123,57,LUNG,PULMONARY SARCOIDOSIS,pathological LUNG hallmark,106-119-124,26-32-36-46,(CBD) and PULMONARY SARCOIDOSIS,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease.",119,36 46,119,36,123,57,1,RO-disease_has_primary_anatomic_site,902241,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease",lung,pulmonary sarcoidosis
502244406,7/11/2014 11:04:52,,1320667277,7/11/2014 11:04:41,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,119,36,,,123,57,LUNG,PULMONARY SARCOIDOSIS,LUNG,119,36-46,PULMONARY SARCOIDOSIS,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease.",119,36 46,119,36,123,57,1,RO-disease_has_primary_anatomic_site,902241,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease",lung,pulmonary sarcoidosis
502244406,7/11/2014 11:05:03,,1320667344,7/11/2014 11:04:00,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,119,36,,,123,57,LUNG,PULMONARY SARCOIDOSIS,pathological LUNG hallmark,106-119-124,36-46,PULMONARY SARCOIDOSIS,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease.",119,36 46,119,36,123,57,1,RO-disease_has_primary_anatomic_site,902241,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease",lung,pulmonary sarcoidosis
502244406,7/11/2014 11:10:14,,1320669752,7/11/2014 11:09:53,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,119,36,,,123,57,LUNG,PULMONARY SARCOIDOSIS,pathological LUNG hallmark,106-119-124,36-46,PULMONARY SARCOIDOSIS,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease.",119,36 46,119,36,123,57,1,RO-disease_has_primary_anatomic_site,902241,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease",lung,pulmonary sarcoidosis
502244406,7/11/2014 11:19:58,,1320675105,7/11/2014 11:19:37,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,119,36,,,123,57,LUNG,PULMONARY SARCOIDOSIS,pathological LUNG,106-119,36-46,PULMONARY SARCOIDOSIS,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease.",119,36 46,119,36,123,57,1,RO-disease_has_primary_anatomic_site,902241,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease",lung,pulmonary sarcoidosis
502244406,7/11/2014 11:26:10,,1320677581,7/11/2014 11:24:50,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,119,36,,,123,57,LUNG,PULMONARY SARCOIDOSIS,sharing the pathological LUNG hallmark of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.,94-102-106-119-124-133-136-140-144-154-164-168-172-186-194-197-199-204-215-218-222-227-230,0-8-18-26-32-36-46-58-62-66-75-83,"Chronic beryllium disease (CBD) and PULMONARY SARCOIDOSIS are two distinct chronic disorders,","Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease.",119,36 46,119,36,123,57,1,RO-disease_has_primary_anatomic_site,902241,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease",lung,pulmonary sarcoidosis
502244406,7/11/2014 11:39:14,,1320682142,7/11/2014 11:39:00,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,119,36,,,123,57,LUNG,PULMONARY SARCOIDOSIS,sharing the pathological LUNG hallmark of the granuloma,94-102-106-119-124-133-136-154,18-26-32-36-46-58-62-66-83,"disease (CBD) and PULMONARY SARCOIDOSIS are two distinct disorders,","Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease.",119,36 46,119,36,123,57,1,RO-disease_has_primary_anatomic_site,902241,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease",lung,pulmonary sarcoidosis
502244406,7/11/2014 11:40:08,,1320682401,7/11/2014 11:39:14,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,119,36,,,123,57,LUNG,PULMONARY SARCOIDOSIS,"Chronic beryllium disease pulmonary sarcoidosis two distinct chronic disorders, sharing the pathological LUNG hallmark of the",0-8-18-36-46-62-66-75-94-102-106-119-124-133-136-83,18-26-32-36-46-58-62-66-75-83-124-133-140-144-154-164-168-172-186-197-199-204,"disease (CBD) and PULMONARY SARCOIDOSIS are two distinct chronic disorders, hallmark of non caseating granuloma and the immunological feature T cell activation","Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease.",119,36 46,119,36,123,57,1,RO-disease_has_primary_anatomic_site,902241,"Chronic beryllium disease (CBD) and pulmonary sarcoidosis are two distinct chronic disorders, sharing the pathological lung hallmark of the non-caseating granuloma and the immunological feature of T cell activation at the site of disease",lung,pulmonary sarcoidosis
502244407,7/11/2014 10:49:02,,1320661367,7/11/2014 10:48:50,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,98,125,,,105,140,THYROID,THYROID ATROPHY,THYROID,98,125-133,THYROID ATROPHY,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism.,98,125 133,98,125,105,140,1,RO-has_finding_site,905186,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism,thyroid,thyroid atrophy
502244407,7/11/2014 11:05:05,,1320667363,7/11/2014 11:04:52,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,98,125,,,105,140,THYROID,THYROID ATROPHY,THYROID,98,125-133,THYROID ATROPHY,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism.,98,125 133,98,125,105,140,1,RO-has_finding_site,905186,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism,thyroid,thyroid atrophy
502244407,7/11/2014 11:06:35,,1320667940,7/11/2014 11:06:18,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,98,125,,,105,140,THYROID,THYROID ATROPHY,THYROID,98,125-133,THYROID ATROPHY,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism.,98,125 133,98,125,105,140,1,RO-has_finding_site,905186,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism,thyroid,thyroid atrophy
502244407,7/11/2014 11:07:47,,1320668341,7/11/2014 11:07:29,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,98,125,,,105,140,THYROID,THYROID ATROPHY,THYROID,98,125-133,THYROID ATROPHY,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism.,98,125 133,98,125,105,140,1,RO-has_finding_site,905186,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism,thyroid,thyroid atrophy
502244407,7/11/2014 11:12:30,,1320671348,7/11/2014 11:12:10,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,98,125,,,105,140,THYROID,THYROID ATROPHY,THYROID,98,125-133,THYROID ATROPHY,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism.,98,125 133,98,125,105,140,1,RO-has_finding_site,905186,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism,thyroid,thyroid atrophy
502244407,7/11/2014 11:22:38,,1320676165,7/11/2014 11:22:23,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,98,125,,,105,140,THYROID,THYROID ATROPHY,THYROID,98,125-133,THYROID ATROPHY,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism.,98,125 133,98,125,105,140,1,RO-has_finding_site,905186,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism,thyroid,thyroid atrophy
502244407,7/11/2014 11:43:03,,1320683196,7/11/2014 11:42:35,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,98,125,,,105,140,THYROID,THYROID ATROPHY,serum immunoglobulins (IgG) the growth of THYROID in the etiology thyroid atrophy endemic cretinism.,42-48-64-84-88-95-98-106-109-113-125-133-144-152,30-42-48-64-76-88-109-113-122-125-133-141-144-152-98,circulating serum immunoglobulins (IgG) inhibit growth thyroid the etiology of THYROID ATROPHY in endemic cretinism.,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism.,98,125 133,98,125,105,140,1,RO-has_finding_site,905186,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism,thyroid,thyroid atrophy
502244407,7/11/2014 11:48:36,,1320685632,7/11/2014 11:46:10,clixsense,1,27969116,NLD,,,91.213.37.165,98,125,,,105,140,THYROID,THYROID ATROPHY,THYROID etiology thyroid atrophy,98-113-125-133,125-133-144-152,THYROID ATROPHY endemic cretinism.,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism.,98,125 133,98,125,105,140,1,RO-has_finding_site,905186,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism,thyroid,thyroid atrophy
502244407,7/11/2014 11:48:38,,1320685641,7/11/2014 11:48:15,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,98,125,,,105,140,THYROID,THYROID ATROPHY,the growth of THYROID,84-88-95-98,109-113-122-125-133-141-144-152,the etiology of THYROID ATROPHY in endemic cretinism.,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism.,98,125 133,98,125,105,140,1,RO-has_finding_site,905186,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism,thyroid,thyroid atrophy
502244407,7/11/2014 11:48:47,,1320685679,7/11/2014 11:48:11,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,98,125,,,105,140,THYROID,THYROID ATROPHY,the growth of THYROID,84-88-95-98,125-133-141-144-152,THYROID ATROPHY in endemic cretinism.,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism.,98,125 133,98,125,105,140,1,RO-has_finding_site,905186,We have evaluated the role of circulating serum immunoglobulins (IgG) which inhibit the growth of thyroid in the etiology of thyroid atrophy in endemic cretinism,thyroid,thyroid atrophy
502244408,7/11/2014 10:50:15,,1320661756,7/11/2014 10:50:05,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,93,140,,,101,156,SEIZURES,PARTIAL SEIZURES,"decreasing occurrence): unilateral SEIZURES, complex partial seizures,",58-69-82-93-103-111-119,111-119-129-140-148-158-162-168,"partial seizures, elementary PARTIAL SEIZURES, and other seizures,","Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify.",93,140 148,93,140,101,156,-1,RO-has_definitional_manifestation,904723,"Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify",seizures,partial seizures
502244408,7/11/2014 10:57:08,,1320663782,7/11/2014 10:57:05,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,93,140,,,101,156,SEIZURES,PARTIAL SEIZURES,"decreasing occurrence): unilateral SEIZURES, complex partial seizures,",58-69-82-93-103-111-119,111-119-129-140-148-158-162-168,"partial seizures, elementary PARTIAL SEIZURES, and other seizures,","Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify.",93,140 148,93,140,101,156,-1,RO-has_definitional_manifestation,904723,"Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify",seizures,partial seizures
502244408,7/11/2014 10:57:59,,1320664120,7/11/2014 10:57:46,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,93,140,,,101,156,SEIZURES,PARTIAL SEIZURES,"unilateral SEIZURES,",82-93,129-140-148,"elementary PARTIAL SEIZURES,","Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify.",93,140 148,93,140,101,156,-1,RO-has_definitional_manifestation,904723,"Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify",seizures,partial seizures
502244408,7/11/2014 10:59:08,,1320664478,7/11/2014 10:57:49,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,93,140,,,101,156,SEIZURES,PARTIAL SEIZURES,"unilateral SEIZURES, complex partial seizures, elementary partial seizures,",82-93-103-111-119-129-140-148,103-111-119-129-140-148,"complex partial seizures, elementary PARTIAL SEIZURES,","Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify.",93,140 148,93,140,101,156,-1,RO-has_definitional_manifestation,904723,"Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify",seizures,partial seizures
502244408,7/11/2014 11:09:59,,1320669505,7/11/2014 11:09:47,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,93,140,,,101,156,SEIZURES,PARTIAL SEIZURES,"SEIZURES,",93,140-148-158,"PARTIAL SEIZURES, and","Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify.",93,140 148,93,140,101,156,-1,RO-has_definitional_manifestation,904723,"Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify",seizures,partial seizures
502244408,7/11/2014 11:11:43,,1320670784,7/11/2014 11:11:26,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,93,140,,,101,156,SEIZURES,PARTIAL SEIZURES,"unilateral SEIZURES,",82-93,129-140-148,"elementary PARTIAL SEIZURES,","Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify.",93,140 148,93,140,101,156,-1,RO-has_definitional_manifestation,904723,"Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify",seizures,partial seizures
502244408,7/11/2014 11:13:43,,1320672257,7/11/2014 11:13:24,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,93,140,,,101,156,SEIZURES,PARTIAL SEIZURES,"SEIZURES,",93,140-148,"PARTIAL SEIZURES,","Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify.",93,140 148,93,140,101,156,-1,RO-has_definitional_manifestation,904723,"Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify",seizures,partial seizures
502244408,7/11/2014 11:21:25,,1320675670,7/11/2014 11:21:05,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,93,140,,,101,156,SEIZURES,PARTIAL SEIZURES,"unilateral SEIZURES,",82-93,129-140-148,"elementary PARTIAL SEIZURES,","Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify.",93,140 148,93,140,101,156,-1,RO-has_definitional_manifestation,904723,"Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify",seizures,partial seizures
502244408,7/11/2014 11:41:36,,1320682784,7/11/2014 11:41:23,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,93,140,,,101,156,SEIZURES,PARTIAL SEIZURES,"unilateral SEIZURES, complex partial seizures,",82-93-103-111-119,111-119-129-140-148,"partial seizures, elementary PARTIAL SEIZURES,","Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify.",93,140 148,93,140,101,156,-1,RO-has_definitional_manifestation,904723,"Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify",seizures,partial seizures
502244408,7/11/2014 11:44:56,,1320683947,7/11/2014 11:44:17,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,93,140,,,101,156,SEIZURES,PARTIAL SEIZURES,"unilateral SEIZURES,",82-93,129-140-148,"elementary PARTIAL SEIZURES,","Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify.",93,140 148,93,140,101,156,-1,RO-has_definitional_manifestation,904723,"Seizures at onset were of the following type (in order of decreasing occurrence): unilateral seizures, complex partial seizures, elementary partial seizures, and other seizures, often difficult to classify",seizures,partial seizures
502244409,7/11/2014 10:56:04,,1320663452,7/11/2014 10:55:38,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,86,47,,,96,67,LEGIONELLA,LEGIONELLA INFECTION,Legionella infection LEGIONELLA.,47-86-58,47-58-86,LEGIONELLA INFECTION Legionella.,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella.",86,47 58,86,47,96,67,-1,RO-has_causative_agent,903796,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella",Legionella,Legionella infection
502244409,7/11/2014 10:59:36,,1320664694,7/11/2014 10:59:27,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,86,47,,,96,67,LEGIONELLA,LEGIONELLA INFECTION,LEGIONELLA.,86,47-58,LEGIONELLA INFECTION,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella.",86,47 58,86,47,96,67,-1,RO-has_causative_agent,903796,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella",Legionella,Legionella infection
502244409,7/11/2014 11:00:50,,1320665169,7/11/2014 10:59:32,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,86,47,,,96,67,LEGIONELLA,LEGIONELLA INFECTION,LEGIONELLA.,86,47-58,LEGIONELLA INFECTION,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella.",86,47 58,86,47,96,67,-1,RO-has_causative_agent,903796,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella",Legionella,Legionella infection
502244409,7/11/2014 11:03:19,,1320666573,7/11/2014 11:02:55,clixsense,1,23138831,NLD,,,77.174.95.58,86,47,,,96,67,LEGIONELLA,LEGIONELLA INFECTION,LEGIONELLA.,86,47-58,LEGIONELLA INFECTION,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella.",86,47 58,86,47,96,67,-1,RO-has_causative_agent,903796,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella",Legionella,Legionella infection
502244409,7/11/2014 11:08:07,,1320668517,7/11/2014 11:07:56,instagc,1,23149109,USA,NC,Durham,75.189.206.205,86,47,,,96,67,LEGIONELLA,LEGIONELLA INFECTION,LEGIONELLA.,86,47-58,LEGIONELLA INFECTION,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella.",86,47 58,86,47,96,67,-1,RO-has_causative_agent,903796,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella",Legionella,Legionella infection
502244409,7/11/2014 11:09:30,,1320669212,7/11/2014 11:09:03,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,86,47,,,96,67,LEGIONELLA,LEGIONELLA INFECTION,LEGIONELLA.,86,47-58,LEGIONELLA INFECTION,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella.",86,47 58,86,47,96,67,-1,RO-has_causative_agent,903796,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella",Legionella,Legionella infection
502244409,7/11/2014 11:13:22,,1320672001,7/11/2014 11:12:52,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,86,47,,,96,67,LEGIONELLA,LEGIONELLA INFECTION,LEGIONELLA.,86,47-58,LEGIONELLA INFECTION,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella.",86,47 58,86,47,96,67,-1,RO-has_causative_agent,903796,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella",Legionella,Legionella infection
502244409,7/11/2014 11:22:22,,1320676047,7/11/2014 11:22:12,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,86,47,,,96,67,LEGIONELLA,LEGIONELLA INFECTION,LEGIONELLA.,86,47-58,LEGIONELLA INFECTION,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella.",86,47 58,86,47,96,67,-1,RO-has_causative_agent,903796,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella",Legionella,Legionella infection
502244409,7/11/2014 11:24:21,,1320676839,7/11/2014 11:24:02,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,86,47,,,96,67,LEGIONELLA,LEGIONELLA INFECTION,LEGIONELLA.,86,47-58,LEGIONELLA INFECTION,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella.",86,47 58,86,47,96,67,-1,RO-has_causative_agent,903796,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella",Legionella,Legionella infection
502244409,7/11/2014 11:37:50,,1320681688,7/11/2014 11:37:41,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,86,47,,,96,67,LEGIONELLA,LEGIONELLA INFECTION,were resistant to LEGIONELLA.,68-73-83-86,23-38-44-47-58-68-73-83-86,bifidobacteria prior to LEGIONELLA INFECTION were resistant to Legionella.,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella.",86,47 58,86,47,96,67,-1,RO-has_causative_agent,903796,"However, nematodes fed bifidobacteria prior to Legionella infection were resistant to Legionella",Legionella,Legionella infection
502244410,7/11/2014 10:50:59,,1320661967,7/11/2014 10:50:55,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,43,0,,,61,4,MENTAL RETARDATION,SLOS,"classical multiple malformation, MENTAL RETARDATION syndrome, and was",10-20-29-43-50-62-72-76,0-5-8-10,SLOS is a classical,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",43 50,0,43,0,61,4,1,RO-has_manifestation,906365,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis",mental retardation,SLOS
502244410,7/11/2014 10:53:54,,1320662725,7/11/2014 10:53:18,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,43,0,,,61,4,MENTAL RETARDATION,SLOS,"SLOS classical multiple malformation, MENTAL RETARDATION and was",0-10-20-29-43-50-72-76,0-5-8-10-43-50-62,"SLOS is a classical mental retardation syndrome,","SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",43 50,0,43,0,61,4,1,RO-has_manifestation,906365,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis",mental retardation,SLOS
502244410,7/11/2014 10:56:57,,1320663717,7/11/2014 10:56:15,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,43,0,,,61,4,MENTAL RETARDATION,SLOS,"MENTAL RETARDATION syndrome,",43-50-62,0,SLOS,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",43 50,0,43,0,61,4,1,RO-has_manifestation,906365,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis",mental retardation,SLOS
502244410,7/11/2014 11:03:06,,1320666468,7/11/2014 11:02:50,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,43,0,,,61,4,MENTAL RETARDATION,SLOS,"MENTAL RETARDATION syndrome,",43-50-62,0,SLOS,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",43 50,0,43,0,61,4,1,RO-has_manifestation,906365,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis",mental retardation,SLOS
502244410,7/11/2014 11:04:22,,1320667026,7/11/2014 11:04:11,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,43,0,,,61,4,MENTAL RETARDATION,SLOS,MENTAL RETARDATION,43-50,0,SLOS,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",43 50,0,43,0,61,4,1,RO-has_manifestation,906365,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis",mental retardation,SLOS
502244410,7/11/2014 11:04:26,,1320667052,7/11/2014 11:04:05,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,43,0,,,61,4,MENTAL RETARDATION,SLOS,"MENTAL RETARDATION syndrome,",43-50-62,0,SLOS,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",43 50,0,43,0,61,4,1,RO-has_manifestation,906365,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis",mental retardation,SLOS
502244410,7/11/2014 11:05:05,,1320667360,7/11/2014 11:04:41,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,43,0,,,61,4,MENTAL RETARDATION,SLOS,"MENTAL RETARDATION syndrome,",43-50-62,0,SLOS,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",43 50,0,43,0,61,4,1,RO-has_manifestation,906365,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis",mental retardation,SLOS
502244410,7/11/2014 11:08:53,,1320668905,7/11/2014 11:08:37,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,43,0,,,61,4,MENTAL RETARDATION,SLOS,MENTAL RETARDATION,43-50,0,SLOS,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",43 50,0,43,0,61,4,1,RO-has_manifestation,906365,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis",mental retardation,SLOS
502244410,7/11/2014 11:11:23,,1320670589,7/11/2014 11:10:35,instagc,1,23149109,USA,NC,Durham,75.189.206.205,43,0,,,61,4,MENTAL RETARDATION,SLOS,MENTAL RETARDATION,43-50,0,SLOS,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",43 50,0,43,0,61,4,1,RO-has_manifestation,906365,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis",mental retardation,SLOS
502244410,7/11/2014 11:25:42,,1320677387,7/11/2014 11:25:23,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,43,0,,,61,4,MENTAL RETARDATION,SLOS,MENTAL RETARDATION,43-50,0,SLOS,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",43 50,0,43,0,61,4,1,RO-has_manifestation,906365,"SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis",mental retardation,SLOS
502244411,7/11/2014 10:51:21,,1320662080,7/11/2014 10:50:14,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,29,7,,,37,19,ASPHYXIA,ASPHYXIATION,"asphyxiation ASPHYXIA resuscitation unconsciousness s., suffocation inhalation.",7-29-41-58-75-123-165,0-7-22-29-41-58-123-165,SYN: ASPHYXIATION SEE: asphyxia resuscitation unconsciousness suffocation inhalation.,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation.",29,7,29,7,37,19,-1,RO-cause_of,900273,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation",asphyxia,asphyxiation
502244411,7/11/2014 10:52:14,,1320662326,7/11/2014 10:52:11,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,29,7,,,37,19,ASPHYXIA,ASPHYXIATION,"SYN: asphyxiation SEE: ASPHYXIA resuscitation unconsciousness s.,",0-7-22-29-41-58-75,0-7-22-29-41,SYN: ASPHYXIATION SEE: asphyxia resuscitation,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation.",29,7,29,7,37,19,-1,RO-cause_of,900273,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation",asphyxia,asphyxiation
502244411,7/11/2014 11:10:34,,1320669963,7/11/2014 11:10:06,instagc,1,23149109,USA,NC,Durham,75.189.206.205,29,7,,,37,19,ASPHYXIA,ASPHYXIATION,ASPHYXIA,29,7,ASPHYXIATION,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation.",29,7,29,7,37,19,-1,RO-cause_of,900273,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation",asphyxia,asphyxiation
502244411,7/11/2014 11:25:23,,1320677279,7/11/2014 11:25:05,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,29,7,,,37,19,ASPHYXIA,ASPHYXIATION,ASPHYXIA,29,7,ASPHYXIATION,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation.",29,7,29,7,37,19,-1,RO-cause_of,900273,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation",asphyxia,asphyxiation
502244411,7/11/2014 11:28:40,,1320678573,7/11/2014 11:28:21,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,29,7,,,37,19,ASPHYXIA,ASPHYXIATION,ASPHYXIA,29,7,ASPHYXIATION,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation.",29,7,29,7,37,19,-1,RO-cause_of,900273,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation",asphyxia,asphyxiation
502244411,7/11/2014 11:37:34,,1320681596,7/11/2014 11:37:26,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,29,7,,,37,19,ASPHYXIA,ASPHYXIATION,"SYN: asphyxiation SEE: ASPHYXIA resuscitation unconsciousness s.,",0-7-22-29-41-58-75,0-7-22-29-41,SYN: ASPHYXIATION SEE: asphyxia resuscitation,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation.",29,7,29,7,37,19,-1,RO-cause_of,900273,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation",asphyxia,asphyxiation
502244411,7/11/2014 11:43:26,,1320683335,7/11/2014 11:43:04,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,29,7,,,37,19,ASPHYXIA,ASPHYXIATION,"SYN: asphyxiation SEE: ASPHYXIA resuscitation unconsciousness s., Accentuated risk of accidental suffocation",0-7-22-29-41-58-75-92-104-109-112-123,0-7-22-29-41-58-79-92-112-123,SYN: ASPHYXIATION SEE: asphyxia resuscitation unconsciousness risk Accentuated accidental suffocation,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation.",29,7,29,7,37,19,-1,RO-cause_of,900273,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation",asphyxia,asphyxiation
502244411,7/11/2014 11:44:14,,1320683622,7/11/2014 11:42:29,prodege,1,6855306,CAN,ON,Barrie,99.239.77.74,29,7,,,37,19,ASPHYXIA,ASPHYXIATION,ASPHYXIA,29,7,ASPHYXIATION,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation.",29,7,29,7,37,19,-1,RO-cause_of,900273,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation",asphyxia,asphyxiation
502244411,7/11/2014 11:45:27,,1320684247,7/11/2014 11:45:07,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,29,7,,,37,19,ASPHYXIA,ASPHYXIATION,asphyxiation ASPHYXIA,7-29,7-29,ASPHYXIATION asphyxia,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation.",29,7,29,7,37,19,-1,RO-cause_of,900273,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation",asphyxia,asphyxiation
502244411,7/11/2014 11:47:06,,1320685071,7/11/2014 11:44:51,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.197,29,7,,,37,19,ASPHYXIA,ASPHYXIATION,ASPHYXIA,29,7,ASPHYXIATION,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation.",29,7,29,7,37,19,-1,RO-cause_of,900273,"SYN:   asphyxiation   SEE:   asphyxia ;  resuscitation ;  unconsciousness  s., risk for     Accentuated risk of accidental suffocation (inadequate air available for inhalation",asphyxia,asphyxiation
502244412,7/11/2014 10:50:40,,1320661914,7/11/2014 10:50:36,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,148,53,,,159,72,HEPATITIS B,HEPATITIS B VACCINE,incidence of vertical HEPATITIS B transmission.,126-136-139-148-158-160,39-42-48-53-63-65-73-79-82,at birth with HEPATITIS B VACCINE could be an,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission.",148 158,53 63 65,148,53,159,72,1,RO-may_prevent,907304,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission",hepatitis B,hepatitis B vaccine
502244412,7/11/2014 10:56:52,,1320663703,7/11/2014 10:56:50,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,148,53,,,159,72,HEPATITIS B,HEPATITIS B VACCINE,incidence of vertical HEPATITIS B transmission.,126-136-139-148-158-160,39-42-48-53-63-65-73-79-82,at birth with HEPATITIS B VACCINE could be an,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission.",148 158,53 63 65,148,53,159,72,1,RO-may_prevent,907304,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission",hepatitis B,hepatitis B vaccine
502244412,7/11/2014 11:06:11,,1320667808,7/11/2014 11:05:29,instagc,1,23149109,USA,NC,Durham,75.189.206.205,148,53,,,159,72,HEPATITIS B,HEPATITIS B VACCINE,HEPATITIS B,148-158,53-63-65,HEPATITIS B VACCINE,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission.",148 158,53 63 65,148,53,159,72,1,RO-may_prevent,907304,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission",hepatitis B,hepatitis B vaccine
502244412,7/11/2014 11:09:52,,1320669422,7/11/2014 11:09:29,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,148,53,,,159,72,HEPATITIS B,HEPATITIS B VACCINE,vertical HEPATITIS B transmission.,139-148-158-160,53-63-65,HEPATITIS B VACCINE,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission.",148 158,53 63 65,148,53,159,72,1,RO-may_prevent,907304,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission",hepatitis B,hepatitis B vaccine
502244412,7/11/2014 11:14:26,,1320672699,7/11/2014 11:14:10,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,148,53,,,159,72,HEPATITIS B,HEPATITIS B VACCINE,vertical HEPATITIS B transmission.,139-148-158-160,53-63-65,HEPATITIS B VACCINE,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission.",148 158,53 63 65,148,53,159,72,1,RO-may_prevent,907304,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission",hepatitis B,hepatitis B vaccine
502244412,7/11/2014 11:21:54,,1320675877,7/11/2014 11:21:39,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,148,53,,,159,72,HEPATITIS B,HEPATITIS B VACCINE,HEPATITIS B,148-158,53-63-65,HEPATITIS B VACCINE,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission.",148 158,53 63 65,148,53,159,72,1,RO-may_prevent,907304,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission",hepatitis B,hepatitis B vaccine
502244412,7/11/2014 11:34:42,,1320680735,7/11/2014 11:33:33,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,148,53,,,159,72,HEPATITIS B,HEPATITIS B VACCINE,vaccine strategy despite a low incidence of vertical HEPATITIS B transmission.,95-103-120-122-126-136-139-148-158-160-112,39-42-48-53-63-65-73-79-82-85-95-103-11,vaccination at birth with HEPATITIS B VACCINE could be an effective vaccine strategy,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission.",148 158,53 63 65,148,53,159,72,1,RO-may_prevent,907304,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission",hepatitis B,hepatitis B vaccine
502244412,7/11/2014 11:37:35,,1320681599,7/11/2014 11:36:01,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,148,53,,,159,72,HEPATITIS B,HEPATITIS B VACCINE,incidence of vertical HEPATITIS B transmission.,126-136-139-148-158-160,39-42-48-53-63-65-73-79-82,at birth with HEPATITIS B VACCINE could be an,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission.",148 158,53 63 65,148,53,159,72,1,RO-may_prevent,907304,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission",hepatitis B,hepatitis B vaccine
502244412,7/11/2014 11:42:08,,1320682935,7/11/2014 11:41:50,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,148,53,,,159,72,HEPATITIS B,HEPATITIS B VACCINE,vertical HEPATITIS B transmission.,139-148-158-160,53-63-65,HEPATITIS B VACCINE,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission.",148 158,53 63 65,148,53,159,72,1,RO-may_prevent,907304,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission",hepatitis B,hepatitis B vaccine
502244412,7/11/2014 11:48:50,,1320685707,7/11/2014 11:48:32,prodege,1,27969454,USA,,,69.76.133.211,148,53,,,159,72,HEPATITIS B,HEPATITIS B VACCINE,low incidence of vertical HEPATITIS B transmission.,126-136-139-148-158-160-122,39-42-48-53-63-65,at birth with HEPATITIS B VACCINE,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission.",148 158,53 63 65,148,53,159,72,1,RO-may_prevent,907304,"Therefore, vaccination of all children at birth with hepatitis B vaccine could be an effective vaccine strategy despite a low incidence of vertical hepatitis B transmission",hepatitis B,hepatitis B vaccine
502244413,7/11/2014 10:52:05,,1320662298,7/11/2014 10:52:02,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,79,120,,,87,129,MYXEDEMA,THYROXINE,metabolic responses in MYXEDEMA to large doses,56-66-76-79-88-91-97,103-106-118-120,of intravenous L THYROXINE.,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine.",79,120,79,120,87,129,1,RO-may_treat,907952,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine",myxedema,thyroxine
502244413,7/11/2014 10:52:18,,1320662336,7/11/2014 10:51:29,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,79,120,,,87,129,MYXEDEMA,THYROXINE,metabolic responses in MYXEDEMA to large doses,56-66-76-79-88-91-97,103-106-120,of intravenous THYROXINE.,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine.",79,120,79,120,87,129,1,RO-may_treat,907952,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine",myxedema,thyroxine
502244413,7/11/2014 10:57:17,,1320663846,7/11/2014 10:57:04,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,79,120,,,87,129,MYXEDEMA,THYROXINE,MYXEDEMA,79,106-118-120,intravenous L THYROXINE.,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine.",79,120,79,120,87,129,1,RO-may_treat,907952,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine",myxedema,thyroxine
502244413,7/11/2014 11:06:05,,1320667792,7/11/2014 11:05:48,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,79,120,,,87,129,MYXEDEMA,THYROXINE,MYXEDEMA,79,106-118-120,intravenous L THYROXINE.,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine.",79,120,79,120,87,129,1,RO-may_treat,907952,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine",myxedema,thyroxine
502244413,7/11/2014 11:06:51,,1320668038,7/11/2014 11:06:40,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,79,120,,,87,129,MYXEDEMA,THYROXINE,MYXEDEMA,79,120,THYROXINE.,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine.",79,120,79,120,87,129,1,RO-may_treat,907952,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine",myxedema,thyroxine
502244413,7/11/2014 11:07:25,,1320668214,7/11/2014 11:07:12,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,79,120,,,87,129,MYXEDEMA,THYROXINE,MYXEDEMA,79,118-120,L THYROXINE.,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine.",79,120,79,120,87,129,1,RO-may_treat,907952,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine",myxedema,thyroxine
502244413,7/11/2014 11:09:30,,1320669214,7/11/2014 11:09:20,instagc,1,23149109,USA,NC,Durham,75.189.206.205,79,120,,,87,129,MYXEDEMA,THYROXINE,MYXEDEMA,79,118-120,L THYROXINE.,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine.",79,120,79,120,87,129,1,RO-may_treat,907952,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine",myxedema,thyroxine
502244413,7/11/2014 11:24:42,,1320676967,7/11/2014 11:24:22,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,79,120,,,87,129,MYXEDEMA,THYROXINE,MYXEDEMA,79,120,THYROXINE.,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine.",79,120,79,120,87,129,1,RO-may_treat,907952,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine",myxedema,thyroxine
502244413,7/11/2014 11:24:55,,1320677077,7/11/2014 11:24:42,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,79,120,,,87,129,MYXEDEMA,THYROXINE,MYXEDEMA,79,118-120,L THYROXINE.,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine.",79,120,79,120,87,129,1,RO-may_treat,907952,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine",myxedema,thyroxine
502244413,7/11/2014 11:40:19,,1320682452,7/11/2014 11:40:06,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,79,120,,,87,129,MYXEDEMA,THYROXINE,metabolic responses in MYXEDEMA to large doses,56-66-76-79-88-91-97,103-106-118-120,of intravenous L THYROXINE.,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine.",79,120,79,120,87,129,1,RO-may_treat,907952,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine",myxedema,thyroxine
502244414,7/11/2014 10:51:25,,1320662096,7/11/2014 10:51:20,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,177,188,,,186,191,DYSPLASIA,CIN,and cervical intraepithelial DYSPLASIA incidence of,148-152-161-177-193-203,161-177-187-193-203-206,"intraepithelial dysplasia (CIN, incidence of up","HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates.",177,,177,188,186,191,-1,RO-disease_has_finding,901622,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates",dysplasia,CIN
502244414,7/11/2014 11:00:44,,1320665135,7/11/2014 10:59:34,instagc,1,23149109,USA,NC,Durham,75.189.206.205,177,188,,,186,191,DYSPLASIA,CIN,cervical intraepithelial DYSPLASIA,152-177-161,152-161-177,cervical intraepithelial dysplasia,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates.",177,,177,188,186,191,-1,RO-disease_has_finding,901622,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates",dysplasia,CIN
502244414,7/11/2014 11:07:26,,1320668216,7/11/2014 11:07:14,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,177,188,,,186,191,DYSPLASIA,CIN,DYSPLASIA,177,177,dysplasia,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates.",177,,177,188,186,191,-1,RO-disease_has_finding,901622,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates",dysplasia,CIN
502244414,7/11/2014 11:10:34,,1320669961,7/11/2014 11:10:16,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,177,188,,,186,191,DYSPLASIA,CIN,cervical intraepithelial DYSPLASIA,152-161-177,161-177-152,cervical intraepithelial dysplasia,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates.",177,,177,188,186,191,-1,RO-disease_has_finding,901622,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates",dysplasia,CIN
502244414,7/11/2014 11:14:07,,1320672543,7/11/2014 11:13:45,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,177,188,,,186,191,DYSPLASIA,CIN,DYSPLASIA,177,187,"(CIN,","HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates.",177,,177,188,186,191,-1,RO-disease_has_finding,901622,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates",dysplasia,CIN
502244414,7/11/2014 11:17:38,,1320674086,7/11/2014 11:16:35,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,177,188,,,186,191,DYSPLASIA,CIN,cervical intraepithelial DYSPLASIA,152-161-177,161-177-152,cervical intraepithelial dysplasia,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates.",177,,177,188,186,191,-1,RO-disease_has_finding,901622,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates",dysplasia,CIN
502244414,7/11/2014 11:29:46,,1320678966,7/11/2014 11:29:30,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,177,188,,,186,191,DYSPLASIA,CIN,DYSPLASIA,177,161-177,intraepithelial dysplasia,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates.",177,,177,188,186,191,-1,RO-disease_has_finding,901622,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates",dysplasia,CIN
502244414,7/11/2014 11:35:08,,1320680881,7/11/2014 11:32:09,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,177,188,,,186,191,DYSPLASIA,CIN,papillomavirus and cervical intraepithelial DYSPLASIA incidence of cervical cancer,148-152-161-177-193-203-244-253-40,40-161-177-187-193-203-206-244-253,"papillomavirus intraepithelial dysplasia (CIN, incidence of up cervical cancer","HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates.",177,,177,188,186,191,-1,RO-disease_has_finding,901622,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates",dysplasia,CIN
502244414,7/11/2014 11:42:47,,1320683134,7/11/2014 11:41:43,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,177,188,,,186,191,DYSPLASIA,CIN,and cervical intraepithelial DYSPLASIA incidence,148-152-161-177-193,161-177-187-193-203-206-212,"intraepithelial dysplasia (CIN, incidence of up 60%),","HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates.",177,,177,188,186,191,-1,RO-disease_has_finding,901622,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates",dysplasia,CIN
502244414,7/11/2014 11:42:53,,1320683150,7/11/2014 11:42:09,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,177,188,,,186,191,DYSPLASIA,CIN,cervical intraepithelial DYSPLASIA,152-161-177,152-161-177,cervical intraepithelial dysplasia,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates.",177,,177,188,186,191,-1,RO-disease_has_finding,901622,"HIV-infected women have increased human papillomavirus (HPV) infection rates, persistence of oncogenic subtypes (types 16, 18, 31, 33, 35, and 39), and cervical intraepithelial dysplasia (CIN, incidence of up to 60%), but no proven increase in cervical cancer rates",dysplasia,CIN
502244415,7/11/2014 10:57:01,,1320663745,7/11/2014 10:56:57,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,402,444,,,420,451,ALLERGIC REACTIONS,ALLERGY,diuresis Electrolyte depletion ALLERGIC REACTIONS in patients with,371-380-392-402-411-421-424-433,424-433-438-444-453-457-462,patients with sulfa ALLERGY Use with caution,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",402 411,444,402,444,420,451,1,RO-cause_of,900184,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse",Allergic reactions,allergy
502244415,7/11/2014 11:03:32,,1320666645,7/11/2014 11:02:53,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,402,444,,,420,451,ALLERGIC REACTIONS,ALLERGY,ALLERGIC REACTIONS,402-411,438-444,sulfa ALLERGY,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",402 411,444,402,444,420,451,1,RO-cause_of,900184,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse",Allergic reactions,allergy
502244415,7/11/2014 11:05:31,,1320667553,7/11/2014 11:04:36,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,402,444,,,420,451,ALLERGIC REACTIONS,ALLERGY,diuresis Electrolyte depletion ALLERGIC REACTIONS,371-380-392-402-411,438-444,sulfa ALLERGY,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",402 411,444,402,444,420,451,1,RO-cause_of,900184,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse",Allergic reactions,allergy
502244415,7/11/2014 11:05:41,,1320667639,7/11/2014 11:05:20,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,402,444,,,420,451,ALLERGIC REACTIONS,ALLERGY,diuresis Electrolyte depletion ALLERGIC REACTIONS,371-380-392-402-411,438-444,sulfa ALLERGY,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",402 411,444,402,444,420,451,1,RO-cause_of,900184,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse",Allergic reactions,allergy
502244415,7/11/2014 11:07:14,,1320668150,7/11/2014 11:06:54,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,402,444,,,420,451,ALLERGIC REACTIONS,ALLERGY,ALLERGIC REACTIONS,402-411,444,ALLERGY,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",402 411,444,402,444,420,451,1,RO-cause_of,900184,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse",Allergic reactions,allergy
502244415,7/11/2014 11:23:53,,1320676695,7/11/2014 11:22:43,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,402,444,,,420,451,ALLERGIC REACTIONS,ALLERGY,Excessive diuresis Electrolyte depletion ALLERGIC REACTIONS in patients with sulfa allergy,371-380-392-402-411-421-424-433-438-444-361,361-371-380-392-402-411-421-424-433-438-444-453-457-462-470-473-483-492-496-508-520,Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa ALLERGY Use with caution as excessive diuresis may precipitate hemodynamic collapse.,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",402 411,444,402,444,420,451,1,RO-cause_of,900184,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse",Allergic reactions,allergy
502244415,7/11/2014 11:25:10,,1320677165,7/11/2014 11:24:55,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,402,444,,,420,451,ALLERGIC REACTIONS,ALLERGY,ALLERGIC REACTIONS with,402-411-433,438-444,sulfa ALLERGY,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",402 411,444,402,444,420,451,1,RO-cause_of,900184,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse",Allergic reactions,allergy
502244415,7/11/2014 11:38:18,,1320681859,7/11/2014 11:37:37,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,402,444,,,420,451,ALLERGIC REACTIONS,ALLERGY,diuresis Electrolyte depletion ALLERGIC REACTIONS,371-380-392-402-411,433-438-444,with sulfa ALLERGY,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",402 411,444,402,444,420,451,1,RO-cause_of,900184,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse",Allergic reactions,allergy
502244415,7/11/2014 11:40:43,,1320682573,7/11/2014 11:40:09,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,402,444,,,420,451,ALLERGIC REACTIONS,ALLERGY,diuresis Electrolyte depletion ALLERGIC REACTIONS in patients with sulfa allergy,371-380-392-402-411-421-424-433-438-444,424-433-438-444-453-457-462-473-483-492-496-508-520,patients with sulfa ALLERGY Use with caution excessive diuresis may precipitate hemodynamic collapse.,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",402 411,444,402,444,420,451,1,RO-cause_of,900184,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse",Allergic reactions,allergy
502244415,7/11/2014 11:44:03,,1320683497,7/11/2014 11:43:17,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,402,444,,,420,451,ALLERGIC REACTIONS,ALLERGY,diuresis Electrolyte depletion ALLERGIC REACTIONS in patients with,371-380-392-402-411-421-424-433,424-433-438-444-453-457-462,patients with sulfa ALLERGY Use with caution,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",402 411,444,402,444,420,451,1,RO-cause_of,900184,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20-80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive diuresis Electrolyte depletion Allergic reactions in patients with sulfa allergy  Use with caution as excessive diuresis may precipitate hemodynamic collapse",Allergic reactions,allergy
502244416,7/11/2014 10:59:13,,1320664551,7/11/2014 10:58:56,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,23,93,,,31,109,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE,23,93-100,DENTAL FLUOROSIS,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",23,93 100,23,93,31,109,-1,RO-has_causative_agent,903506,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time",fluoride,dental fluorosis
502244416,7/11/2014 11:00:18,,1320664928,7/11/2014 10:59:00,clixsense,1,23138831,NLD,,,77.174.95.58,23,93,,,31,109,FLUORIDE,DENTAL FLUOROSIS,"Considering that blood FLUORIDE concentration varies according to fluoride exposure that dental fluorosis is related to amount of enamel formed under given fluoride dose,",0-12-17-23-32-46-53-63-66-75-88-93-100-110-113-121-128-135-138-145-152-160-166-175,66-75-84-88-93-100-110-113-121-128-135-138-152-160-166-175-145,"fluoride exposure and that DENTAL FLUOROSIS is related to amount of enamel formed under given fluoride dose,","Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",23,93 100,23,93,31,109,-1,RO-has_causative_agent,903506,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time",fluoride,dental fluorosis
502244416,7/11/2014 11:01:00,,1320665225,7/11/2014 11:00:46,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,23,93,,,31,109,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE,23,93-100,DENTAL FLUOROSIS,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",23,93 100,23,93,31,109,-1,RO-has_causative_agent,903506,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time",fluoride,dental fluorosis
502244416,7/11/2014 11:03:24,,1320666579,7/11/2014 11:03:08,instagc,1,23149109,USA,NC,Durham,75.189.206.205,23,93,,,31,109,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE concentration,23-32,93-100,DENTAL FLUOROSIS,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",23,93 100,23,93,31,109,-1,RO-has_causative_agent,903506,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time",fluoride,dental fluorosis
502244416,7/11/2014 11:07:21,,1320668204,7/11/2014 11:07:04,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,23,93,,,31,109,FLUORIDE,DENTAL FLUOROSIS,blood FLUORIDE concentration,17-23-32,93-100,DENTAL FLUOROSIS,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",23,93 100,23,93,31,109,-1,RO-has_causative_agent,903506,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time",fluoride,dental fluorosis
502244416,7/11/2014 11:23:46,,1320676649,7/11/2014 11:23:31,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,23,93,,,31,109,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE,23,93-100,DENTAL FLUOROSIS,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",23,93 100,23,93,31,109,-1,RO-has_causative_agent,903506,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time",fluoride,dental fluorosis
502244416,7/11/2014 11:41:10,,1320682668,7/11/2014 11:40:30,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,23,93,,,31,109,FLUORIDE,DENTAL FLUOROSIS,Considering that blood FLUORIDE concentration varies,0-12-17-23-32-46,75-84-88-93-100-110-113-121-138,exposure and that DENTAL FLUOROSIS is related to enamel,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",23,93 100,23,93,31,109,-1,RO-has_causative_agent,903506,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time",fluoride,dental fluorosis
502244416,7/11/2014 11:43:50,,1320683459,7/11/2014 11:43:23,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,23,93,,,31,109,FLUORIDE,DENTAL FLUOROSIS,blood FLUORIDE concentration,17-23-32,93-100-110-113-121,DENTAL FLUOROSIS is related to,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",23,93 100,23,93,31,109,-1,RO-has_causative_agent,903506,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time",fluoride,dental fluorosis
502244416,7/11/2014 11:45:52,,1320684415,7/11/2014 11:45:28,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,23,93,,,31,109,FLUORIDE,DENTAL FLUOROSIS,blood FLUORIDE concentration,23-32-17,93-100,DENTAL FLUOROSIS,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",23,93 100,23,93,31,109,-1,RO-has_causative_agent,903506,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time",fluoride,dental fluorosis
502244416,7/11/2014 11:49:25,,1320685890,7/11/2014 11:48:48,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,23,93,,,31,109,FLUORIDE,DENTAL FLUOROSIS,"Considering that blood FLUORIDE concentration varies according fluoride exposure dental fluorosis related amount enamel formed under a given fluoride dose,",0-12-17-23-32-46-53-66-75-93-100-113-128-138-145-152-158-160-166-175,75-84-88-93-100-110-113-121-128-138-145-152-160-166-175-224-234-249-261-269,"exposure and that DENTAL FLUOROSIS is related to amount enamel formed under given fluoride dose, fluorosis produced oscillating chronic fluoride","Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",23,93 100,23,93,31,109,-1,RO-has_causative_agent,903506,"Considering that blood fluoride concentration varies according to fluoride exposure and that dental fluorosis is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time",fluoride,dental fluorosis
502244417,7/11/2014 11:00:30,,1320665030,7/11/2014 10:59:44,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,37,6,,,62,22,HYPERSENSITIVITY REACTION,HYPERSENSITIVITY,HYPERSENSITIVITY REACTION,37-54,6,HYPERSENSITIVITY,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy.",37 54,6,37,6,62,22,-1,RO-cause_of,900471,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy",hypersensitivity reaction,Hypersensitivity
502244417,7/11/2014 11:04:21,,1320667022,7/11/2014 11:03:33,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,37,6,,,62,22,HYPERSENSITIVITY REACTION,HYPERSENSITIVITY,HYPERSENSITIVITY REACTION,37-54,6,HYPERSENSITIVITY,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy.",37 54,6,37,6,62,22,-1,RO-cause_of,900471,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy",hypersensitivity reaction,Hypersensitivity
502244417,7/11/2014 11:11:21,,1320670548,7/11/2014 11:10:59,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,37,6,,,62,22,HYPERSENSITIVITY REACTION,HYPERSENSITIVITY,HYPERSENSITIVITY REACTION,37-54,6-23,HYPERSENSITIVITY Reactions,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy.",37 54,6,37,6,62,22,-1,RO-cause_of,900471,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy",hypersensitivity reaction,Hypersensitivity
502244417,7/11/2014 11:11:35,,1320670697,7/11/2014 11:11:16,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,37,6,,,62,22,HYPERSENSITIVITY REACTION,HYPERSENSITIVITY,HYPERSENSITIVITY REACTION,37-54,6,HYPERSENSITIVITY,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy.",37 54,6,37,6,62,22,-1,RO-cause_of,900471,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy",hypersensitivity reaction,Hypersensitivity
502244417,7/11/2014 11:24:14,,1320676803,7/11/2014 11:23:59,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,37,6,,,62,22,HYPERSENSITIVITY REACTION,HYPERSENSITIVITY,HYPERSENSITIVITY REACTION,37-54,6-23,HYPERSENSITIVITY Reactions,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy.",37 54,6,37,6,62,22,-1,RO-cause_of,900471,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy",hypersensitivity reaction,Hypersensitivity
502244417,7/11/2014 11:29:04,,1320678668,7/11/2014 11:28:45,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,37,6,,,62,22,HYPERSENSITIVITY REACTION,HYPERSENSITIVITY,HYPERSENSITIVITY REACTION,37-54,6,HYPERSENSITIVITY,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy.",37 54,6,37,6,62,22,-1,RO-cause_of,900471,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy",hypersensitivity reaction,Hypersensitivity
502244417,7/11/2014 11:36:55,,1320681417,7/11/2014 11:36:40,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,37,6,,,62,22,HYPERSENSITIVITY REACTION,HYPERSENSITIVITY,"Hypersensitivity Reactions If HYPERSENSITIVITY REACTION occurs, discontinue therapy.",6-23-34-37-54-63-71-83,0-6-23-34-37,&gt; HYPERSENSITIVITY Reactions If hypersensitivity,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy.",37 54,6,37,6,62,22,-1,RO-cause_of,900471,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy",hypersensitivity reaction,Hypersensitivity
502244417,7/11/2014 11:47:20,,1320685162,7/11/2014 11:46:54,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,37,6,,,62,22,HYPERSENSITIVITY REACTION,HYPERSENSITIVITY,HYPERSENSITIVITY REACTION,37-54,6-23,HYPERSENSITIVITY Reactions,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy.",37 54,6,37,6,62,22,-1,RO-cause_of,900471,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy",hypersensitivity reaction,Hypersensitivity
502244417,7/11/2014 11:47:52,,1320685384,7/11/2014 11:47:39,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,37,6,,,62,22,HYPERSENSITIVITY REACTION,HYPERSENSITIVITY,"Hypersensitivity Reactions If HYPERSENSITIVITY REACTION occurs, discontinue therapy.",6-23-34-37-54-63-71-83,0-6-23-34-37-54-63-71-83,"&gt; HYPERSENSITIVITY Reactions If hypersensitivity reaction occurs, discontinue therapy.","&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy.",37 54,6,37,6,62,22,-1,RO-cause_of,900471,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy",hypersensitivity reaction,Hypersensitivity
502244417,7/11/2014 11:47:54,,1320685397,7/11/2014 11:47:42,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,37,6,,,62,22,HYPERSENSITIVITY REACTION,HYPERSENSITIVITY,HYPERSENSITIVITY REACTION,37-54,0-6-37,&gt; HYPERSENSITIVITY hypersensitivity,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy.",37 54,6,37,6,62,22,-1,RO-cause_of,900471,"&gt;     Hypersensitivity Reactions  If hypersensitivity reaction occurs, discontinue therapy",hypersensitivity reaction,Hypersensitivity
502244418,7/11/2014 10:52:09,,1320662301,7/11/2014 10:52:06,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,40,121,,,58,130,ALLERGIC REACTIONS,ALLERGIES,"unlike other countries, ALLERGIC REACTIONS to ants are",16-23-29-40-49-59-62-67,106-110-115-121-131-134-138,the well known ALLERGIES to bee and,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom.",40 49,121,40,121,58,130,-1,RO-cause_of,900125,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom",allergic reactions,allergies
502244418,7/11/2014 10:56:29,,1320663577,7/11/2014 10:56:24,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,40,121,,,58,130,ALLERGIC REACTIONS,ALLERGIES,"unlike other countries, ALLERGIC REACTIONS to ants are",16-23-29-40-49-59-62-67,106-110-115-121-131-134-138,the well known ALLERGIES to bee and,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom.",40 49,121,40,121,58,130,-1,RO-cause_of,900125,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom",allergic reactions,allergies
502244418,7/11/2014 11:04:48,,1320667266,7/11/2014 11:04:21,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,40,121,,,58,130,ALLERGIC REACTIONS,ALLERGIES,ALLERGIC REACTIONS,40-49,121,ALLERGIES,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom.",40 49,121,40,121,58,130,-1,RO-cause_of,900125,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom",allergic reactions,allergies
502244418,7/11/2014 11:10:48,,1320670109,7/11/2014 11:10:18,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,40,121,,,58,130,ALLERGIC REACTIONS,ALLERGIES,ALLERGIC REACTIONS,40-49,121,ALLERGIES,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom.",40 49,121,40,121,58,130,-1,RO-cause_of,900125,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom",allergic reactions,allergies
502244418,7/11/2014 11:44:37,,1320683787,7/11/2014 11:44:21,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,40,121,,,58,130,ALLERGIC REACTIONS,ALLERGIES,ALLERGIC REACTIONS,40-49,121-131-134-138-142-147,ALLERGIES to bee and wasp venom.,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom.",40 49,121,40,121,58,130,-1,RO-cause_of,900125,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom",allergic reactions,allergies
502244418,7/11/2014 11:45:02,,1320684020,7/11/2014 11:44:39,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,40,121,,,58,130,ALLERGIC REACTIONS,ALLERGIES,"unlike other countries, ALLERGIC REACTIONS to ants are well known allergies to bee wasp venom.",16-23-29-40-49-59-62-67-110-115-121-131-134-142-147,40-106-110-115-121-131-134-138-142-147-49,allergic reactions the well known ALLERGIES to bee and wasp venom.,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom.",40 49,121,40,121,58,130,-1,RO-cause_of,900125,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom",allergic reactions,allergies
502244418,7/11/2014 11:46:15,,1320684627,7/11/2014 11:45:44,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,40,121,,,58,130,ALLERGIC REACTIONS,ALLERGIES,ALLERGIC REACTIONS,40-49,121,ALLERGIES,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom.",40 49,121,40,121,58,130,-1,RO-cause_of,900125,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom",allergic reactions,allergies
502244418,7/11/2014 11:46:37,,1320684771,7/11/2014 11:46:17,prodege,1,27969454,USA,,,69.76.133.211,40,121,,,58,130,ALLERGIC REACTIONS,ALLERGIES,"unlike other countries, ALLERGIC REACTIONS to ants",16-23-29-40-49-59-62,106-110-115-121-131-134-138-142-147,the well known ALLERGIES to bee and wasp venom.,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom.",40 49,121,40,121,58,130,-1,RO-cause_of,900125,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom",allergic reactions,allergies
502244418,7/11/2014 11:47:46,,1320685337,7/11/2014 11:47:31,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.197,40,121,,,58,130,ALLERGIC REACTIONS,ALLERGIES,ALLERGIC REACTIONS,40-49,121,ALLERGIES,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom.",40 49,121,40,121,58,130,-1,RO-cause_of,900125,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom",allergic reactions,allergies
502244418,7/11/2014 11:49:48,,1320685956,7/11/2014 11:49:05,instagc,1,19874561,GBR,C3,Saint Ives,80.4.147.13,40,121,,,58,130,ALLERGIC REACTIONS,ALLERGIES,ALLERGIC REACTIONS to ants,40-49-59-62,121-131-134-138-142-147,ALLERGIES to bee and wasp venom.,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom.",40 49,121,40,121,58,130,-1,RO-cause_of,900125,"In Switzerland, unlike other countries, allergic reactions to ants are a rare phenomenon when compared to the well known allergies to bee and wasp venom",allergic reactions,allergies
502244419,7/11/2014 10:50:25,,1320661821,7/11/2014 10:50:22,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,81,97,,,95,102,MILD DYSPLASIA,CIN 1,referral smears showed MILD DYSPLASIA 1.,58-67-74-81-86-101,81-86-96-101,mild dysplasia (CIN 1.,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1.,81 86,101,81,97,95,102,1,RO-disease_has_finding,901696,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1,mild dysplasia,CIN 1
502244419,7/11/2014 11:00:12,,1320664907,7/11/2014 10:59:49,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,81,97,,,95,102,MILD DYSPLASIA,CIN 1,MILD DYSPLASIA (CIN 1.,81-86-96-101,81-86-101-96,mild dysplasia (CIN 1.,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1.,81 86,101,81,97,95,102,1,RO-disease_has_finding,901696,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1,mild dysplasia,CIN 1
502244419,7/11/2014 11:02:38,,1320666254,7/11/2014 11:01:44,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,81,97,,,95,102,MILD DYSPLASIA,CIN 1,MILD DYSPLASIA (CIN 1.,81-86-96-101,81-86-96-101,mild dysplasia (CIN 1.,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1.,81 86,101,81,97,95,102,1,RO-disease_has_finding,901696,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1,mild dysplasia,CIN 1
502244419,7/11/2014 11:03:10,,1320666487,7/11/2014 11:02:21,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,81,97,,,95,102,MILD DYSPLASIA,CIN 1,MILD DYSPLASIA (CIN 1.,81-86-96-101,81-86-101-96,mild dysplasia (CIN 1.,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1.,81 86,101,81,97,95,102,1,RO-disease_has_finding,901696,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1,mild dysplasia,CIN 1
502244419,7/11/2014 11:08:35,,1320668738,7/11/2014 11:08:14,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,81,97,,,95,102,MILD DYSPLASIA,CIN 1,MILD DYSPLASIA,81-86,96-101,(CIN 1.,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1.,81 86,101,81,97,95,102,1,RO-disease_has_finding,901696,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1,mild dysplasia,CIN 1
502244419,7/11/2014 11:12:34,,1320671416,7/11/2014 11:12:18,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,81,97,,,95,102,MILD DYSPLASIA,CIN 1,MILD DYSPLASIA,81-86,81-96-101-86,mild dysplasia (CIN 1.,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1.,81 86,101,81,97,95,102,1,RO-disease_has_finding,901696,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1,mild dysplasia,CIN 1
502244419,7/11/2014 11:18:43,,1320674546,7/11/2014 11:18:18,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,81,97,,,95,102,MILD DYSPLASIA,CIN 1,MILD DYSPLASIA,81-86,101,1,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1.,81 86,101,81,97,95,102,1,RO-disease_has_finding,901696,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1,mild dysplasia,CIN 1
502244419,7/11/2014 11:45:10,,1320684093,7/11/2014 11:44:20,prodege,1,27969454,USA,,,69.76.133.211,81,97,,,95,102,MILD DYSPLASIA,CIN 1,referral smears showed MILD DYSPLASIA (CIN 1.,58-67-74-81-86-101-96,58-67-81-86-96-101-74,referral smears showed mild dysplasia (CIN 1.,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1.,81 86,101,81,97,95,102,1,RO-disease_has_finding,901696,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1,mild dysplasia,CIN 1
502244419,7/11/2014 11:45:55,,1320684452,7/11/2014 11:45:34,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,81,97,,,95,102,MILD DYSPLASIA,CIN 1,Colposcopy biopsy referral smears showed MILD DYSPLASIA 1.,0-58-67-74-81-86-101-15,0-15-27-43-58-81-86-96-101-67,Colposcopy biopsy performed patients referral smears mild dysplasia (CIN 1.,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1.,81 86,101,81,97,95,102,1,RO-disease_has_finding,901696,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1,mild dysplasia,CIN 1
502244419,7/11/2014 11:51:13,,1320686665,7/11/2014 11:50:45,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.197,81,97,,,95,102,MILD DYSPLASIA,CIN 1,MILD DYSPLASIA (CIN 1.,81-86-96-101,86-96-101-81,mild dysplasia (CIN 1.,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1.,81 86,101,81,97,95,102,1,RO-disease_has_finding,901696,Colposcopy and biopsy were performed in 97 patients whose referral smears showed mild dysplasia (CIN 1,mild dysplasia,CIN 1
502244420,7/11/2014 10:53:17,,1320662567,7/11/2014 10:53:03,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,31,106,,,43,133,TUBERCULOSIS,PURIFIED PROTEIN DERIVATIVE,"skin tests for TUBERCULOSIS, or",16-21-27-31-53,83-92-106-115-123,replaced by PURIFIED PROTEIN DERIVATIVE.,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative.",31,106 115 123,31,106,43,133,1,RO-may_diagnose,906547,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative",tuberculosis,purified protein derivative
502244420,7/11/2014 10:59:48,,1320664742,7/11/2014 10:59:37,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,31,106,,,43,133,TUBERCULOSIS,PURIFIED PROTEIN DERIVATIVE,"TUBERCULOSIS,",31,95-106-115-123,tuberculin PURIFIED PROTEIN DERIVATIVE.,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative.",31,106 115 123,31,106,43,133,1,RO-may_diagnose,906547,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative",tuberculosis,purified protein derivative
502244420,7/11/2014 11:01:34,,1320665596,7/11/2014 11:01:11,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,31,106,,,43,133,TUBERCULOSIS,PURIFIED PROTEIN DERIVATIVE,"TUBERCULOSIS,",31,95-106-115-123,tuberculin PURIFIED PROTEIN DERIVATIVE.,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative.",31,106 115 123,31,106,43,133,1,RO-may_diagnose,906547,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative",tuberculosis,purified protein derivative
502244420,7/11/2014 11:02:08,,1320665986,7/11/2014 11:01:31,clixsense,1,23138831,NLD,,,77.174.95.58,31,106,,,43,133,TUBERCULOSIS,PURIFIED PROTEIN DERIVATIVE,"TUBERCULOSIS,",31,106-115-123,PURIFIED PROTEIN DERIVATIVE.,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative.",31,106 115 123,31,106,43,133,1,RO-may_diagnose,906547,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative",tuberculosis,purified protein derivative
502244420,7/11/2014 11:03:07,,1320666483,7/11/2014 11:02:38,instagc,1,23149109,USA,NC,Durham,75.189.206.205,31,106,,,43,133,TUBERCULOSIS,PURIFIED PROTEIN DERIVATIVE,"TUBERCULOSIS,",31,106-115-123,PURIFIED PROTEIN DERIVATIVE.,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative.",31,106 115 123,31,106,43,133,1,RO-may_diagnose,906547,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative",tuberculosis,purified protein derivative
502244420,7/11/2014 11:04:41,,1320667190,7/11/2014 11:04:27,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,31,106,,,43,133,TUBERCULOSIS,PURIFIED PROTEIN DERIVATIVE,"TUBERCULOSIS,",31,95-106-115-123,tuberculin PURIFIED PROTEIN DERIVATIVE.,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative.",31,106 115 123,31,106,43,133,1,RO-may_diagnose,906547,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative",tuberculosis,purified protein derivative
502244420,7/11/2014 11:05:24,,1320667502,7/11/2014 11:04:49,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,31,106,,,43,133,TUBERCULOSIS,PURIFIED PROTEIN DERIVATIVE,"TUBERCULOSIS, Koch's,",31-45,95-106-115-123,tuberculin PURIFIED PROTEIN DERIVATIVE.,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative.",31,106 115 123,31,106,43,133,1,RO-may_diagnose,906547,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative",tuberculosis,purified protein derivative
502244420,7/11/2014 11:06:52,,1320668051,7/11/2014 11:06:12,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,31,106,,,43,133,TUBERCULOSIS,PURIFIED PROTEIN DERIVATIVE,"TUBERCULOSIS,",31,95-106-115-123,tuberculin PURIFIED PROTEIN DERIVATIVE.,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative.",31,106 115 123,31,106,43,133,1,RO-may_diagnose,906547,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative",tuberculosis,purified protein derivative
502244420,7/11/2014 11:07:12,,1320668142,7/11/2014 11:07:04,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,31,106,,,43,133,TUBERCULOSIS,PURIFIED PROTEIN DERIVATIVE,"TUBERCULOSIS,",31,106-115-123,PURIFIED PROTEIN DERIVATIVE.,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative.",31,106 115 123,31,106,43,133,1,RO-may_diagnose,906547,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative",tuberculosis,purified protein derivative
502244420,7/11/2014 11:24:12,,1320676791,7/11/2014 11:24:02,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,31,106,,,43,133,TUBERCULOSIS,PURIFIED PROTEIN DERIVATIVE,"TUBERCULOSIS, Koch's,",31-45,106-115-123,PURIFIED PROTEIN DERIVATIVE.,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative.",31,106 115 123,31,106,43,133,1,RO-may_diagnose,906547,"In contemporary skin tests for tuberculosis, Koch's, or ""old,"" tuberculin has been replaced by tuberculin purified protein derivative",tuberculosis,purified protein derivative
502244421,7/11/2014 10:49:52,,1320661633,7/11/2014 10:49:43,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,85,0,,,103,16,DIABETES INSIPIDUS,WOLFRAM SYNDROME,"DIABETES INSIPIDUS,",85-94,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",85 94,0 8,85,0,103,16,1,RO-has_manifestation,906382,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities",diabetes insipidus,Wolfram syndrome
502244421,7/11/2014 10:55:08,,1320663144,7/11/2014 10:54:37,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,85,0,,,103,16,DIABETES INSIPIDUS,WOLFRAM SYNDROME,"Wolfram syndrome (WFS) DIABETES INSIPIDUS, diabetes mellitus, optic atrophy, deafness,",0-8-85-94-105-114-124-130-139-17,0-8-17-85-94-105-114-124-130-139,"WOLFRAM SYNDROME (WFS) diabetes insipidus, diabetes mellitus, optic atrophy, deafness,","Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",85 94,0 8,85,0,103,16,1,RO-has_manifestation,906382,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities",diabetes insipidus,Wolfram syndrome
502244421,7/11/2014 10:55:11,,1320663151,7/11/2014 10:54:03,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,85,0,,,103,16,DIABETES INSIPIDUS,WOLFRAM SYNDROME,"DIABETES INSIPIDUS, mellitus,",85-94-114,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",85 94,0 8,85,0,103,16,1,RO-has_manifestation,906382,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities",diabetes insipidus,Wolfram syndrome
502244421,7/11/2014 11:06:16,,1320667831,7/11/2014 11:05:59,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,85,0,,,103,16,DIABETES INSIPIDUS,WOLFRAM SYNDROME,"DIABETES INSIPIDUS,",85-94,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",85 94,0 8,85,0,103,16,1,RO-has_manifestation,906382,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities",diabetes insipidus,Wolfram syndrome
502244421,7/11/2014 11:08:22,,1320668634,7/11/2014 11:07:48,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,85,0,,,103,16,DIABETES INSIPIDUS,WOLFRAM SYNDROME,"DIABETES INSIPIDUS,",85-94,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",85 94,0 8,85,0,103,16,1,RO-has_manifestation,906382,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities",diabetes insipidus,Wolfram syndrome
502244421,7/11/2014 11:08:33,,1320668703,7/11/2014 11:08:08,instagc,1,23149109,USA,NC,Durham,75.189.206.205,85,0,,,103,16,DIABETES INSIPIDUS,WOLFRAM SYNDROME,"DIABETES INSIPIDUS,",85-94,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",85 94,0 8,85,0,103,16,1,RO-has_manifestation,906382,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities",diabetes insipidus,Wolfram syndrome
502244421,7/11/2014 11:10:44,,1320670066,7/11/2014 11:10:27,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,85,0,,,103,16,DIABETES INSIPIDUS,WOLFRAM SYNDROME,"DIABETES INSIPIDUS,",85-94,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",85 94,0 8,85,0,103,16,1,RO-has_manifestation,906382,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities",diabetes insipidus,Wolfram syndrome
502244421,7/11/2014 11:23:42,,1320676622,7/11/2014 11:23:17,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,85,0,,,103,16,DIABETES INSIPIDUS,WOLFRAM SYNDROME,"DIABETES INSIPIDUS, diabetes mellitus,",85-94-105-114,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",85 94,0 8,85,0,103,16,1,RO-has_manifestation,906382,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities",diabetes insipidus,Wolfram syndrome
502244421,7/11/2014 11:25:03,,1320677141,7/11/2014 11:24:42,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,85,0,,,103,16,DIABETES INSIPIDUS,WOLFRAM SYNDROME,"DIABETES INSIPIDUS,",85-94,0-8,WOLFRAM SYNDROME,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",85 94,0 8,85,0,103,16,1,RO-has_manifestation,906382,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities",diabetes insipidus,Wolfram syndrome
502244421,7/11/2014 11:43:23,,1320683297,7/11/2014 11:42:53,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,85,0,,,103,16,DIABETES INSIPIDUS,WOLFRAM SYNDROME,"DIABETES INSIPIDUS, diabetes mellitus, optic",85-94-105-114-124,0-8-23-26,WOLFRAM SYNDROME is a,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",85 94,0 8,85,0,103,16,1,RO-has_manifestation,906382,"Wolfram syndrome (WFS) is a rare diffuse neurodegenerative disorder characterized by diabetes insipidus, diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities",diabetes insipidus,Wolfram syndrome
502244422,7/11/2014 10:47:39,,1320660857,7/11/2014 10:46:22,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,0,20,,,16,37,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,0-7,20-30-33,CARCINOMA IN SITU,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",0 7,20 30 33,0,20,16,37,-1,RO-disease_has_finding,901558,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary",Severe dysplasia,carcinoma in situ
502244422,7/11/2014 10:51:12,,1320662009,7/11/2014 10:51:09,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,0,20,,,16,37,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA or carcinoma in,0-7-17-20-30,0-7-17-20-30-33-38-47-55,Severe dysplasia or CARCINOMA IN SITU warrants further evaluation,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",0 7,20 30 33,0,20,16,37,-1,RO-disease_has_finding,901558,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary",Severe dysplasia,carcinoma in situ
502244422,7/11/2014 11:03:36,,1320666681,7/11/2014 11:03:20,clixsense,1,23138831,NLD,,,77.174.95.58,0,20,,,16,37,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA or carcinoma,0-7-17-20,0-7-17-20-30-33,Severe dysplasia or CARCINOMA IN SITU,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",0 7,20 30 33,0,20,16,37,-1,RO-disease_has_finding,901558,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary",Severe dysplasia,carcinoma in situ
502244422,7/11/2014 11:03:40,,1320666710,7/11/2014 11:02:30,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,0,20,,,16,37,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA carcinoma in situ,0-7-20-30-33,0-7-20-30-33,Severe dysplasia CARCINOMA IN SITU,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",0 7,20 30 33,0,20,16,37,-1,RO-disease_has_finding,901558,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary",Severe dysplasia,carcinoma in situ
502244422,7/11/2014 11:05:21,,1320667465,7/11/2014 11:05:05,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,0,20,,,16,37,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,0-7,20-30-33,CARCINOMA IN SITU,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",0 7,20 30 33,0,20,16,37,-1,RO-disease_has_finding,901558,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary",Severe dysplasia,carcinoma in situ
502244422,7/11/2014 11:07:51,,1320668370,7/11/2014 11:07:34,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,0,20,,,16,37,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,0-7,20-30-33,CARCINOMA IN SITU,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",0 7,20 30 33,0,20,16,37,-1,RO-disease_has_finding,901558,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary",Severe dysplasia,carcinoma in situ
502244422,7/11/2014 11:08:51,,1320668885,7/11/2014 11:08:33,instagc,1,23149109,USA,NC,Durham,75.189.206.205,0,20,,,16,37,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,0-7,20-30-33,CARCINOMA IN SITU,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",0 7,20 30 33,0,20,16,37,-1,RO-disease_has_finding,901558,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary",Severe dysplasia,carcinoma in situ
502244422,7/11/2014 11:13:24,,1320672035,7/11/2014 11:12:52,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,0,20,,,16,37,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,0-7,20-30-33,CARCINOMA IN SITU,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",0 7,20 30 33,0,20,16,37,-1,RO-disease_has_finding,901558,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary",Severe dysplasia,carcinoma in situ
502244422,7/11/2014 11:22:21,,1320676043,7/11/2014 11:21:22,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,0,20,,,16,37,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,0-7,20-30-33,CARCINOMA IN SITU,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",0 7,20 30 33,0,20,16,37,-1,RO-disease_has_finding,901558,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary",Severe dysplasia,carcinoma in situ
502244422,7/11/2014 11:23:00,,1320676292,7/11/2014 11:22:49,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,0,20,,,16,37,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,0-7,20-30-33,CARCINOMA IN SITU,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",0 7,20 30 33,0,20,16,37,-1,RO-disease_has_finding,901558,"Severe dysplasia or carcinoma in situ warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary",Severe dysplasia,carcinoma in situ
502244423,7/11/2014 10:49:42,,1320661585,7/11/2014 10:49:03,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,45,126,,,57,136,TUBERCULOSIS,TUBERCULIN,M. TUBERCULOSIS,42-45,126,TUBERCULIN,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",45,126,45,126,57,136,1,RO-may_diagnose,906978,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria",tuberculosis,tuberculin
502244423,7/11/2014 11:02:54,,1320666396,7/11/2014 11:02:34,clixsense,1,23138831,NLD,,,77.174.95.58,45,126,,,57,136,TUBERCULOSIS,TUBERCULIN,"MTSA 10 (for M. TUBERCULOSIS specific antigen 10),",34-37-42-45-58-67-75-29,126,TUBERCULIN,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",45,126,45,126,57,136,1,RO-may_diagnose,906978,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria",tuberculosis,tuberculin
502244423,7/11/2014 11:30:36,,1320679241,7/11/2014 11:29:20,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,45,126,,,57,136,TUBERCULOSIS,TUBERCULIN,"The antigen, which was named MTSA - 10 (for M. TUBERCULOSIS specific antigen 10),",0-4-13-19-23-29-34-37-42-45-58-67-75-33,83-85-91-101-107-117-120-122-126-137-142-147-105,a prime candidate for a component of a new TUBERCULIN that will allow,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",45,126,45,126,57,136,1,RO-may_diagnose,906978,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria",tuberculosis,tuberculin
502244423,7/11/2014 11:37:40,,1320681640,7/11/2014 11:37:35,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,45,126,,,57,136,TUBERCULOSIS,TUBERCULIN,"10 (for M. TUBERCULOSIS specific antigen 10),",34-37-42-45-58-67-75,117-120-122-126-137-142-147,of a new TUBERCULIN that will allow,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",45,126,45,126,57,136,1,RO-may_diagnose,906978,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria",tuberculosis,tuberculin
502244423,7/11/2014 11:38:36,,1320681918,7/11/2014 11:37:46,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,45,126,,,57,136,TUBERCULOSIS,TUBERCULIN,"10 (for M. TUBERCULOSIS specific antigen 10),",34-37-42-45-58-67-75,117-120-122-126,of a new TUBERCULIN,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",45,126,45,126,57,136,1,RO-may_diagnose,906978,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria",tuberculosis,tuberculin
502244423,7/11/2014 11:44:01,,1320683493,7/11/2014 11:43:47,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,45,126,,,57,136,TUBERCULOSIS,TUBERCULIN,M. TUBERCULOSIS,42-45,126,TUBERCULIN,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",45,126,45,126,57,136,1,RO-may_diagnose,906978,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria",tuberculosis,tuberculin
502244423,7/11/2014 11:50:33,,1320686399,7/11/2014 11:50:12,prodege,1,27969454,USA,,,69.76.133.211,45,126,,,57,136,TUBERCULOSIS,TUBERCULIN,"MTSA 10 (for M. TUBERCULOSIS specific antigen 10),",34-37-42-45-58-67-75-29,117-120-122-126-137-142-147,of a new TUBERCULIN that will allow,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",45,126,45,126,57,136,1,RO-may_diagnose,906978,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria",tuberculosis,tuberculin
502244423,7/11/2014 11:50:37,,1320686409,7/11/2014 11:50:03,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,45,126,,,57,136,TUBERCULOSIS,TUBERCULIN,"The antigen, which was named MTSA 10 (for M. TUBERCULOSIS specific antigen 10),",0-4-13-19-23-29-34-37-42-45-58-67-75,117-120-122-126-137-142-147-153-168-173-178-186-193-196-209-224-236-241,of a new TUBERCULIN that will allow discrimination by skin test latent M. tuberculosis infection vaccination with BCG,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",45,126,45,126,57,136,1,RO-may_diagnose,906978,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria",tuberculosis,tuberculin
502244423,7/11/2014 11:51:33,,1320686807,7/11/2014 11:51:14,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.197,45,126,,,57,136,TUBERCULOSIS,TUBERCULIN,"MTSA 10 (for M. TUBERCULOSIS specific antigen 10),",34-37-42-45-58-67-75-29,126,TUBERCULIN,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",45,126,45,126,57,136,1,RO-may_diagnose,906978,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria",tuberculosis,tuberculin
502244423,7/11/2014 11:51:43,,1320686895,7/11/2014 11:50:48,clixsense,1,27969116,NLD,,,91.213.37.165,45,126,,,57,136,TUBERCULOSIS,TUBERCULIN,"MTSA 10 (for M. TUBERCULOSIS specific antigen 10),",34-37-42-45-58-67-75-29,126-193-196-209,TUBERCULIN M. tuberculosis infection,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",45,126,45,126,57,136,1,RO-may_diagnose,906978,"The antigen, which was named MTSA-10 (for M. tuberculosis-specific antigen 10), is a prime candidate for a component of a new tuberculin that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria",tuberculosis,tuberculin
502244424,7/11/2014 10:51:19,,1320662044,7/11/2014 10:51:15,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,25,140,,,38,145,HAEMOPHILIA A,FVIII,"most severe form, HAEMOPHILIA A is a life",7-12-19-25-37-39-42-44,127-134-139-147,factor VIII (FVIII) gene.,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene.",25 37,,25,140,38,145,-1,RO-has_manifestation,906205,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene",haemophilia A,FVIII
502244424,7/11/2014 10:57:05,,1320663758,7/11/2014 10:57:01,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,25,140,,,38,145,HAEMOPHILIA A,FVIII,"most severe form, HAEMOPHILIA A is a life",7-12-19-25-37-39-42-44,127-134-139-147,factor VIII (FVIII) gene.,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene.",25 37,,25,140,38,145,-1,RO-has_manifestation,906205,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene",haemophilia A,FVIII
502244424,7/11/2014 11:02:20,,1320666067,7/11/2014 11:01:54,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,25,140,,,38,145,HAEMOPHILIA A,FVIII,HAEMOPHILIA A,25-37,25-37,haemophilia A,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene.",25 37,,25,140,38,145,-1,RO-has_manifestation,906205,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene",haemophilia A,FVIII
502244424,7/11/2014 11:05:03,,1320667342,7/11/2014 11:04:43,instagc,1,23149109,USA,NC,Durham,75.189.206.205,25,140,,,38,145,HAEMOPHILIA A,FVIII,HAEMOPHILIA A,25-37,134-139-147-127,factor VIII (FVIII) gene.,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene.",25 37,,25,140,38,145,-1,RO-has_manifestation,906205,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene",haemophilia A,FVIII
502244424,7/11/2014 11:09:54,,1320669442,7/11/2014 11:09:31,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,25,140,,,38,145,HAEMOPHILIA A,FVIII,HAEMOPHILIA A,25-37,127-134-139-147,factor VIII (FVIII) gene.,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene.",25 37,,25,140,38,145,-1,RO-has_manifestation,906205,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene",haemophilia A,FVIII
502244424,7/11/2014 11:10:59,,1320670273,7/11/2014 11:10:40,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,25,140,,,38,145,HAEMOPHILIA A,FVIII,HAEMOPHILIA A,25-37,127-134-139-147,factor VIII (FVIII) gene.,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene.",25 37,,25,140,38,145,-1,RO-has_manifestation,906205,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene",haemophilia A,FVIII
502244424,7/11/2014 11:11:11,,1320670436,7/11/2014 11:10:58,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,25,140,,,38,145,HAEMOPHILIA A,FVIII,HAEMOPHILIA A,25-37,127-134-139-147,factor VIII (FVIII) gene.,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene.",25 37,,25,140,38,145,-1,RO-has_manifestation,906205,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene",haemophilia A,FVIII
502244424,7/11/2014 11:14:41,,1320672829,7/11/2014 11:13:50,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,25,140,,,38,145,HAEMOPHILIA A,FVIII,HAEMOPHILIA A,25-37,139,(FVIII),"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene.",25 37,,25,140,38,145,-1,RO-has_manifestation,906205,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene",haemophilia A,FVIII
502244424,7/11/2014 11:19:24,,1320674830,7/11/2014 11:19:02,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,25,140,,,38,145,HAEMOPHILIA A,FVIII,HAEMOPHILIA A,25-37,127-134-139-147,factor VIII (FVIII) gene.,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene.",25 37,,25,140,38,145,-1,RO-has_manifestation,906205,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene",haemophilia A,FVIII
502244424,7/11/2014 11:29:19,,1320678792,7/11/2014 11:28:39,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,25,140,,,38,145,HAEMOPHILIA A,FVIII,HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder,25-37-39-42-44-49-61-74-83,100-107-110-120-127-134-139-147-123,caused by mutations in the factor VIII (FVIII) gene.,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene.",25 37,,25,140,38,145,-1,RO-has_manifestation,906205,"In its most severe form, haemophilia A is a life-threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) gene",haemophilia A,FVIII
502244425,7/11/2014 10:48:03,,1320660993,7/11/2014 10:47:41,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,400,370,,,412,379,TETRACYCLINE,PREGNANCY,TETRACYCLINE,400,370,PREGNANCY:,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",400,370,400,370,412,379,1,RO-contraindicated_drug,901288,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy",Tetracycline,pregnancy
502244425,7/11/2014 10:56:34,,1320663595,7/11/2014 10:56:30,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,400,370,,,412,379,TETRACYCLINE,PREGNANCY,ACE inhibitors ? TETRACYCLINE Coumadin Methimazole Trimethadione,383-387-398-400-415-426-440,344-357-367-370-383-387-400,alternatives preferred in PREGNANCY: ACE inhibitors Tetracycline,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",400,370,400,370,412,379,1,RO-contraindicated_drug,901288,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy",Tetracycline,pregnancy
502244425,7/11/2014 11:06:09,,1320667805,7/11/2014 11:05:50,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,400,370,,,412,379,TETRACYCLINE,PREGNANCY,TETRACYCLINE,400,370,PREGNANCY:,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",400,370,400,370,412,379,1,RO-contraindicated_drug,901288,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy",Tetracycline,pregnancy
502244425,7/11/2014 11:07:49,,1320668363,7/11/2014 11:07:27,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,400,370,,,412,379,TETRACYCLINE,PREGNANCY,TETRACYCLINE,400,370,PREGNANCY:,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",400,370,400,370,412,379,1,RO-contraindicated_drug,901288,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy",Tetracycline,pregnancy
502244425,7/11/2014 11:12:51,,1320671618,7/11/2014 11:12:18,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,400,370,,,412,379,TETRACYCLINE,PREGNANCY,TETRACYCLINE,400,370,PREGNANCY:,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",400,370,400,370,412,379,1,RO-contraindicated_drug,901288,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy",Tetracycline,pregnancy
502244425,7/11/2014 11:12:56,,1320671683,7/11/2014 11:12:31,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,400,370,,,412,379,TETRACYCLINE,PREGNANCY,TETRACYCLINE,400,370,PREGNANCY:,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",400,370,400,370,412,379,1,RO-contraindicated_drug,901288,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy",Tetracycline,pregnancy
502244425,7/11/2014 11:13:55,,1320672420,7/11/2014 11:13:40,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,400,370,,,412,379,TETRACYCLINE,PREGNANCY,ACE inhibitors ? TETRACYCLINE Coumadin Methimazole Trimethadione,383-387-398-400-415-426-440,370,PREGNANCY:,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",400,370,400,370,412,379,1,RO-contraindicated_drug,901288,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy",Tetracycline,pregnancy
502244425,7/11/2014 11:29:13,,1320678764,7/11/2014 11:28:59,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,400,370,,,412,379,TETRACYCLINE,PREGNANCY,? TETRACYCLINE,398-400,370,PREGNANCY:,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",400,370,400,370,412,379,1,RO-contraindicated_drug,901288,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy",Tetracycline,pregnancy
502244425,7/11/2014 11:31:49,,1320679754,7/11/2014 11:31:22,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,400,370,,,412,379,TETRACYCLINE,PREGNANCY,TETRACYCLINE,400,370,PREGNANCY:,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",400,370,400,370,412,379,1,RO-contraindicated_drug,901288,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy",Tetracycline,pregnancy
502244425,7/11/2014 11:41:28,,1320682757,7/11/2014 11:41:21,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,400,370,,,412,379,TETRACYCLINE,PREGNANCY,ACE inhibitors ? TETRACYCLINE Coumadin Methimazole Trimethadione,383-387-398-400-415-426-440,344-357-367-370-383-387-400,alternatives preferred in PREGNANCY: ACE inhibitors Tetracycline,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",400,370,400,370,412,379,1,RO-contraindicated_drug,901288,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in pregnancy: ? ACE inhibitors ? Tetracycline ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy",Tetracycline,pregnancy
502244426,7/11/2014 11:06:11,,1320667817,7/11/2014 11:05:31,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,112,204,,,118,224,TESTES,SPERMATOGENIC ARREST,TESTES,112,204-218,SPERMATOGENIC ARREST.,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest.,112,204 218,112,204,118,224,1,RO-has_finding_site,905466,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest,testes,spermatogenic arrest
502244426,7/11/2014 11:06:28,,1320667910,7/11/2014 11:06:11,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,112,204,,,118,224,TESTES,SPERMATOGENIC ARREST,TESTES,112,204-218,SPERMATOGENIC ARREST.,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest.,112,204 218,112,204,118,224,1,RO-has_finding_site,905466,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest,testes,spermatogenic arrest
502244426,7/11/2014 11:07:06,,1320668104,7/11/2014 11:06:26,instagc,1,23149109,USA,NC,Durham,75.189.206.205,112,204,,,118,224,TESTES,SPERMATOGENIC ARREST,TESTES,112,204-218,SPERMATOGENIC ARREST.,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest.,112,204 218,112,204,118,224,1,RO-has_finding_site,905466,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest,testes,spermatogenic arrest
502244426,7/11/2014 11:26:28,,1320677655,7/11/2014 11:26:14,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,112,204,,,118,224,TESTES,SPERMATOGENIC ARREST,TESTES,112,204-218,SPERMATOGENIC ARREST.,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest.,112,204 218,112,204,118,224,1,RO-has_finding_site,905466,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest,testes,spermatogenic arrest
502244426,7/11/2014 11:32:29,,1320680015,7/11/2014 11:31:35,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,112,204,,,118,224,TESTES,SPERMATOGENIC ARREST,NYD SP16 in the TESTES of patients with Sertoli cell only syndrome,96-100-105-108-112-119-122-131-136-144-149-154,136-144-149-154-163-167-187-190-199-204-218-176,Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST.,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest.,112,204 218,112,204,118,224,1,RO-has_finding_site,905466,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest,testes,spermatogenic arrest
502244426,7/11/2014 11:44:17,,1320683645,7/11/2014 11:43:51,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,112,204,,,118,224,TESTES,SPERMATOGENIC ARREST,TESTES,112,204-218,SPERMATOGENIC ARREST.,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest.,112,204 218,112,204,118,224,1,RO-has_finding_site,905466,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest,testes,spermatogenic arrest
502244426,7/11/2014 11:45:33,,1320684306,7/11/2014 11:45:03,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,112,204,,,118,224,TESTES,SPERMATOGENIC ARREST,abnormal expression in infertile male patients SP16 in the TESTES of patients with,20-29-40-43-53-100-105-108-112-119-122-131-58,136-144-149-154-167-187-190-199-204-218-176,Sertoli cell only syndrome variable expression in patients with SPERMATOGENIC ARREST.,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest.,112,204 218,112,204,118,224,1,RO-has_finding_site,905466,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest,testes,spermatogenic arrest
502244426,7/11/2014 11:47:40,,1320685309,7/11/2014 11:47:22,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,112,204,,,118,224,TESTES,SPERMATOGENIC ARREST,TESTES Sertoli cell only syndrome,112-136-144-149-154,136-144-149-204-218-154,Sertoli cell only syndrome SPERMATOGENIC ARREST.,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest.,112,204 218,112,204,118,224,1,RO-has_finding_site,905466,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest,testes,spermatogenic arrest
502244426,7/11/2014 11:47:51,,1320685388,7/11/2014 11:47:19,prodege,1,27969454,USA,,,69.76.133.211,112,204,,,118,224,TESTES,SPERMATOGENIC ARREST,NYD SP16 in the TESTES of patients with Sertoli cell only syndrome,96-100-105-108-112-119-122-131-136-144-149-154,187-190-199-204-218,in patients with SPERMATOGENIC ARREST.,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest.,112,204 218,112,204,118,224,1,RO-has_finding_site,905466,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest,testes,spermatogenic arrest
502244426,7/11/2014 11:48:30,,1320685606,7/11/2014 11:48:15,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.197,112,204,,,118,224,TESTES,SPERMATOGENIC ARREST,TESTES,112,204-218,SPERMATOGENIC ARREST.,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest.,112,204 218,112,204,118,224,1,RO-has_finding_site,905466,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD-SP16 in the testes of patients with Sertoli-cell-only syndrome and variable expression in patients with spermatogenic arrest,testes,spermatogenic arrest
502244427,7/11/2014 10:51:35,,1320662146,7/11/2014 10:51:32,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,241,169,,,260,184,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,the,221,165-198,and and,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease.",,,241,169,260,184,-1,RO-has_manifestation,906082,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease",Alzheimer's disease,Down's syndrome
502244427,7/11/2014 10:56:17,,1320663523,7/11/2014 10:56:15,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,241,169,,,260,184,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,the,221,165-198,and and,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease.",,,241,169,260,184,-1,RO-has_manifestation,906082,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease",Alzheimer's disease,Down's syndrome
502244427,7/11/2014 11:02:29,,1320666216,7/11/2014 11:01:39,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,241,169,,,260,184,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,the,221,165-198,and and,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease.",,,241,169,260,184,-1,RO-has_manifestation,906082,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease",Alzheimer's disease,Down's syndrome
502244427,7/11/2014 11:04:40,,1320667183,7/11/2014 11:03:45,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,241,169,,,260,184,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,B-protein,-1,-1,B-protein,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease.",,,241,169,260,184,-1,RO-has_manifestation,906082,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease",Alzheimer's disease,Down's syndrome
502244427,7/11/2014 11:08:27,,1320668680,7/11/2014 11:07:22,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,241,169,,,260,184,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,B-protein,-1,,,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease.",,,241,169,260,184,-1,RO-has_manifestation,906082,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease",Alzheimer's disease,Down's syndrome
502244427,7/11/2014 11:08:49,,1320668867,7/11/2014 11:08:39,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,241,169,,,260,184,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,B-protein the,221--1,165-198,and and,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease.",,,241,169,260,184,-1,RO-has_manifestation,906082,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease",Alzheimer's disease,Down's syndrome
502244427,7/11/2014 11:14:49,,1320672849,7/11/2014 11:14:08,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,241,169,,,260,184,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,B-protein,-1,-1,B-protein,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease.",,,241,169,260,184,-1,RO-has_manifestation,906082,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease",Alzheimer's disease,Down's syndrome
502244427,7/11/2014 11:43:09,,1320683252,7/11/2014 11:42:48,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,241,169,,,260,184,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,B-protein Amyloid B a is,0-8-68-158--1,165-198,and and,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease.",,,241,169,260,184,-1,RO-has_manifestation,906082,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease",Alzheimer's disease,Down's syndrome
502244427,7/11/2014 11:43:15,,1320683277,7/11/2014 11:42:56,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,241,169,,,260,184,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,B-protein,-1,241-253,Alzheimer's disease,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease.",,,241,169,260,184,-1,RO-has_manifestation,906082,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease",Alzheimer's disease,Down's syndrome
502244427,7/11/2014 11:48:13,,1320685512,7/11/2014 11:47:20,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,241,169,,,260,184,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,B-protein,-1,-1,B-protein,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease.",,,241,169,260,184,-1,RO-has_manifestation,906082,"Amyloid B-protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease and Down's syndrome (trisomy 21) and may be involved in the pathogenesis of Alzheimer's disease",Alzheimer's disease,Down's syndrome
502244428,7/11/2014 11:05:46,,1320667663,7/11/2014 11:05:28,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,114,142,,,126,154,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA,114,142,METHOTREXATE,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes.,114,142,114,142,126,154,1,RO-may_treat,908313,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes,osteosarcoma,methotrexate
502244428,7/11/2014 11:11:09,,1320670404,7/11/2014 11:10:43,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,114,142,,,126,154,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA,114,142,METHOTREXATE,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes.,114,142,114,142,126,154,1,RO-may_treat,908313,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes,osteosarcoma,methotrexate
502244428,7/11/2014 11:12:30,,1320671341,7/11/2014 11:12:08,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,114,142,,,126,154,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA,114,132-137-142,high dose METHOTREXATE,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes.,114,142,114,142,126,154,1,RO-may_treat,908313,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes,osteosarcoma,methotrexate
502244428,7/11/2014 11:27:18,,1320677957,7/11/2014 11:26:59,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,114,142,,,126,154,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA,114,142,METHOTREXATE,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes.,114,142,114,142,126,154,1,RO-may_treat,908313,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes,osteosarcoma,methotrexate
502244428,7/11/2014 11:39:38,,1320682261,7/11/2014 11:39:21,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,114,142,,,126,154,OSTEOSARCOMA,METHOTREXATE,the treatment of OSTEOSARCOMA high,97-101-111-114-132,127-132-137-142,with high dose METHOTREXATE,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes.,114,142,114,142,126,154,1,RO-may_treat,908313,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes,osteosarcoma,methotrexate
502244428,7/11/2014 11:44:37,,1320683801,7/11/2014 11:44:08,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,114,142,,,126,154,OSTEOSARCOMA,METHOTREXATE,the treatment of OSTEOSARCOMA with high dose methotrexate various chemotherapy regimes.,97-101-111-114-127-132-137-142-200-208-221,101-111-127-132-137-142-155-159-169-183-195-200-208-221-114,treatment of osteosarcoma with high dose METHOTREXATE and summarize other experiences with various chemotherapy regimes.,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes.,114,142,114,142,126,154,1,RO-may_treat,908313,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes,osteosarcoma,methotrexate
502244428,7/11/2014 11:45:48,,1320684390,7/11/2014 11:45:11,prodege,1,27969454,USA,,,69.76.133.211,114,142,,,126,154,OSTEOSARCOMA,METHOTREXATE,the treatment of OSTEOSARCOMA with high dose methotrexate,97-101-111-114-127-132-137-142,97-101-114-127-132-137-142-111,the treatment of osteosarcoma with high dose METHOTREXATE,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes.,114,142,114,142,126,154,1,RO-may_treat,908313,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes,osteosarcoma,methotrexate
502244428,7/11/2014 11:47:31,,1320685237,7/11/2014 11:47:07,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.197,114,142,,,126,154,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA,114,142,METHOTREXATE,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes.,114,142,114,142,126,154,1,RO-may_treat,908313,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes,osteosarcoma,methotrexate
502244428,7/11/2014 11:49:23,,1320685882,7/11/2014 11:48:39,clixsense,1,6337874,CAN,ON,Scarborough,99.244.221.29,114,142,,,126,154,OSTEOSARCOMA,METHOTREXATE,the treatment of OSTEOSARCOMA,97-101-111-114,127-132-137-142,with high dose METHOTREXATE,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes.,114,142,114,142,126,154,1,RO-may_treat,908313,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes,osteosarcoma,methotrexate
502244428,7/11/2014 11:50:11,,1320686139,7/11/2014 11:49:33,clixsense,1,27969116,NLD,,,91.213.37.165,114,142,,,126,154,OSTEOSARCOMA,METHOTREXATE,OSTEOSARCOMA methotrexate,114-142,114-142,osteosarcoma METHOTREXATE,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes.,114,142,114,142,126,154,1,RO-may_treat,908313,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of osteosarcoma with high dose methotrexate and summarize other groups' experiences with various chemotherapy regimes,osteosarcoma,methotrexate
502244429,7/11/2014 10:52:42,,1320662459,7/11/2014 10:52:39,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,178,123,,,195,143,MYASTHENIA GRAVIS,EDROPHONIUM CHLORIDE,13 patients with MYASTHENIA GRAVIS and 8,161-164-173-178-189-201-205,110-113-122-135-145-150-158,of Tensilon (EDROPHONIUM CHLORIDE) were studied in,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls.,178 189,135,178,123,195,143,1,RO-may_diagnose,906603,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls,myasthenia gravis,edrophonium chloride
502244429,7/11/2014 10:56:55,,1320663710,7/11/2014 10:56:34,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,178,123,,,195,143,MYASTHENIA GRAVIS,EDROPHONIUM CHLORIDE,MYASTHENIA GRAVIS,178-189,122-135,(EDROPHONIUM CHLORIDE),Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls.,178 189,135,178,123,195,143,1,RO-may_diagnose,906603,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls,myasthenia gravis,edrophonium chloride
502244429,7/11/2014 10:56:56,,1320663711,7/11/2014 10:56:53,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,178,123,,,195,143,MYASTHENIA GRAVIS,EDROPHONIUM CHLORIDE,13 patients with MYASTHENIA GRAVIS and 8,161-164-173-178-189-201-205,110-113-122-135-145-150-158,of Tensilon (EDROPHONIUM CHLORIDE) were studied in,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls.,178 189,135,178,123,195,143,1,RO-may_diagnose,906603,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls,myasthenia gravis,edrophonium chloride
502244429,7/11/2014 11:02:15,,1320666030,7/11/2014 11:01:36,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,178,123,,,195,143,MYASTHENIA GRAVIS,EDROPHONIUM CHLORIDE,MYASTHENIA GRAVIS,178-189,113-122-135,Tensilon (EDROPHONIUM CHLORIDE),Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls.,178 189,135,178,123,195,143,1,RO-may_diagnose,906603,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls,myasthenia gravis,edrophonium chloride
502244429,7/11/2014 11:03:57,,1320666837,7/11/2014 11:03:37,clixsense,1,23138831,NLD,,,77.174.95.58,178,123,,,195,143,MYASTHENIA GRAVIS,EDROPHONIUM CHLORIDE,MYASTHENIA GRAVIS (MG),178-189-196,113-122-135,Tensilon (EDROPHONIUM CHLORIDE),Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls.,178 189,135,178,123,195,143,1,RO-may_diagnose,906603,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls,myasthenia gravis,edrophonium chloride
502244429,7/11/2014 11:06:25,,1320667894,7/11/2014 11:06:11,instagc,1,23149109,USA,NC,Durham,75.189.206.205,178,123,,,195,143,MYASTHENIA GRAVIS,EDROPHONIUM CHLORIDE,MYASTHENIA GRAVIS,178-189,135-122,(EDROPHONIUM CHLORIDE),Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls.,178 189,135,178,123,195,143,1,RO-may_diagnose,906603,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls,myasthenia gravis,edrophonium chloride
502244429,7/11/2014 11:08:58,,1320668934,7/11/2014 11:08:41,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,178,123,,,195,143,MYASTHENIA GRAVIS,EDROPHONIUM CHLORIDE,MYASTHENIA GRAVIS,178-189,113-122-135,Tensilon (EDROPHONIUM CHLORIDE),Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls.,178 189,135,178,123,195,143,1,RO-may_diagnose,906603,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls,myasthenia gravis,edrophonium chloride
502244429,7/11/2014 11:10:17,,1320669801,7/11/2014 11:09:53,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,178,123,,,195,143,MYASTHENIA GRAVIS,EDROPHONIUM CHLORIDE,MYASTHENIA GRAVIS,178-189,122-135,(EDROPHONIUM CHLORIDE),Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls.,178 189,135,178,123,195,143,1,RO-may_diagnose,906603,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls,myasthenia gravis,edrophonium chloride
502244429,7/11/2014 11:24:44,,1320676996,7/11/2014 11:24:31,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,178,123,,,195,143,MYASTHENIA GRAVIS,EDROPHONIUM CHLORIDE,13 MYASTHENIA GRAVIS,161-178-189,122-135,(EDROPHONIUM CHLORIDE),Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls.,178 189,135,178,123,195,143,1,RO-may_diagnose,906603,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls,myasthenia gravis,edrophonium chloride
502244429,7/11/2014 11:38:25,,1320681875,7/11/2014 11:38:11,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,178,123,,,195,143,MYASTHENIA GRAVIS,EDROPHONIUM CHLORIDE,13 patients with MYASTHENIA GRAVIS and 8 controls.,161-164-173-178-189-201-205-214,110-113-122-135-145-150-158-164,of Tensilon (EDROPHONIUM CHLORIDE) were studied in patients,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls.,178 189,135,178,123,195,143,1,RO-may_diagnose,906603,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (edrophonium chloride) were studied in 13 patients with myasthenia gravis (MG) and 8 normal controls,myasthenia gravis,edrophonium chloride
502244430,7/11/2014 10:52:25,,1320662361,7/11/2014 10:52:16,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,27,108,,,32,127,BONES,NON-UNION FRACTURES,segmental defects in BONES can result from,6-16-24-27-33-37-44,80-91-105-108-112-118,"congenital malformation, or NON UNION FRACTURES.","Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures.",27,108 112 118,27,108,32,127,1,RO-has_finding_site,905335,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures",bones,non-union fractures
502244430,7/11/2014 11:05:58,,1320667747,7/11/2014 11:05:43,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,27,108,,,32,127,BONES,NON-UNION FRACTURES,BONES,27,80-91-105-108-112-118,"congenital malformation, or NON UNION FRACTURES.","Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures.",27,108 112 118,27,108,32,127,1,RO-has_finding_site,905335,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures",bones,non-union fractures
502244430,7/11/2014 11:10:41,,1320670001,7/11/2014 11:10:07,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,27,108,,,32,127,BONES,NON-UNION FRACTURES,BONES,27,108-112-118,NON UNION FRACTURES.,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures.",27,108 112 118,27,108,32,127,1,RO-has_finding_site,905335,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures",bones,non-union fractures
502244430,7/11/2014 11:11:41,,1320670747,7/11/2014 11:11:22,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,27,108,,,32,127,BONES,NON-UNION FRACTURES,segmental defects in BONES,6-16-24-27,108-112-118,NON UNION FRACTURES.,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures.",27,108 112 118,27,108,32,127,1,RO-has_finding_site,905335,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures",bones,non-union fractures
502244430,7/11/2014 11:12:49,,1320671587,7/11/2014 11:12:35,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,27,108,,,32,127,BONES,NON-UNION FRACTURES,segmental defects in BONES,6-16-24-27,80-91-105-108-112-118,"congenital malformation, or NON UNION FRACTURES.","Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures.",27,108 112 118,27,108,32,127,1,RO-has_finding_site,905335,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures",bones,non-union fractures
502244430,7/11/2014 11:37:45,,1320681672,7/11/2014 11:36:36,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,27,108,,,32,127,BONES,NON-UNION FRACTURES,segmental defects in BONES,6-16-24-27,80-91-105-108-112-118,"congenital malformation, or NON UNION FRACTURES.","Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures.",27,108 112 118,27,108,32,127,1,RO-has_finding_site,905335,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures",bones,non-union fractures
502244430,7/11/2014 11:46:44,,1320684863,7/11/2014 11:46:12,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,27,108,,,32,127,BONES,NON-UNION FRACTURES,segmental defects in BONES,6-16-24-27,80-91-108-112-118,"congenital malformation, NON UNION FRACTURES.","Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures.",27,108 112 118,27,108,32,127,1,RO-has_finding_site,905335,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures",bones,non-union fractures
502244430,7/11/2014 11:47:38,,1320685304,7/11/2014 11:47:11,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,27,108,,,32,127,BONES,NON-UNION FRACTURES,"segmental defects in BONES can result from tumor removal, massive trauma, congenital malformation, non - union fractures.",6-16-24-27-33-37-44-49-55-64-72-80-91-108-111-112-118,6-16-24-27-37-44-49-55-80-91-105-108-112-118-72,"segmental defects in bones result from tumor removal, trauma, congenital malformation, or NON UNION FRACTURES.","Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures.",27,108 112 118,27,108,32,127,1,RO-has_finding_site,905335,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures",bones,non-union fractures
502244430,7/11/2014 11:50:17,,1320686205,7/11/2014 11:49:20,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,27,108,,,32,127,BONES,NON-UNION FRACTURES,"segmental defects in BONES can result from tumor removal,",6-16-24-27-33-37-44-49-55,6-16-33-37-44-49-55-64-80-91-105-108-112-118-72,"segmental defects can result from tumor removal, massive trauma, congenital malformation, or NON UNION FRACTURES.","Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures.",27,108 112 118,27,108,32,127,1,RO-has_finding_site,905335,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures",bones,non-union fractures
502244430,7/11/2014 11:51:25,,1320686747,7/11/2014 11:49:49,instagc,1,19874561,GBR,C3,Saint Ives,80.4.147.13,27,108,,,32,127,BONES,NON-UNION FRACTURES,Large segmental defects in BONES,6-16-24-27-0,108-112-118,NON UNION FRACTURES.,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures.",27,108 112 118,27,108,32,127,1,RO-has_finding_site,905335,"Large segmental defects in bones can result from tumor removal, massive trauma, congenital malformation, or non-union fractures",bones,non-union fractures
502244431,7/11/2014 10:50:54,,1320661960,7/11/2014 10:50:50,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,65,23,,,80,32,INFLUENZA VIRUS,INFLUENZA,are: collection of INFLUENZA VIRUS isolates and analysis,46-51-62-65-75-81-90-94,4-9-20-23-33-46-51,main objectives of INFLUENZA surveillance are: collection,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics.,65 75,23,65,23,80,32,-1,RO-has_causative_agent,903838,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics,influenza virus,influenza
502244431,7/11/2014 11:02:08,,1320665985,7/11/2014 11:01:35,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,65,23,,,80,32,INFLUENZA VIRUS,INFLUENZA,INFLUENZA VIRUS isolates,65-75-81,23,INFLUENZA,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics.,65 75,23,65,23,80,32,-1,RO-has_causative_agent,903838,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics,influenza virus,influenza
502244431,7/11/2014 11:09:29,,1320669208,7/11/2014 11:09:14,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,65,23,,,80,32,INFLUENZA VIRUS,INFLUENZA,INFLUENZA VIRUS isolates,65-75-81,23-33,INFLUENZA surveillance,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics.,65 75,23,65,23,80,32,-1,RO-has_causative_agent,903838,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics,influenza virus,influenza
502244431,7/11/2014 11:22:11,,1320675978,7/11/2014 11:21:54,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,65,23,,,80,32,INFLUENZA VIRUS,INFLUENZA,INFLUENZA VIRUS,65-75,23,INFLUENZA,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics.,65 75,23,65,23,80,32,-1,RO-has_causative_agent,903838,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics,influenza virus,influenza
502244431,7/11/2014 11:22:42,,1320676186,7/11/2014 11:20:33,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,65,23,,,80,32,INFLUENZA VIRUS,INFLUENZA,main objectives of surveillance are: collection of INFLUENZA VIRUS isolates and analysis of their antigenic characteristics,4-9-20-46-51-62-65-75-81-90-94-103-106-112-122-33,4-9-20-23-33-46-51-62-65-75-81-90-94-103-106-112-122,main objectives of INFLUENZA surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics.,65 75,23,65,23,80,32,-1,RO-has_causative_agent,903838,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics,influenza virus,influenza
502244431,7/11/2014 11:25:25,,1320677285,7/11/2014 11:25:11,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,65,23,,,80,32,INFLUENZA VIRUS,INFLUENZA,INFLUENZA VIRUS,65-75,23,INFLUENZA,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics.,65 75,23,65,23,80,32,-1,RO-has_causative_agent,903838,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics,influenza virus,influenza
502244431,7/11/2014 11:29:50,,1320678985,7/11/2014 11:29:05,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,65,23,,,80,32,INFLUENZA VIRUS,INFLUENZA,INFLUENZA VIRUS,65-75,23,INFLUENZA,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics.,65 75,23,65,23,80,32,-1,RO-has_causative_agent,903838,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics,influenza virus,influenza
502244431,7/11/2014 11:49:47,,1320685954,7/11/2014 11:49:11,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.197,65,23,,,80,32,INFLUENZA VIRUS,INFLUENZA,INFLUENZA VIRUS isolates,65-75-81,23-33,INFLUENZA surveillance,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics.,65 75,23,65,23,80,32,-1,RO-has_causative_agent,903838,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics,influenza virus,influenza
502244431,7/11/2014 11:51:15,,1320686672,7/11/2014 11:50:34,prodege,1,27969454,USA,,,69.76.133.211,65,23,,,80,32,INFLUENZA VIRUS,INFLUENZA,collection of INFLUENZA VIRUS isolates,51-62-65-75-81,4-9-20-23-33-46-51,main objectives of INFLUENZA surveillance are: collection,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics.,65 75,23,65,23,80,32,-1,RO-has_causative_agent,903838,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics,influenza virus,influenza
502244431,7/11/2014 11:54:56,,1320688130,7/11/2014 11:54:03,instagc,1,19874561,GBR,C3,Saint Ives,80.4.147.13,65,23,,,80,32,INFLUENZA VIRUS,INFLUENZA,INFLUENZA VIRUS,65-75,23,INFLUENZA,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics.,65 75,23,65,23,80,32,-1,RO-has_causative_agent,903838,The main objectives of influenza surveillance are: collection of influenza virus isolates and analysis of their antigenic characteristics so that the most appropriate virus variants can be recommended as constituents of influenza vaccines for use during the next epidemiological season; collection and analysis of information on influenza morbidity and mortality; and earliest possible detection of influenza epidemics,influenza virus,influenza
502244432,7/11/2014 10:52:50,,1320662469,7/11/2014 10:52:36,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,122,191,,,132,204,DEPRESSION,DEXAMETHASONE,"among patients with DEPRESSION, which can be",102-108-117-122-134-140-144,173-178-182-191-226,with the combined DEXAMETHASONE releasing,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test.",122,191,122,191,132,204,1,RO-may_diagnose,906529,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test",depression,dexamethasone
502244432,7/11/2014 11:02:52,,1320666341,7/11/2014 11:02:16,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,122,191,,,132,204,DEPRESSION,DEXAMETHASONE,"DEPRESSION,",122,191,DEXAMETHASONE,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test.",122,191,122,191,132,204,1,RO-may_diagnose,906529,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test",depression,dexamethasone
502244432,7/11/2014 11:10:57,,1320670239,7/11/2014 11:10:35,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,122,191,,,132,204,DEPRESSION,DEXAMETHASONE,"DEPRESSION,",122,182-191-211,combined DEXAMETHASONE corticotrophin,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test.",122,191,122,191,132,204,1,RO-may_diagnose,906529,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test",depression,dexamethasone
502244432,7/11/2014 11:19:00,,1320674637,7/11/2014 11:18:44,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,122,191,,,132,204,DEPRESSION,DEXAMETHASONE,"DEPRESSION,",122,191,DEXAMETHASONE,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test.",122,191,122,191,132,204,1,RO-may_diagnose,906529,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test",depression,dexamethasone
502244432,7/11/2014 11:27:33,,1320678110,7/11/2014 11:27:18,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,122,191,,,132,204,DEPRESSION,DEXAMETHASONE,"DEPRESSION,",122,191,DEXAMETHASONE,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test.",122,191,122,191,132,204,1,RO-may_diagnose,906529,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test",depression,dexamethasone
502244432,7/11/2014 11:30:36,,1320679269,7/11/2014 11:30:12,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,122,191,,,132,204,DEPRESSION,DEXAMETHASONE,"DEPRESSION,",122,191,DEXAMETHASONE,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test.",122,191,122,191,132,204,1,RO-may_diagnose,906529,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test",depression,dexamethasone
502244432,7/11/2014 11:45:43,,1320684378,7/11/2014 11:45:21,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,122,191,,,132,204,DEPRESSION,DEXAMETHASONE,"DEPRESSION,",122,182-191,combined DEXAMETHASONE,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test.",122,191,122,191,132,204,1,RO-may_diagnose,906529,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test",depression,dexamethasone
502244432,7/11/2014 11:47:19,,1320685165,7/11/2014 11:47:00,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,122,191,,,132,204,DEPRESSION,DEXAMETHASONE,"DEPRESSION,",122,191,DEXAMETHASONE,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test.",122,191,122,191,132,204,1,RO-may_diagnose,906529,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test",depression,dexamethasone
502244432,7/11/2014 11:48:30,,1320685600,7/11/2014 11:47:52,prodege,1,27969454,USA,,,69.76.133.211,122,191,,,132,204,DEPRESSION,DEXAMETHASONE,"among patients with DEPRESSION,",102-108-117-122,173-178-182-191-205-211-226-236-244-250,with the combined DEXAMETHASONE (dex) corticotrophin releasing hormone (CRH) test.,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test.",122,191,122,191,132,204,1,RO-may_diagnose,906529,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test",depression,dexamethasone
502244432,7/11/2014 11:49:32,,1320685929,7/11/2014 11:48:37,clixsense,1,27969116,NLD,,,91.213.37.165,122,191,,,132,204,DEPRESSION,DEXAMETHASONE,"DEPRESSION, dexamethasone (dex) / corticotrophin hormone (CRH)",122-191-205-210-211-236-244,191-205-211-236-244,DEXAMETHASONE (dex) corticotrophin hormone (CRH),"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test.",122,191,122,191,132,204,1,RO-may_diagnose,906529,"Impaired regulation of the hypothalamus-pituitary-adrenocortical (HPA) system is a consistent finding among patients with depression, which can be most sensitively detected with the combined dexamethasone (dex)/corticotrophin releasing hormone (CRH) test",depression,dexamethasone
502244433,7/11/2014 10:52:01,,1320662284,7/11/2014 10:51:57,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,113,60,,,134,81,MANDIBULAR HYPOPLASIA,HEMIFACIAL MICROSOMIA,patients with bilateral MANDIBULAR HYPOPLASIA.,89-98-103-113-124,35-44-49-60-71-82-86-89,patients with unilateral HEMIFACIAL MICROSOMIA and 19 patients,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia.,113 124,60 71,113,60,134,81,-1,RO-has_manifestation,906013,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia,mandibular hypoplasia,hemifacial microsomia
502244433,7/11/2014 10:58:55,,1320664408,7/11/2014 10:58:46,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,113,60,,,134,81,MANDIBULAR HYPOPLASIA,HEMIFACIAL MICROSOMIA,bilateral MANDIBULAR HYPOPLASIA.,103-113-124,49-60-71,unilateral HEMIFACIAL MICROSOMIA,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia.,113 124,60 71,113,60,134,81,-1,RO-has_manifestation,906013,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia,mandibular hypoplasia,hemifacial microsomia
502244433,7/11/2014 11:03:29,,1320666629,7/11/2014 11:03:08,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,113,60,,,134,81,MANDIBULAR HYPOPLASIA,HEMIFACIAL MICROSOMIA,bilateral MANDIBULAR HYPOPLASIA.,113-124-103,49-60-71,unilateral HEMIFACIAL MICROSOMIA,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia.,113 124,60 71,113,60,134,81,-1,RO-has_manifestation,906013,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia,mandibular hypoplasia,hemifacial microsomia
502244433,7/11/2014 11:07:20,,1320668197,7/11/2014 11:06:54,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,113,60,,,134,81,MANDIBULAR HYPOPLASIA,HEMIFACIAL MICROSOMIA,bilateral MANDIBULAR HYPOPLASIA.,103-113-124,49-60-71,unilateral HEMIFACIAL MICROSOMIA,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia.,113 124,60 71,113,60,134,81,-1,RO-has_manifestation,906013,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia,mandibular hypoplasia,hemifacial microsomia
502244433,7/11/2014 11:08:52,,1320668902,7/11/2014 11:08:41,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,113,60,,,134,81,MANDIBULAR HYPOPLASIA,HEMIFACIAL MICROSOMIA,bilateral MANDIBULAR HYPOPLASIA.,103-113-124,49-60-71,unilateral HEMIFACIAL MICROSOMIA,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia.,113 124,60 71,113,60,134,81,-1,RO-has_manifestation,906013,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia,mandibular hypoplasia,hemifacial microsomia
502244433,7/11/2014 11:19:37,,1320674924,7/11/2014 11:19:24,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,113,60,,,134,81,MANDIBULAR HYPOPLASIA,HEMIFACIAL MICROSOMIA,bilateral MANDIBULAR HYPOPLASIA.,103-113-124,49-60-71,unilateral HEMIFACIAL MICROSOMIA,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia.,113 124,60 71,113,60,134,81,-1,RO-has_manifestation,906013,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia,mandibular hypoplasia,hemifacial microsomia
502244433,7/11/2014 11:23:18,,1320676475,7/11/2014 11:22:58,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,113,60,,,134,81,MANDIBULAR HYPOPLASIA,HEMIFACIAL MICROSOMIA,MANDIBULAR HYPOPLASIA.,113-124,60-71,HEMIFACIAL MICROSOMIA,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia.,113 124,60 71,113,60,134,81,-1,RO-has_manifestation,906013,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia,mandibular hypoplasia,hemifacial microsomia
502244433,7/11/2014 11:41:42,,1320682813,7/11/2014 11:41:37,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,113,60,,,134,81,MANDIBULAR HYPOPLASIA,HEMIFACIAL MICROSOMIA,patients with bilateral MANDIBULAR HYPOPLASIA.,89-98-103-113-124,35-44-49-60-71-82-86-89,patients with unilateral HEMIFACIAL MICROSOMIA and 19 patients,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia.,113 124,60 71,113,60,134,81,-1,RO-has_manifestation,906013,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia,mandibular hypoplasia,hemifacial microsomia
502244433,7/11/2014 11:42:00,,1320682909,7/11/2014 11:41:31,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,113,60,,,134,81,MANDIBULAR HYPOPLASIA,HEMIFACIAL MICROSOMIA,unilateral hemifacial microsomia patients with bilateral MANDIBULAR HYPOPLASIA.,49-60-89-98-103-113-124-71,35-44-49-60-71-82-86-89-103-113-124,patients with unilateral HEMIFACIAL MICROSOMIA and 19 patients bilateral mandibular hypoplasia.,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia.,113 124,60 71,113,60,134,81,-1,RO-has_manifestation,906013,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia,mandibular hypoplasia,hemifacial microsomia
502244433,7/11/2014 11:42:18,,1320682990,7/11/2014 11:42:07,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,113,60,,,134,81,MANDIBULAR HYPOPLASIA,HEMIFACIAL MICROSOMIA,bilateral MANDIBULAR HYPOPLASIA.,103-113-124,49-60-71,unilateral HEMIFACIAL MICROSOMIA,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia.,113 124,60 71,113,60,134,81,-1,RO-has_manifestation,906013,This procedure has been used in 87 patients with unilateral hemifacial microsomia and 19 patients with bilateral mandibular hypoplasia,mandibular hypoplasia,hemifacial microsomia
502244434,7/11/2014 10:50:02,,1320661693,7/11/2014 10:49:53,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,82,4,,,92,17,DEPRESSION,DEXAMETHASONE,DEPRESSION.,82,4,DEXAMETHASONE,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression.",82,4,82,4,92,17,1,RO-may_diagnose,906827,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression",depression,dexamethasone
502244434,7/11/2014 11:01:35,,1320665614,7/11/2014 11:01:12,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,82,4,,,92,17,DEPRESSION,DEXAMETHASONE,DEPRESSION.,82,4,DEXAMETHASONE,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression.",82,4,82,4,92,17,1,RO-may_diagnose,906827,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression",depression,dexamethasone
502244434,7/11/2014 11:06:38,,1320667956,7/11/2014 11:06:29,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,82,4,,,92,17,DEPRESSION,DEXAMETHASONE,DEPRESSION.,82,4,DEXAMETHASONE,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression.",82,4,82,4,92,17,1,RO-may_diagnose,906827,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression",depression,dexamethasone
502244434,7/11/2014 11:08:46,,1320668850,7/11/2014 11:08:29,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,82,4,,,92,17,DEPRESSION,DEXAMETHASONE,DEPRESSION.,82,4-18,DEXAMETHASONE suppression,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression.",82,4,82,4,92,17,1,RO-may_diagnose,906827,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression",depression,dexamethasone
502244434,7/11/2014 11:09:46,,1320669353,7/11/2014 11:09:32,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,82,4,,,92,17,DEPRESSION,DEXAMETHASONE,DEPRESSION.,82,4,DEXAMETHASONE,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression.",82,4,82,4,92,17,1,RO-may_diagnose,906827,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression",depression,dexamethasone
502244434,7/11/2014 11:11:33,,1320670681,7/11/2014 11:11:25,instagc,1,23149109,USA,NC,Durham,75.189.206.205,82,4,,,92,17,DEPRESSION,DEXAMETHASONE,DEPRESSION.,82,4,DEXAMETHASONE,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression.",82,4,82,4,92,17,1,RO-may_diagnose,906827,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression",depression,dexamethasone
502244434,7/11/2014 11:12:10,,1320671109,7/11/2014 11:11:57,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,82,4,,,92,17,DEPRESSION,DEXAMETHASONE,DEPRESSION.,82,4,DEXAMETHASONE,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression.",82,4,82,4,92,17,1,RO-may_diagnose,906827,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression",depression,dexamethasone
502244434,7/11/2014 11:23:58,,1320676713,7/11/2014 11:23:47,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,82,4,,,92,17,DEPRESSION,DEXAMETHASONE,DEPRESSION.,82,4,DEXAMETHASONE,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression.",82,4,82,4,92,17,1,RO-may_diagnose,906827,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression",depression,dexamethasone
502244434,7/11/2014 11:38:38,,1320681943,7/11/2014 11:37:51,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,82,4,,,92,17,DEPRESSION,DEXAMETHASONE,"dexamethasone suppression test detection, diagnosis, and managemnt of DEPRESSION.",4-18-30-43-65-69-79-82-54,0-4-18-30-35-43-54-69-82,"The DEXAMETHASONE suppression test for detection, diagnosis, managemnt depression.","The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression.",82,4,82,4,92,17,1,RO-may_diagnose,906827,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression",depression,dexamethasone
502244434,7/11/2014 11:41:36,,1320682782,7/11/2014 11:41:29,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,82,4,,,92,17,DEPRESSION,DEXAMETHASONE,and managemnt of DEPRESSION.,65-69-79-82,0-4-18-30-35-54,"The DEXAMETHASONE suppression test for diagnosis,","The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression.",82,4,82,4,92,17,1,RO-may_diagnose,906827,"The dexamethasone suppression test for the detection, diagnosis, and managemnt of depression",depression,dexamethasone
502244435,7/11/2014 10:50:49,,1320661941,7/11/2014 10:50:41,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,16,0,,,39,11,ALLERGIC CONJUNCTIVITIS,OLOPATADINE,Olopatadine for ALLERGIC CONJUNCTIVITIS.,0-12-16-25,0-12-16-25,OLOPATADINE for allergic conjunctivitis.,Olopatadine for allergic conjunctivitis.,16 25,0,16,0,39,11,1,RO-may_treat,907615,Olopatadine for allergic conjunctivitis,allergic conjunctivitis,Olopatadine
502244435,7/11/2014 10:55:16,,1320663209,7/11/2014 10:55:09,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,16,0,,,39,11,ALLERGIC CONJUNCTIVITIS,OLOPATADINE,Olopatadine for ALLERGIC CONJUNCTIVITIS.,0-12-16-25,0-12-16-25,OLOPATADINE for allergic conjunctivitis.,Olopatadine for allergic conjunctivitis.,16 25,0,16,0,39,11,1,RO-may_treat,907615,Olopatadine for allergic conjunctivitis,allergic conjunctivitis,Olopatadine
502244435,7/11/2014 10:57:02,,1320663751,7/11/2014 10:56:55,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,16,0,,,39,11,ALLERGIC CONJUNCTIVITIS,OLOPATADINE,ALLERGIC CONJUNCTIVITIS.,16-25,0,OLOPATADINE,Olopatadine for allergic conjunctivitis.,16 25,0,16,0,39,11,1,RO-may_treat,907615,Olopatadine for allergic conjunctivitis,allergic conjunctivitis,Olopatadine
502244435,7/11/2014 10:57:26,,1320663921,7/11/2014 10:56:58,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,16,0,,,39,11,ALLERGIC CONJUNCTIVITIS,OLOPATADINE,ALLERGIC CONJUNCTIVITIS.,16-25,0,OLOPATADINE,Olopatadine for allergic conjunctivitis.,16 25,0,16,0,39,11,1,RO-may_treat,907615,Olopatadine for allergic conjunctivitis,allergic conjunctivitis,Olopatadine
502244435,7/11/2014 11:01:09,,1320665323,7/11/2014 11:00:51,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,16,0,,,39,11,ALLERGIC CONJUNCTIVITIS,OLOPATADINE,ALLERGIC CONJUNCTIVITIS.,16-25,0,OLOPATADINE,Olopatadine for allergic conjunctivitis.,16 25,0,16,0,39,11,1,RO-may_treat,907615,Olopatadine for allergic conjunctivitis,allergic conjunctivitis,Olopatadine
502244435,7/11/2014 11:13:25,,1320672050,7/11/2014 11:13:15,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,16,0,,,39,11,ALLERGIC CONJUNCTIVITIS,OLOPATADINE,ALLERGIC CONJUNCTIVITIS.,16-25,0,OLOPATADINE,Olopatadine for allergic conjunctivitis.,16 25,0,16,0,39,11,1,RO-may_treat,907615,Olopatadine for allergic conjunctivitis,allergic conjunctivitis,Olopatadine
502244435,7/11/2014 11:16:27,,1320673631,7/11/2014 11:13:58,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,16,0,,,39,11,ALLERGIC CONJUNCTIVITIS,OLOPATADINE,ALLERGIC CONJUNCTIVITIS.,16-25,0-16-25-12,OLOPATADINE for allergic conjunctivitis.,Olopatadine for allergic conjunctivitis.,16 25,0,16,0,39,11,1,RO-may_treat,907615,Olopatadine for allergic conjunctivitis,allergic conjunctivitis,Olopatadine
502244435,7/11/2014 11:40:06,,1320682383,7/11/2014 11:39:55,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,16,0,,,39,11,ALLERGIC CONJUNCTIVITIS,OLOPATADINE,Olopatadine ALLERGIC CONJUNCTIVITIS.,16-25-0,0-16-25,OLOPATADINE allergic conjunctivitis.,Olopatadine for allergic conjunctivitis.,16 25,0,16,0,39,11,1,RO-may_treat,907615,Olopatadine for allergic conjunctivitis,allergic conjunctivitis,Olopatadine
502244435,7/11/2014 11:40:57,,1320682619,7/11/2014 11:40:43,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,16,0,,,39,11,ALLERGIC CONJUNCTIVITIS,OLOPATADINE,Olopatadine for ALLERGIC CONJUNCTIVITIS.,0-12-16-25,0-12-16-25,OLOPATADINE for allergic conjunctivitis.,Olopatadine for allergic conjunctivitis.,16 25,0,16,0,39,11,1,RO-may_treat,907615,Olopatadine for allergic conjunctivitis,allergic conjunctivitis,Olopatadine
502244435,7/11/2014 11:49:05,,1320685750,7/11/2014 11:48:38,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,16,0,,,39,11,ALLERGIC CONJUNCTIVITIS,OLOPATADINE,Olopatadine for ALLERGIC CONJUNCTIVITIS.,0-12-16-25,0-12-16-25,OLOPATADINE for allergic conjunctivitis.,Olopatadine for allergic conjunctivitis.,16 25,0,16,0,39,11,1,RO-may_treat,907615,Olopatadine for allergic conjunctivitis,allergic conjunctivitis,Olopatadine
502244436,7/11/2014 10:51:46,,1320662220,7/11/2014 10:51:42,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,3,42,,,7,49,BONE,RICKETS,WT BONE explanted into Hyp,0-3-8-18-23,23-27-32-42-50-54-68,"Hyp mice developed RICKETS and osteomalacia, but","WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",3,42,3,42,7,49,1,RO-disease_has_primary_anatomic_site,902183,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization",bone,rickets
502244436,7/11/2014 10:56:43,,1320663662,7/11/2014 10:56:40,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,3,42,,,7,49,BONE,RICKETS,WT BONE explanted into Hyp,0-3-8-18-23,23-27-32-42-50-54-68,"Hyp mice developed RICKETS and osteomalacia, but","WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",3,42,3,42,7,49,1,RO-disease_has_primary_anatomic_site,902183,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization",bone,rickets
502244436,7/11/2014 11:02:37,,1320666252,7/11/2014 11:01:40,instagc,1,23149109,USA,NC,Durham,75.189.206.205,3,42,,,7,49,BONE,RICKETS,WT BONE,3-0,42,RICKETS,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",3,42,3,42,7,49,1,RO-disease_has_primary_anatomic_site,902183,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization",bone,rickets
502244436,7/11/2014 11:04:39,,1320667172,7/11/2014 11:04:23,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,3,42,,,7,49,BONE,RICKETS,BONE,3,42,RICKETS,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",3,42,3,42,7,49,1,RO-disease_has_primary_anatomic_site,902183,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization",bone,rickets
502244436,7/11/2014 11:07:10,,1320668133,7/11/2014 11:06:32,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,3,42,,,7,49,BONE,RICKETS,WT BONE,0-3,42,RICKETS,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",3,42,3,42,7,49,1,RO-disease_has_primary_anatomic_site,902183,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization",bone,rickets
502244436,7/11/2014 11:09:52,,1320669424,7/11/2014 11:09:27,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,3,42,,,7,49,BONE,RICKETS,WT BONE,0-3,42,RICKETS,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",3,42,3,42,7,49,1,RO-disease_has_primary_anatomic_site,902183,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization",bone,rickets
502244436,7/11/2014 11:10:43,,1320670034,7/11/2014 11:10:27,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,3,42,,,7,49,BONE,RICKETS,WT BONE,0-3,42,RICKETS,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",3,42,3,42,7,49,1,RO-disease_has_primary_anatomic_site,902183,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization",bone,rickets
502244436,7/11/2014 11:12:50,,1320671601,7/11/2014 11:12:26,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,3,42,,,7,49,BONE,RICKETS,BONE,3,42,RICKETS,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",3,42,3,42,7,49,1,RO-disease_has_primary_anatomic_site,902183,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization",bone,rickets
502244436,7/11/2014 11:25:40,,1320677372,7/11/2014 11:25:26,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,3,42,,,7,49,BONE,RICKETS,WT BONE,0-3,42,RICKETS,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",3,42,3,42,7,49,1,RO-disease_has_primary_anatomic_site,902183,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization",bone,rickets
502244436,7/11/2014 11:32:35,,1320680052,7/11/2014 11:32:13,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,3,42,,,7,49,BONE,RICKETS,BONE,3,42,RICKETS,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",3,42,3,42,7,49,1,RO-disease_has_primary_anatomic_site,902183,"WT bone explanted into Hyp mice developed rickets and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization",bone,rickets
502244437,7/11/2014 10:48:48,,1320661273,7/11/2014 10:48:34,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,31,103,,,43,120,HYPERTENSION,PHAEOCHROMOCYTOMA,HYPERTENSION,31,103,PHAEOCHROMOCYTOMA,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour.,31,103,31,103,43,120,1,RO-disease_may_have_finding,902902,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour,hypertension,phaeochromocytoma
502244437,7/11/2014 10:51:08,,1320661997,7/11/2014 10:51:05,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,31,103,,,43,120,HYPERTENSION,PHAEOCHROMOCYTOMA,of symptoms and HYPERTENSION in a patient,15-18-27-31-44-47-49,86-89-99-103-121-128-134,an operation for PHAEOCHROMOCYTOMA should alert the,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour.,31,103,31,103,43,120,1,RO-disease_may_have_finding,902902,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour,hypertension,phaeochromocytoma
502244437,7/11/2014 10:56:13,,1320663508,7/11/2014 10:56:10,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,31,103,,,43,120,HYPERTENSION,PHAEOCHROMOCYTOMA,of symptoms and HYPERTENSION in a patient,15-18-27-31-44-47-49,86-89-99-103-121-128-134,an operation for PHAEOCHROMOCYTOMA should alert the,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour.,31,103,31,103,43,120,1,RO-disease_may_have_finding,902902,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour,hypertension,phaeochromocytoma
502244437,7/11/2014 11:06:26,,1320667911,7/11/2014 11:06:07,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,31,103,,,43,120,HYPERTENSION,PHAEOCHROMOCYTOMA,HYPERTENSION,31,103,PHAEOCHROMOCYTOMA,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour.,31,103,31,103,43,120,1,RO-disease_may_have_finding,902902,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour,hypertension,phaeochromocytoma
502244437,7/11/2014 11:08:25,,1320668657,7/11/2014 11:08:06,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,31,103,,,43,120,HYPERTENSION,PHAEOCHROMOCYTOMA,HYPERTENSION,31,103,PHAEOCHROMOCYTOMA,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour.,31,103,31,103,43,120,1,RO-disease_may_have_finding,902902,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour,hypertension,phaeochromocytoma
502244437,7/11/2014 11:08:40,,1320668776,7/11/2014 11:08:23,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,31,103,,,43,120,HYPERTENSION,PHAEOCHROMOCYTOMA,HYPERTENSION,31,103,PHAEOCHROMOCYTOMA,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour.,31,103,31,103,43,120,1,RO-disease_may_have_finding,902902,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour,hypertension,phaeochromocytoma
502244437,7/11/2014 11:12:09,,1320671104,7/11/2014 11:11:52,instagc,1,23149109,USA,NC,Durham,75.189.206.205,31,103,,,43,120,HYPERTENSION,PHAEOCHROMOCYTOMA,HYPERTENSION,31,103,PHAEOCHROMOCYTOMA,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour.,31,103,31,103,43,120,1,RO-disease_may_have_finding,902902,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour,hypertension,phaeochromocytoma
502244437,7/11/2014 11:21:38,,1320675731,7/11/2014 11:21:25,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,31,103,,,43,120,HYPERTENSION,PHAEOCHROMOCYTOMA,HYPERTENSION,31,103,PHAEOCHROMOCYTOMA,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour.,31,103,31,103,43,120,1,RO-disease_may_have_finding,902902,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour,hypertension,phaeochromocytoma
502244437,7/11/2014 11:24:41,,1320676958,7/11/2014 11:24:14,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,31,103,,,43,120,HYPERTENSION,PHAEOCHROMOCYTOMA,HYPERTENSION,31,103,PHAEOCHROMOCYTOMA,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour.,31,103,31,103,43,120,1,RO-disease_may_have_finding,902902,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour,hypertension,phaeochromocytoma
502244437,7/11/2014 11:28:24,,1320678421,7/11/2014 11:28:02,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,31,103,,,43,120,HYPERTENSION,PHAEOCHROMOCYTOMA,HYPERTENSION,31,103,PHAEOCHROMOCYTOMA,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour.,31,103,31,103,43,120,1,RO-disease_may_have_finding,902902,The recurrence of symptoms and hypertension in a patient who has previously undergone an operation for phaeochromocytoma should alert the physician to the need to investigate for recurrent tumour,hypertension,phaeochromocytoma
502244438,7/11/2014 11:04:42,,1320667226,7/11/2014 11:04:15,instagc,1,23149109,USA,NC,Durham,75.189.206.205,196,236,,,212,253,SEVERE DYSPLASIA,CARCINOMA IN SITU,"SEVERE DYSPLASIA,",196-203,236-246-249,CARCINOMA IN SITU.,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ.",196 203,236 246 249,196,236,212,253,-1,RO-disease_has_finding,901561,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ",severe dysplasia,carcinoma in situ
502244438,7/11/2014 11:07:46,,1320668323,7/11/2014 11:07:21,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,196,236,,,212,253,SEVERE DYSPLASIA,CARCINOMA IN SITU,"SEVERE DYSPLASIA,",196-203,236-246-249,CARCINOMA IN SITU.,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ.",196 203,236 246 249,196,236,212,253,-1,RO-disease_has_finding,901561,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ",severe dysplasia,carcinoma in situ
502244438,7/11/2014 11:09:02,,1320668970,7/11/2014 11:08:38,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,196,236,,,212,253,SEVERE DYSPLASIA,CARCINOMA IN SITU,"SEVERE DYSPLASIA,",196-203,236-246-249,CARCINOMA IN SITU.,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ.",196 203,236 246 249,196,236,212,253,-1,RO-disease_has_finding,901561,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ",severe dysplasia,carcinoma in situ
502244438,7/11/2014 11:13:39,,1320672213,7/11/2014 11:13:25,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,196,236,,,212,253,SEVERE DYSPLASIA,CARCINOMA IN SITU,"SEVERE DYSPLASIA,",196-203,236-246-249,CARCINOMA IN SITU.,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ.",196 203,236 246 249,196,236,212,253,-1,RO-disease_has_finding,901561,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ",severe dysplasia,carcinoma in situ
502244438,7/11/2014 11:37:50,,1320681686,7/11/2014 11:36:41,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,196,236,,,212,253,SEVERE DYSPLASIA,CARCINOMA IN SITU,"high grade squamous intraepithelial lesion moderate dysplasia, 13 samples of SEVERE DYSPLASIA, and 3 of",35-40-46-55-71-156-182-185-193-196-203-214-218-220-165,156-165-176-179-182-185-193-196-203-218-223-225-233-236-246-249-220,"moderate dysplasia, 12 of 13 samples of severe dysplasia, 3 of 3 samples of CARCINOMA IN SITU.","Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ.",196 203,236 246 249,196,236,212,253,-1,RO-disease_has_finding,901561,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ",severe dysplasia,carcinoma in situ
502244438,7/11/2014 11:38:51,,1320682025,7/11/2014 11:38:36,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,196,236,,,212,253,SEVERE DYSPLASIA,CARCINOMA IN SITU,"13 samples of SEVERE DYSPLASIA,",182-185-193-196-203,223-225-233-236-246-249,3 samples of CARCINOMA IN SITU.,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ.",196 203,236 246 249,196,236,212,253,-1,RO-disease_has_finding,901561,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ",severe dysplasia,carcinoma in situ
502244438,7/11/2014 11:49:09,,1320685768,7/11/2014 11:48:55,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.197,196,236,,,212,253,SEVERE DYSPLASIA,CARCINOMA IN SITU,"SEVERE DYSPLASIA,",196-203,236-246-249,CARCINOMA IN SITU.,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ.",196 203,236 246 249,196,236,212,253,-1,RO-disease_has_finding,901561,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ",severe dysplasia,carcinoma in situ
502244438,7/11/2014 11:49:13,,1320685802,7/11/2014 11:48:51,prodege,1,27969454,USA,,,69.76.133.211,196,236,,,212,253,SEVERE DYSPLASIA,CARCINOMA IN SITU,"12 of 13 samples of SEVERE DYSPLASIA, and 3 of 3 samples of carcinoma in situ.",176-182-185-193-196-203-214-218-220-223-225-233-236-246-249-179,223-225-233-236-246-249,3 samples of CARCINOMA IN SITU.,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ.",196 203,236 246 249,196,236,212,253,-1,RO-disease_has_finding,901561,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ",severe dysplasia,carcinoma in situ
502244438,7/11/2014 11:50:46,,1320686489,7/11/2014 11:50:12,clixsense,1,27969116,NLD,,,91.213.37.165,196,236,,,212,253,SEVERE DYSPLASIA,CARCINOMA IN SITU,"dysplasia, SEVERE DYSPLASIA, carcinoma situ.",165-196-203-236-249,203-236-246-249,"dysplasia, CARCINOMA IN SITU.","Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ.",196 203,236 246 249,196,236,212,253,-1,RO-disease_has_finding,901561,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ",severe dysplasia,carcinoma in situ
502244438,7/11/2014 11:51:30,,1320686799,7/11/2014 11:50:53,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,196,236,,,212,253,SEVERE DYSPLASIA,CARCINOMA IN SITU,"samples of SEVERE DYSPLASIA,",185-193-196-203,225-233-236-246-249,samples of CARCINOMA IN SITU.,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ.",196 203,236 246 249,196,236,212,253,-1,RO-disease_has_finding,901561,"Twenty-five of 26 samples (96%) of high-grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of severe dysplasia, and 3 of 3 samples of carcinoma in situ",severe dysplasia,carcinoma in situ
502244439,7/11/2014 11:00:45,,1320665145,7/11/2014 11:00:31,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,136,176,,,149,199,MYELOFIBROSIS,MEGAKARYOCYTIC MYELOSIS,MYELOFIBROSIS,136,176-191,MEGAKARYOCYTIC MYELOSIS,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted.",136,176 191,136,176,149,199,-1,RO-disease_may_have_finding,902524,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted",myelofibrosis,megakaryocytic myelosis
502244439,7/11/2014 11:02:33,,1320666224,7/11/2014 11:02:09,clixsense,1,23138831,NLD,,,77.174.95.58,136,176,,,149,199,MYELOFIBROSIS,MEGAKARYOCYTIC MYELOSIS,granulocytic leukemia or MYELOFIBROSIS,111-124-133-136,170-176-191,acute MEGAKARYOCYTIC MYELOSIS,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted.",136,176 191,136,176,149,199,-1,RO-disease_may_have_finding,902524,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted",myelofibrosis,megakaryocytic myelosis
502244439,7/11/2014 11:04:35,,1320667133,7/11/2014 11:03:41,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,136,176,,,149,199,MYELOFIBROSIS,MEGAKARYOCYTIC MYELOSIS,granulocytic leukemia MYELOFIBROSIS,111-124-136,176-191,MEGAKARYOCYTIC MYELOSIS,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted.",136,176 191,136,176,149,199,-1,RO-disease_may_have_finding,902524,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted",myelofibrosis,megakaryocytic myelosis
502244439,7/11/2014 11:05:26,,1320667525,7/11/2014 11:05:06,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,136,176,,,149,199,MYELOFIBROSIS,MEGAKARYOCYTIC MYELOSIS,MYELOFIBROSIS,136,170-176-191,acute MEGAKARYOCYTIC MYELOSIS,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted.",136,176 191,136,176,149,199,-1,RO-disease_may_have_finding,902524,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted",myelofibrosis,megakaryocytic myelosis
502244439,7/11/2014 11:06:25,,1320667890,7/11/2014 11:06:03,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,136,176,,,149,199,MYELOFIBROSIS,MEGAKARYOCYTIC MYELOSIS,MYELOFIBROSIS,136,176-191,MEGAKARYOCYTIC MYELOSIS,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted.",136,176 191,136,176,149,199,-1,RO-disease_may_have_finding,902524,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted",myelofibrosis,megakaryocytic myelosis
502244439,7/11/2014 11:07:55,,1320668401,7/11/2014 11:07:38,instagc,1,23149109,USA,NC,Durham,75.189.206.205,136,176,,,149,199,MYELOFIBROSIS,MEGAKARYOCYTIC MYELOSIS,MYELOFIBROSIS,136,176-191-170,acute MEGAKARYOCYTIC MYELOSIS,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted.",136,176 191,136,176,149,199,-1,RO-disease_may_have_finding,902524,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted",myelofibrosis,megakaryocytic myelosis
502244439,7/11/2014 11:26:12,,1320677585,7/11/2014 11:25:55,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,136,176,,,149,199,MYELOFIBROSIS,MEGAKARYOCYTIC MYELOSIS,MYELOFIBROSIS,136,176-191,MEGAKARYOCYTIC MYELOSIS,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted.",136,176 191,136,176,149,199,-1,RO-disease_may_have_finding,902524,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted",myelofibrosis,megakaryocytic myelosis
502244439,7/11/2014 11:40:24,,1320682481,7/11/2014 11:40:07,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,136,176,,,149,199,MYELOFIBROSIS,MEGAKARYOCYTIC MYELOSIS,granulocytic leukemia MYELOFIBROSIS acute megakaryocytic myelosis,111-124-136-170-176-191,170-176-191,acute MEGAKARYOCYTIC MYELOSIS,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted.",136,176 191,136,176,149,199,-1,RO-disease_may_have_finding,902524,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted",myelofibrosis,megakaryocytic myelosis
502244439,7/11/2014 11:46:53,,1320684970,7/11/2014 11:46:16,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,136,176,,,149,199,MYELOFIBROSIS,MEGAKARYOCYTIC MYELOSIS,acute granulocytic leukemia or MYELOFIBROSIS,105-111-124-133-136,167-170-176-191,of acute MEGAKARYOCYTIC MYELOSIS,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted.",136,176 191,136,176,149,199,-1,RO-disease_may_have_finding,902524,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted",myelofibrosis,megakaryocytic myelosis
502244439,7/11/2014 11:50:44,,1320686477,7/11/2014 11:50:18,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.197,136,176,,,149,199,MYELOFIBROSIS,MEGAKARYOCYTIC MYELOSIS,MYELOFIBROSIS,136,170-176-191,acute MEGAKARYOCYTIC MYELOSIS,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted.",136,176 191,136,176,149,199,-1,RO-disease_may_have_finding,902524,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or myelofibrosis that a diagnosis of acute megakaryocytic myelosis was warranted",myelofibrosis,megakaryocytic myelosis
502244440,7/11/2014 10:56:09,,1320663477,7/11/2014 10:56:05,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,90,135,,,98,154,HEADACHE,HEMICRANIA CONTINUA,"chronic tension type HEADACHE, new daily persistent",69-77-85-90-100-104-110,110-121-131-135-146,"persistent headache, and HEMICRANIA CONTINUA.","Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua.",90,135 146,90,135,98,154,-1,RO-has_definitional_manifestation,904651,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua",headache,hemicrania continua
502244440,7/11/2014 10:58:44,,1320664363,7/11/2014 10:58:33,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,90,135,,,98,154,HEADACHE,HEMICRANIA CONTINUA,"chronic tension type HEADACHE,",69-77-85-90,135-146,HEMICRANIA CONTINUA.,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua.",90,135 146,90,135,98,154,-1,RO-has_definitional_manifestation,904651,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua",headache,hemicrania continua
502244440,7/11/2014 11:01:30,,1320665552,7/11/2014 11:01:01,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,90,135,,,98,154,HEADACHE,HEMICRANIA CONTINUA,"HEADACHE,",90,135-146,HEMICRANIA CONTINUA.,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua.",90,135 146,90,135,98,154,-1,RO-has_definitional_manifestation,904651,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua",headache,hemicrania continua
502244440,7/11/2014 11:01:38,,1320665655,7/11/2014 11:00:44,instagc,1,23149109,USA,NC,Durham,75.189.206.205,90,135,,,98,154,HEADACHE,HEMICRANIA CONTINUA,"chronic tension type HEADACHE,",69-77-90-85,135-146,HEMICRANIA CONTINUA.,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua.",90,135 146,90,135,98,154,-1,RO-has_definitional_manifestation,904651,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua",headache,hemicrania continua
502244440,7/11/2014 11:02:31,,1320666222,7/11/2014 11:02:09,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,90,135,,,98,154,HEADACHE,HEMICRANIA CONTINUA,"chronic tension type HEADACHE,",69-77-85-90,135-146,HEMICRANIA CONTINUA.,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua.",90,135 146,90,135,98,154,-1,RO-has_definitional_manifestation,904651,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua",headache,hemicrania continua
502244440,7/11/2014 11:03:10,,1320666488,7/11/2014 11:02:39,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,90,135,,,98,154,HEADACHE,HEMICRANIA CONTINUA,"chronic tension type HEADACHE,",69-77-85-90,135-146,HEMICRANIA CONTINUA.,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua.",90,135 146,90,135,98,154,-1,RO-has_definitional_manifestation,904651,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua",headache,hemicrania continua
502244440,7/11/2014 11:06:05,,1320667776,7/11/2014 11:05:47,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,90,135,,,98,154,HEADACHE,HEMICRANIA CONTINUA,"chronic tension type HEADACHE,",69-77-85-90,135-146,HEMICRANIA CONTINUA.,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua.",90,135 146,90,135,98,154,-1,RO-has_definitional_manifestation,904651,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua",headache,hemicrania continua
502244440,7/11/2014 11:09:03,,1320668959,7/11/2014 11:08:46,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,90,135,,,98,154,HEADACHE,HEMICRANIA CONTINUA,"chronic tension type HEADACHE,",69-77-85-90,135-146,HEMICRANIA CONTINUA.,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua.",90,135 146,90,135,98,154,-1,RO-has_definitional_manifestation,904651,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua",headache,hemicrania continua
502244440,7/11/2014 11:11:58,,1320671007,7/11/2014 11:11:41,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,90,135,,,98,154,HEADACHE,HEMICRANIA CONTINUA,"HEADACHE,",90,135-146,HEMICRANIA CONTINUA.,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua.",90,135 146,90,135,98,154,-1,RO-has_definitional_manifestation,904651,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua",headache,hemicrania continua
502244440,7/11/2014 11:18:16,,1320674317,7/11/2014 11:17:38,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,90,135,,,98,154,HEADACHE,HEMICRANIA CONTINUA,"chronic tension type HEADACHE,",69-77-85-90,135-146,HEMICRANIA CONTINUA.,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua.",90,135 146,90,135,98,154,-1,RO-has_definitional_manifestation,904651,"Primary chronic headaches of long duration include chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua",headache,hemicrania continua
502244441,7/11/2014 10:48:16,,1320661066,7/11/2014 10:48:04,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,104,58,,,116,68,HYPERTENSION,NIFEDIPINE,systemic HYPERTENSION.,95-104,47-58,sublingual NIFEDIPINE,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.",104,58,104,58,116,68,1,RO-may_treat,907907,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension",hypertension,nifedipine
502244441,7/11/2014 10:51:04,,1320661978,7/11/2014 10:51:00,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,104,58,,,116,68,HYPERTENSION,NIFEDIPINE,treatment of systemic HYPERTENSION.,82-92-95-104,35-44-47-58-69-72-76,Efficacy of sublingual NIFEDIPINE in the acute,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.",104,58,104,58,116,68,1,RO-may_treat,907907,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension",hypertension,nifedipine
502244441,7/11/2014 11:08:39,,1320668772,7/11/2014 11:08:24,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,104,58,,,116,68,HYPERTENSION,NIFEDIPINE,systemic HYPERTENSION.,95-104,47-58,sublingual NIFEDIPINE,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.",104,58,104,58,116,68,1,RO-may_treat,907907,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension",hypertension,nifedipine
502244441,7/11/2014 11:09:31,,1320669213,7/11/2014 11:09:16,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,104,58,,,116,68,HYPERTENSION,NIFEDIPINE,HYPERTENSION.,104,58,NIFEDIPINE,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.",104,58,104,58,116,68,1,RO-may_treat,907907,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension",hypertension,nifedipine
502244441,7/11/2014 11:13:56,,1320672431,7/11/2014 11:13:45,instagc,1,23149109,USA,NC,Durham,75.189.206.205,104,58,,,116,68,HYPERTENSION,NIFEDIPINE,HYPERTENSION.,104,47-58,sublingual NIFEDIPINE,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.",104,58,104,58,116,68,1,RO-may_treat,907907,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension",hypertension,nifedipine
502244441,7/11/2014 11:37:10,,1320681470,7/11/2014 11:36:56,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,104,58,,,116,68,HYPERTENSION,NIFEDIPINE,treatment of systemic HYPERTENSION.,82-92-95-104,35-44-47-58-69-72-76-104,Efficacy of sublingual NIFEDIPINE in the acute hypertension.,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.",104,58,104,58,116,68,1,RO-may_treat,907907,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension",hypertension,nifedipine
502244441,7/11/2014 11:44:49,,1320683895,7/11/2014 11:44:38,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,104,58,,,116,68,HYPERTENSION,NIFEDIPINE,systemic HYPERTENSION.,95-104,47-58-95-104,sublingual NIFEDIPINE systemic hypertension.,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.",104,58,104,58,116,68,1,RO-may_treat,907907,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension",hypertension,nifedipine
502244441,7/11/2014 11:46:37,,1320684774,7/11/2014 11:46:21,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,104,58,,,116,68,HYPERTENSION,NIFEDIPINE,Efficacy sublingual nifedipine acute treatment of systemic HYPERTENSION.,47-58-76-82-92-95-104-35,35-44-47-58-69-72-76-82-95-104,Efficacy of sublingual NIFEDIPINE in the acute treatment systemic hypertension.,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.",104,58,104,58,116,68,1,RO-may_treat,907907,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension",hypertension,nifedipine
502244441,7/11/2014 11:49:19,,1320685854,7/11/2014 11:48:48,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,104,58,,,116,68,HYPERTENSION,NIFEDIPINE,systemic HYPERTENSION.,95-104,35-44-47-58,Efficacy of sublingual NIFEDIPINE,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.",104,58,104,58,116,68,1,RO-may_treat,907907,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension",hypertension,nifedipine
502244441,7/11/2014 11:49:28,,1320685915,7/11/2014 11:49:07,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,104,58,,,116,68,HYPERTENSION,NIFEDIPINE,treatment of systemic HYPERTENSION.,92-95-104-82,47-58,sublingual NIFEDIPINE,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension.",104,58,104,58,116,68,1,RO-may_treat,907907,"Beer N, Gallegos I, Cohen A et al. Efficacy of sublingual nifedipine in the acute treatment of systemic hypertension",hypertension,nifedipine
502244442,7/11/2014 10:50:35,,1320661888,7/11/2014 10:50:31,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,182,220,,,186,229,HAIR,HAIR LOSS,"distruction of the HAIR follicle, resulting in",163-175-178-182-187-197-207,197-207-210-220-225-230-234-236,resulting in permanent HAIR LOSS and a shiny,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp.",182,220 225,182,220,186,229,1,RO-disease_has_primary_anatomic_site,902268,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp",hair,hair loss
502244442,7/11/2014 10:56:39,,1320663627,7/11/2014 10:56:35,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,182,220,,,186,229,HAIR,HAIR LOSS,"distruction of the HAIR follicle, resulting in",163-175-178-182-187-197-207,197-207-210-220-225-230-234-236,resulting in permanent HAIR LOSS and a shiny,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp.",182,220 225,182,220,186,229,1,RO-disease_has_primary_anatomic_site,902268,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp",hair,hair loss
502244442,7/11/2014 11:09:13,,1320669053,7/11/2014 11:09:00,instagc,1,15445601,USA,FL,Jacksonville,24.129.68.254,182,220,,,186,229,HAIR,HAIR LOSS,"HAIR follicle,",182-187,210-220-225,permanent HAIR LOSS,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp.",182,220 225,182,220,186,229,1,RO-disease_has_primary_anatomic_site,902268,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp",hair,hair loss
502244442,7/11/2014 11:09:46,,1320669352,7/11/2014 11:09:36,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,182,220,,,186,229,HAIR,HAIR LOSS,HAIR,182,220-225,HAIR LOSS,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp.",182,220 225,182,220,186,229,1,RO-disease_has_primary_anatomic_site,902268,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp",hair,hair loss
502244442,7/11/2014 11:15:05,,1320672938,7/11/2014 11:14:47,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,182,220,,,186,229,HAIR,HAIR LOSS,"HAIR follicle,",182-187,210-220-225,permanent HAIR LOSS,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp.",182,220 225,182,220,186,229,1,RO-disease_has_primary_anatomic_site,902268,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp",hair,hair loss
502244442,7/11/2014 11:16:33,,1320673652,7/11/2014 11:15:29,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,182,220,,,186,229,HAIR,HAIR LOSS,HAIR,182,220-225,HAIR LOSS,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp.",182,220 225,182,220,186,229,1,RO-disease_has_primary_anatomic_site,902268,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp",hair,hair loss
502244442,7/11/2014 11:25:23,,1320677281,7/11/2014 11:25:11,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,182,220,,,186,229,HAIR,HAIR LOSS,"HAIR follicle,",182-187,220-225,HAIR LOSS,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp.",182,220 225,182,220,186,229,1,RO-disease_has_primary_anatomic_site,902268,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp",hair,hair loss
502244442,7/11/2014 11:28:20,,1320678408,7/11/2014 11:28:05,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,182,220,,,186,229,HAIR,HAIR LOSS,HAIR,182,220-225,HAIR LOSS,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp.",182,220 225,182,220,186,229,1,RO-disease_has_primary_anatomic_site,902268,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp",hair,hair loss
502244442,7/11/2014 11:28:44,,1320678584,7/11/2014 11:28:25,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,182,220,,,186,229,HAIR,HAIR LOSS,HAIR,182,220-225,HAIR LOSS,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp.",182,220 225,182,220,186,229,1,RO-disease_has_primary_anatomic_site,902268,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp",hair,hair loss
502244442,7/11/2014 11:38:51,,1320682010,7/11/2014 11:38:19,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,182,220,,,186,229,HAIR,HAIR LOSS,HAIR alopecia,182-275,220-225-275,HAIR LOSS alopecia,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp.",182,220 225,182,220,186,229,1,RO-disease_has_primary_anatomic_site,902268,"? Scarring alopecia may be the end result of unrecognized, untreated lichen planus of the scalp and is characterized by perifollicular inflammation and scale with distruction of the hair follicle, resulting in permanent hair loss and a shiny scar-like appearance to areas of alopecia on the scalp",hair,hair loss
502244443,7/11/2014 10:54:01,,1320662738,7/11/2014 10:51:16,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,290,251,,,298,261,SEIZURES,EPILEPSIES,"SEIZURES,",290,251,"EPILEPSIES,","The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies.",290,251,290,251,298,261,-1,RO-has_definitional_manifestation,904884,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies",seizures,epilepsies
502244443,7/11/2014 11:07:38,,1320668289,7/11/2014 11:07:26,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,290,251,,,298,261,SEIZURES,EPILEPSIES,"SEIZURES,",290,251,"EPILEPSIES,","The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies.",290,251,290,251,298,261,-1,RO-has_definitional_manifestation,904884,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies",seizures,epilepsies
502244443,7/11/2014 11:08:07,,1320668516,7/11/2014 11:07:50,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,290,251,,,298,261,SEIZURES,EPILEPSIES,"situation related SEIZURES,",272-282-290,251,"EPILEPSIES,","The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies.",290,251,290,251,298,261,-1,RO-has_definitional_manifestation,904884,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies",seizures,epilepsies
502244443,7/11/2014 11:12:23,,1320671251,7/11/2014 11:11:59,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,290,251,,,298,261,SEIZURES,EPILEPSIES,"SEIZURES,",290,251,"EPILEPSIES,","The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies.",290,251,290,251,298,261,-1,RO-has_definitional_manifestation,904884,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies",seizures,epilepsies
502244443,7/11/2014 11:34:12,,1320680585,7/11/2014 11:33:50,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,290,251,,,298,261,SEIZURES,EPILEPSIES,"SEIZURES,",290,251,"EPILEPSIES,","The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies.",290,251,290,251,298,261,-1,RO-has_definitional_manifestation,904884,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies",seizures,epilepsies
502244443,7/11/2014 11:35:46,,1320681064,7/11/2014 11:32:52,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,290,251,,,298,261,SEIZURES,EPILEPSIES,"epileptic syndrome epilepsies, epilepsies, epilepsies, SEIZURES, seizures, epilepsies.",64-74-153-220-251-290-318-351,64-74-153-232-236-240-251-290-318-351,"epileptic syndrome epilepsies, 1.9 for undermined EPILEPSIES, seizures, seizures, epilepsies.","The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies.",290,251,290,251,298,261,-1,RO-has_definitional_manifestation,904884,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies",seizures,epilepsies
502244443,7/11/2014 11:40:05,,1320682373,7/11/2014 11:39:15,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,290,251,,,298,261,SEIZURES,EPILEPSIES,"for situation related SEIZURES, 18.3 for isolated seizures,",268-272-282-290-300-305-309-318,232-236-240-251-263-268-272-290,"1.9 for undermined EPILEPSIES, 29.0 for situation seizures,","The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies.",290,251,290,251,298,261,-1,RO-has_definitional_manifestation,904884,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies",seizures,epilepsies
502244443,7/11/2014 11:42:06,,1320682927,7/11/2014 11:41:51,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,290,251,,,298,261,SEIZURES,EPILEPSIES,"SEIZURES, seizures,",290-318,251,"EPILEPSIES,","The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies.",290,251,290,251,298,261,-1,RO-has_definitional_manifestation,904884,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies",seizures,epilepsies
502244443,7/11/2014 11:44:07,,1320683525,7/11/2014 11:43:27,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,290,251,,,298,261,SEIZURES,EPILEPSIES,"epileptic syndrome idiopathic symptomatic localization related epilepsies, idiopathic symptomatic generalized epilepsies, undermined epilepsies, for situation related SEIZURES, 18.3 for isolated seizures, television epilepsies.",64-74-96-120-132-145-153-173-196-208-220-240-251-268-272-282-290-300-305-309-318-340-351,64-208-220-232-236-240-251-263-268-272-282-290-309-318-340-351-74,"epileptic syndrome generalized epilepsies, 1.9 for undermined EPILEPSIES, 29.0 for situation related seizures, isolated seizures, television epilepsies.","The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies.",290,251,290,251,298,261,-1,RO-has_definitional_manifestation,904884,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies",seizures,epilepsies
502244443,7/11/2014 11:47:17,,1320685150,7/11/2014 11:46:38,prodege,1,27969454,USA,,,69.76.133.211,290,251,,,298,261,SEIZURES,EPILEPSIES,"for situation related SEIZURES, 18.3 for isolated seizures, 0.3 for television epilepsies.",268-272-282-290-300-305-309-318-332-336-340-351,232-236-240-251-263-268-272-282-290-300-305-309-318-332-336-340-351,"1.9 for undermined EPILEPSIES, 29.0 for situation related seizures, 18.3 for isolated seizures, 0.3 for television epilepsies.","The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies.",290,251,290,251,298,261,-1,RO-has_definitional_manifestation,904884,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization-related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined epilepsies, 29.0 for situation-related seizures, 18.3 for isolated seizures, and 0.3 for television epilepsies",seizures,epilepsies
502244444,7/11/2014 10:51:41,,1320662157,7/11/2014 10:51:36,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,117,55,,,140,66,URINARY TRACT INFECTION,NORFLOXACIN,treatment of uncomplicated URINARY TRACT INFECTION in the elderly.,90-100-103-117-125-131-141-144-148,35-46-52-55-67-71-83,controlled trial of NORFLOXACIN and amoxycillin in,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly.",117 125 131,55,117,55,140,66,1,RO-may_treat,907612,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly",urinary tract infection,norfloxacin
502244444,7/11/2014 10:56:04,,1320663465,7/11/2014 10:55:52,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,117,55,,,140,66,URINARY TRACT INFECTION,NORFLOXACIN,uncomplicated URINARY TRACT INFECTION,103-117-125-131,55,NORFLOXACIN,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly.",117 125 131,55,117,55,140,66,1,RO-may_treat,907612,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly",urinary tract infection,norfloxacin
502244444,7/11/2014 11:05:47,,1320667670,7/11/2014 11:05:22,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,117,55,,,140,66,URINARY TRACT INFECTION,NORFLOXACIN,uncomplicated URINARY TRACT INFECTION,103-117-125-131,55,NORFLOXACIN,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly.",117 125 131,55,117,55,140,66,1,RO-may_treat,907612,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly",urinary tract infection,norfloxacin
502244444,7/11/2014 11:11:42,,1320670775,7/11/2014 11:11:10,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,117,55,,,140,66,URINARY TRACT INFECTION,NORFLOXACIN,URINARY TRACT INFECTION,117-125-131,55,NORFLOXACIN,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly.",117 125 131,55,117,55,140,66,1,RO-may_treat,907612,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly",urinary tract infection,norfloxacin
502244444,7/11/2014 11:20:20,,1320675183,7/11/2014 11:19:58,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,117,55,,,140,66,URINARY TRACT INFECTION,NORFLOXACIN,URINARY TRACT INFECTION,117-125-131,55,NORFLOXACIN,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly.",117 125 131,55,117,55,140,66,1,RO-may_treat,907612,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly",urinary tract infection,norfloxacin
502244444,7/11/2014 11:24:49,,1320677026,7/11/2014 11:23:54,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,117,55,,,140,66,URINARY TRACT INFECTION,NORFLOXACIN,A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated URINARY TRACT INFECTION in the elderly.,35-46-52-55-67-71-83-86-90-100-103-117-125-131-141-144-148-33,33-35-46-52-55-67-71-83-86-90-100-103-117-125-131-141-144-148,A controlled trial of NORFLOXACIN and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly.,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly.",117 125 131,55,117,55,140,66,1,RO-may_treat,907612,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly",urinary tract infection,norfloxacin
502244444,7/11/2014 11:25:54,,1320677456,7/11/2014 11:25:41,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,117,55,,,140,66,URINARY TRACT INFECTION,NORFLOXACIN,URINARY TRACT INFECTION,117-125-131,55,NORFLOXACIN,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly.",117 125 131,55,117,55,140,66,1,RO-may_treat,907612,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly",urinary tract infection,norfloxacin
502244444,7/11/2014 11:40:30,,1320682523,7/11/2014 11:40:19,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,117,55,,,140,66,URINARY TRACT INFECTION,NORFLOXACIN,treatment of uncomplicated URINARY TRACT INFECTION in the elderly.,90-100-103-117-125-131-141-144-148,35-46-52-55-67-71-83-90,controlled trial of NORFLOXACIN and amoxycillin in treatment,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly.",117 125 131,55,117,55,140,66,1,RO-may_treat,907612,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly",urinary tract infection,norfloxacin
502244444,7/11/2014 11:41:22,,1320682739,7/11/2014 11:41:07,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,117,55,,,140,66,URINARY TRACT INFECTION,NORFLOXACIN,URINARY TRACT INFECTION,117-125-131,55-71,NORFLOXACIN amoxycillin,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly.",117 125 131,55,117,55,140,66,1,RO-may_treat,907612,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly",urinary tract infection,norfloxacin
502244444,7/11/2014 11:42:35,,1320683061,7/11/2014 11:42:01,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,117,55,,,140,66,URINARY TRACT INFECTION,NORFLOXACIN,norfloxacin amoxycillin treatment of uncomplicated URINARY TRACT INFECTION in the elderly.,55-90-100-103-117-125-131-141-144-148-71,35-46-52-55-67-71-83-90-103-117-125-131,controlled trial of NORFLOXACIN and amoxycillin in treatment uncomplicated urinary tract infection,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly.",117 125 131,55,117,55,140,66,1,RO-may_treat,907612,"Hill S, Yeates M, Pathy J et al. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly",urinary tract infection,norfloxacin
502244445,7/11/2014 10:52:34,,1320662421,7/11/2014 10:52:30,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,48,74,,,61,94,GALACTOSAEMIA,EPIMERASE DEFICIENCY,"cases with classic GALACTOSAEMIA, three with epimerase",29-35-40-48-63-69-74,48-63-69-74-84-96-100-105,"galactosaemia, three with EPIMERASE DEFICIENCY, six with compound","Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found.",48,74 84,48,74,61,94,-1,RO-has_manifestation,906358,"Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found",galactosaemia,epimerase deficiency
502244445,7/11/2014 11:08:45,,1320668851,7/11/2014 11:08:26,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,48,74,,,61,94,GALACTOSAEMIA,EPIMERASE DEFICIENCY,"GALACTOSAEMIA,",48,74-84,"EPIMERASE DEFICIENCY,","Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found.",48,74 84,48,74,61,94,-1,RO-has_manifestation,906358,"Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found",galactosaemia,epimerase deficiency
502244445,7/11/2014 11:09:00,,1320668935,7/11/2014 11:08:51,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,48,74,,,61,94,GALACTOSAEMIA,EPIMERASE DEFICIENCY,"GALACTOSAEMIA, with",48-69,74-84,"EPIMERASE DEFICIENCY,","Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found.",48,74 84,48,74,61,94,-1,RO-has_manifestation,906358,"Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found",galactosaemia,epimerase deficiency
502244445,7/11/2014 11:09:57,,1320669479,7/11/2014 11:09:29,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,48,74,,,61,94,GALACTOSAEMIA,EPIMERASE DEFICIENCY,"GALACTOSAEMIA,",48,74-84,"EPIMERASE DEFICIENCY,","Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found.",48,74 84,48,74,61,94,-1,RO-has_manifestation,906358,"Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found",galactosaemia,epimerase deficiency
502244445,7/11/2014 11:12:01,,1320671025,7/11/2014 11:11:44,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,48,74,,,61,94,GALACTOSAEMIA,EPIMERASE DEFICIENCY,"classic GALACTOSAEMIA,",40-48,74-84,"EPIMERASE DEFICIENCY,","Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found.",48,74 84,48,74,61,94,-1,RO-has_manifestation,906358,"Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found",galactosaemia,epimerase deficiency
502244445,7/11/2014 11:27:15,,1320677951,7/11/2014 11:26:53,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,48,74,,,61,94,GALACTOSAEMIA,EPIMERASE DEFICIENCY,"GALACTOSAEMIA,",48,74-84,"EPIMERASE DEFICIENCY,","Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found.",48,74 84,48,74,61,94,-1,RO-has_manifestation,906358,"Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found",galactosaemia,epimerase deficiency
502244445,7/11/2014 11:27:49,,1320678193,7/11/2014 11:27:34,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,48,74,,,61,94,GALACTOSAEMIA,EPIMERASE DEFICIENCY,"GALACTOSAEMIA,",48,74-84,"EPIMERASE DEFICIENCY,","Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found.",48,74 84,48,74,61,94,-1,RO-has_manifestation,906358,"Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found",galactosaemia,epimerase deficiency
502244445,7/11/2014 11:28:38,,1320678546,7/11/2014 11:26:11,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,48,74,,,61,94,GALACTOSAEMIA,EPIMERASE DEFICIENCY,"cases with classic GALACTOSAEMIA, three with epimerase deficiency,",29-35-40-48-63-69-74-84,48-63-69-74-84-96-100-105-114-122-136-140-154-158-163-168-178-185-198-203,"galactosaemia, three with EPIMERASE DEFICIENCY, six with compound Duarte2 heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found.","Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found.",48,74 84,48,74,61,94,-1,RO-has_manifestation,906358,"Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found",galactosaemia,epimerase deficiency
502244445,7/11/2014 11:36:36,,1320681339,7/11/2014 11:35:47,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,48,74,,,61,94,GALACTOSAEMIA,EPIMERASE DEFICIENCY,"classic GALACTOSAEMIA,",48-40,74-84-105,"EPIMERASE DEFICIENCY, compound","Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found.",48,74 84,48,74,61,94,-1,RO-has_manifestation,906358,"Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found",galactosaemia,epimerase deficiency
502244445,7/11/2014 11:43:46,,1320683442,7/11/2014 11:43:18,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,48,74,,,61,94,GALACTOSAEMIA,EPIMERASE DEFICIENCY,"classic GALACTOSAEMIA, epimerase deficiency, compound Duarte2 heterozygotes compound2 Duarte homozygosity",40-48-74-84-105-114-122-168-178-185,40-48-74-84-105-114-122-168-185-178,"classic galactosaemia, EPIMERASE DEFICIENCY, compound Duarte2 heterozygotes compound2 Duarte homozygosity","Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found.",48,74 84,48,74,61,94,-1,RO-has_manifestation,906358,"Among 199,642 newborns, nine cases with classic galactosaemia, three with epimerase deficiency, six with compound Duarte2/heterozygotes for galactosaemia and four with compound2 Duarte homozygosity were found",galactosaemia,epimerase deficiency
502244446,7/11/2014 10:51:56,,1320662251,7/11/2014 10:51:47,inboxpounds,1,26876927,GBR,H9,London,81.105.192.192,112,129,,,125,144,RENAL FAILURE,LCAT DEFICIENCY,sole determinants of RENAL FAILURE in LCAT deficiency.,91-96-109-112-118-126-129-134,112-118-126-129-134,renal failure in LCAT DEFICIENCY.,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency.,112 118,129 134,112,129,125,144,-1,RO-has_manifestation,906108,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency,renal failure,LCAT deficiency
502244446,7/11/2014 11:02:48,,1320666328,7/11/2014 11:02:32,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,112,129,,,125,144,RENAL FAILURE,LCAT DEFICIENCY,RENAL FAILURE,112-118,129-134,LCAT DEFICIENCY.,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency.,112 118,129 134,112,129,125,144,-1,RO-has_manifestation,906108,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency,renal failure,LCAT deficiency
502244446,7/11/2014 11:04:58,,1320667295,7/11/2014 11:04:42,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,112,129,,,125,144,RENAL FAILURE,LCAT DEFICIENCY,RENAL FAILURE,112-118,112-118-126-129-134,renal failure in LCAT DEFICIENCY.,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency.,112 118,129 134,112,129,125,144,-1,RO-has_manifestation,906108,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency,renal failure,LCAT deficiency
502244446,7/11/2014 11:06:52,,1320668015,7/11/2014 11:06:27,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,112,129,,,125,144,RENAL FAILURE,LCAT DEFICIENCY,RENAL FAILURE,112-118,129-134,LCAT DEFICIENCY.,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency.,112 118,129 134,112,129,125,144,-1,RO-has_manifestation,906108,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency,renal failure,LCAT deficiency
502244446,7/11/2014 11:07:37,,1320668287,7/11/2014 11:07:06,instagc,1,23149109,USA,NC,Durham,75.189.206.205,112,129,,,125,144,RENAL FAILURE,LCAT DEFICIENCY,RENAL FAILURE,112-118,129-134,LCAT DEFICIENCY.,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency.,112 118,129 134,112,129,125,144,-1,RO-has_manifestation,906108,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency,renal failure,LCAT deficiency
502244446,7/11/2014 11:14:09,,1320672567,7/11/2014 11:13:54,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,112,129,,,125,144,RENAL FAILURE,LCAT DEFICIENCY,RENAL FAILURE in LCAT deficiency.,112-118-126-129-134,112-118-126-129-134,renal failure in LCAT DEFICIENCY.,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency.,112 118,129 134,112,129,125,144,-1,RO-has_manifestation,906108,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency,renal failure,LCAT deficiency
502244446,7/11/2014 11:23:30,,1320676564,7/11/2014 11:23:16,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,112,129,,,125,144,RENAL FAILURE,LCAT DEFICIENCY,RENAL FAILURE,112-118,129-134,LCAT DEFICIENCY.,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency.,112 118,129 134,112,129,125,144,-1,RO-has_manifestation,906108,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency,renal failure,LCAT deficiency
502244446,7/11/2014 11:33:46,,1320680422,7/11/2014 11:33:37,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,112,129,,,125,144,RENAL FAILURE,LCAT DEFICIENCY,sole determinants of RENAL FAILURE in LCAT deficiency.,91-96-109-112-118-126-129-134,112-118-126-129-134,renal failure in LCAT DEFICIENCY.,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency.,112 118,129 134,112,129,125,144,-1,RO-has_manifestation,906108,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency,renal failure,LCAT deficiency
502244446,7/11/2014 11:34:56,,1320680806,7/11/2014 11:34:38,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,112,129,,,125,144,RENAL FAILURE,LCAT DEFICIENCY,RENAL FAILURE,112-118,129-134,LCAT DEFICIENCY.,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency.,112 118,129 134,112,129,125,144,-1,RO-has_manifestation,906108,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency,renal failure,LCAT deficiency
502244446,7/11/2014 11:39:54,,1320682328,7/11/2014 11:38:52,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,112,129,,,125,144,RENAL FAILURE,LCAT DEFICIENCY,RENAL FAILURE LCAT deficiency.,112-118-129-134,112-118-129-134,renal failure LCAT DEFICIENCY.,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency.,112 118,129 134,112,129,125,144,-1,RO-has_manifestation,906108,These findings cast doubt on the concept that large molecular weight LDL particles are the sole determinants of renal failure in LCAT deficiency,renal failure,LCAT deficiency
502244447,7/11/2014 11:04:10,,1320666935,7/11/2014 11:04:01,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,97,157,,,101,169,BONE,OSTEOPOROSIS,BONE,97,157,OSTEOPOROSIS.,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis.,97,157,97,157,101,169,1,RO-has_finding_site,905499,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis,bone,osteoporosis
502244447,7/11/2014 11:04:12,,1320666947,7/11/2014 11:03:58,clixsense,1,23138831,NLD,,,77.174.95.58,97,157,,,101,169,BONE,OSTEOPOROSIS,BONE,97,157,OSTEOPOROSIS.,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis.,97,157,97,157,101,169,1,RO-has_finding_site,905499,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis,bone,osteoporosis
502244447,7/11/2014 11:11:39,,1320670748,7/11/2014 11:11:23,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,97,157,,,101,169,BONE,OSTEOPOROSIS,BONE,97,157,OSTEOPOROSIS.,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis.,97,157,97,157,101,169,1,RO-has_finding_site,905499,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis,bone,osteoporosis
502244447,7/11/2014 11:20:36,,1320675372,7/11/2014 11:20:23,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,97,157,,,101,169,BONE,OSTEOPOROSIS,BONE,97,157,OSTEOPOROSIS.,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis.,97,157,97,157,101,169,1,RO-has_finding_site,905499,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis,bone,osteoporosis
502244447,7/11/2014 11:30:30,,1320679234,7/11/2014 11:30:17,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,97,157,,,101,169,BONE,OSTEOPOROSIS,BONE,97,157,OSTEOPOROSIS.,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis.,97,157,97,157,101,169,1,RO-has_finding_site,905499,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis,bone,osteoporosis
502244447,7/11/2014 11:37:25,,1320681554,7/11/2014 11:37:10,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,97,157,,,101,169,BONE,OSTEOPOROSIS,biochemical markers of BONE turnover and their diagnosis,74-86-94-97-102-111-115-130,140-144-154-157,and treatment of OSTEOPOROSIS.,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis.,97,157,97,157,101,169,1,RO-has_finding_site,905499,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis,bone,osteoporosis
502244447,7/11/2014 11:46:11,,1320684573,7/11/2014 11:45:54,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,97,157,,,101,169,BONE,OSTEOPOROSIS,BONE turnover osteoporosis.,97-102-157,157,OSTEOPOROSIS.,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis.,97,157,97,157,101,169,1,RO-has_finding_site,905499,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis,bone,osteoporosis
502244447,7/11/2014 11:48:46,,1320685678,7/11/2014 11:48:28,prodege,1,4545987,USA,CA,Elk Grove,98.208.16.149,97,157,,,101,169,BONE,OSTEOPOROSIS,biochemical markers of BONE turnover and their diagnosis treatment osteoporosis.,74-86-94-97-102-111-115-130-144-157,74-86-97-140-144-154-157-102,biochemical markers bone turnover and treatment of OSTEOPOROSIS.,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis.,97,157,97,157,101,169,1,RO-has_finding_site,905499,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis,bone,osteoporosis
502244447,7/11/2014 11:49:28,,1320685900,7/11/2014 11:49:15,prodege,1,27969454,USA,,,69.76.133.211,97,157,,,101,169,BONE,OSTEOPOROSIS,biochemical markers of BONE turnover,74-86-94-97-102,140-144-154-157,and treatment of OSTEOPOROSIS.,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis.,97,157,97,157,101,169,1,RO-has_finding_site,905499,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis,bone,osteoporosis
502244447,7/11/2014 11:49:55,,1320686006,7/11/2014 11:49:28,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,97,157,,,101,169,BONE,OSTEOPOROSIS,biochemical markers of BONE turnover,74-86-94-97-102,144-154-157,treatment of OSTEOPOROSIS.,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis.,97,157,97,157,101,169,1,RO-has_finding_site,905499,The aim of this paper is to present the current state of knowledge on the biochemical markers of bone turnover and their place at diagnosis and treatment of osteoporosis,bone,osteoporosis
502244448,7/11/2014 10:57:20,,1320663882,7/11/2014 10:57:17,bitcoinget,1,27793135,USA,FL,Jacksonville,76.106.186.209,21,77,,,33,99,HYPERTHERMIA,MALIGNANT HYPERTHERMIA,believe that this HYPERTHERMIA is different from,3-11-16-21-34-37-47,56-65-74-77-87-100-104-109,specific disorder of MALIGNANT HYPERTHERMIA and that sevoflurane,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS.,21,77 87,21,77,33,99,-1,RO-has_manifestation,906256,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS,hyperthermia,malignant hyperthermia
502244448,7/11/2014 11:00:40,,1320665109,7/11/2014 11:00:09,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,21,77,,,33,99,HYPERTHERMIA,MALIGNANT HYPERTHERMIA,HYPERTHERMIA,21,77-87,MALIGNANT HYPERTHERMIA,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS.,21,77 87,21,77,33,99,-1,RO-has_manifestation,906256,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS,hyperthermia,malignant hyperthermia
502244448,7/11/2014 11:09:22,,1320669151,7/11/2014 11:09:01,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,21,77,,,33,99,HYPERTHERMIA,MALIGNANT HYPERTHERMIA,HYPERTHERMIA,21,77-87,MALIGNANT HYPERTHERMIA,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS.,21,77 87,21,77,33,99,-1,RO-has_manifestation,906256,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS,hyperthermia,malignant hyperthermia
502244448,7/11/2014 11:09:27,,1320669203,7/11/2014 11:09:09,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,21,77,,,33,99,HYPERTHERMIA,MALIGNANT HYPERTHERMIA,HYPERTHERMIA,21,77-87,MALIGNANT HYPERTHERMIA,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS.,21,77 87,21,77,33,99,-1,RO-has_manifestation,906256,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS,hyperthermia,malignant hyperthermia
502244448,7/11/2014 11:23:14,,1320676435,7/11/2014 11:23:01,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,21,77,,,33,99,HYPERTHERMIA,MALIGNANT HYPERTHERMIA,HYPERTHERMIA,21,77-87,MALIGNANT HYPERTHERMIA,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS.,21,77 87,21,77,33,99,-1,RO-has_manifestation,906256,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS,hyperthermia,malignant hyperthermia
502244448,7/11/2014 11:28:58,,1320678640,7/11/2014 11:28:41,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,21,77,,,33,99,HYPERTHERMIA,MALIGNANT HYPERTHERMIA,HYPERTHERMIA,21,77-87,MALIGNANT HYPERTHERMIA,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS.,21,77 87,21,77,33,99,-1,RO-has_manifestation,906256,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS,hyperthermia,malignant hyperthermia
502244448,7/11/2014 11:32:11,,1320679911,7/11/2014 11:31:50,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,21,77,,,33,99,HYPERTHERMIA,MALIGNANT HYPERTHERMIA,HYPERTHERMIA,21,77-87,MALIGNANT HYPERTHERMIA,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS.,21,77 87,21,77,33,99,-1,RO-has_manifestation,906256,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS,hyperthermia,malignant hyperthermia
502244448,7/11/2014 11:39:20,,1320682189,7/11/2014 11:38:52,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,21,77,,,33,99,HYPERTHERMIA,MALIGNANT HYPERTHERMIA,HYPERTHERMIA,21,56-65-74-77-87,specific disorder of MALIGNANT HYPERTHERMIA,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS.,21,77 87,21,77,33,99,-1,RO-has_manifestation,906256,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS,hyperthermia,malignant hyperthermia
502244448,7/11/2014 11:44:12,,1320683579,7/11/2014 11:44:04,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,21,77,,,33,99,HYPERTHERMIA,MALIGNANT HYPERTHERMIA,believe that this HYPERTHERMIA is different from,3-11-16-21-34-37-47,56-65-74-77-87-100-104-109,specific disorder of MALIGNANT HYPERTHERMIA and that sevoflurane,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS.,21,77 87,21,77,33,99,-1,RO-has_manifestation,906256,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS,hyperthermia,malignant hyperthermia
502244448,7/11/2014 11:44:20,,1320683668,7/11/2014 11:44:02,prodege,1,15439740,AUS,2,Jannali,27.96.208.89,21,77,,,33,99,HYPERTHERMIA,MALIGNANT HYPERTHERMIA,HYPERTHERMIA malignant hyperthermia SWS.,21-77-87-157,77-87,MALIGNANT HYPERTHERMIA,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS.,21,77 87,21,77,33,99,-1,RO-has_manifestation,906256,We believe that this hyperthermia is different from the specific disorder of malignant hyperthermia and that sevoflurane can be safely used in patients with SWS,hyperthermia,malignant hyperthermia
